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Abstract 
Introduction. It is known that infections may occur after urological 
instrumentation, as some patients develop infective symptoms. The purpose of 
this study was to investigate bacteraemia in patients undergoing transurethral 
resection of the prostate (TURP) and catheter manipulation, using 
contemporary culture methods. Another aim was to explore the potential for 
molecular methods to detect, identify and quantify bacteraemia. We aim to 
evaluate the association between urological instrumentation and the 
development of infective endocarditis (IE). 
Methods. Microbiological molecular methods to identify and quantify bacteria in 
blood were developed. Blood samples were collected at different time points 
during the procedure from patients undergoing TURP and catheter manipulation 
to evaluate the presence of bacteria using both the culture and molecular 
methods. The association between risk factors (patient and procedural) and 
bacteraemia was analysed statistically. A case-control model was used to 
assess the association between the development of IE and a number of risk 
factors, including urological instrumentation. 
Results. Bacteraemia occurred in both sets of patients though most patients 
were asymptomatic. In the TURP group, bacteraemia occurred within the first 
twenty minutes of the procedure in spite of antibiotics prophylaxis. In the 
catheter manipulation group, bacteraemia was present even prior to any 
urological manipulation. The case-control model demonstrated an association 
between urological instrumentation and the development of IE.  
Conclusion. This study has shown that bacteraemia during urological 
instrumentation is more prevalent than previously thought but is largely 
asymptomatic. Moreover, antibiotic prophylaxis in TURP patients fails to stop a 
significant proportion of intra-procedure bacteraemias. Asymptomatic 
bacteraemia may explain the statistical association between urological 
instrumentation and IE has been demonstrated. 
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1Chapter 1: Introduction
1.1 Introduction
It is known that patients can develop infections after the instrumentation of the 
urinary tract. Infective episodes can manifest themselves as simple urinary tract 
infections (UTIs) to more serious infective episodes like septic shock and 
infective endocarditis (IE). The rates of infection associated with instrumentation 
vary and depend on a number of variables including the sterility of urine of the 
patient and which procedure is being carried out as described in Chapter 2.
However, little is known about the rates of bacteraemia associated with 
instrumentation of the urinary tract. The literature addresses the issue of 
bacteraemia in symptomatic patients, with very few studies evaluating 
bacteraemia in patients irrespective of symptoms in the immediate setting of the 
procedure. It is known that a bacteraemia is required for the development of 
bacterial infective endocarditis and the literature is interspersed with case 
reports and case series of patients having had urological instrumentation and 
subsequently developing IE. However, a statistical association between 
urological instrumentation and the development of IE has never been 
demonstrated.
1.2 Aims and objectives of the study
The purpose of this study is two-fold.  Firstly, it assessed whether there is an 
association between urological instrumentation and the development of IE. The 
null hypothesis is that urological instrumentation does not cause IE. The reason 
to study this association was that there has been anecdotal evidence, through 
case reports and case series, that urological instrumentation may be a 
precipitating factor for the development of IE.
Secondly, the incidence, nature and duration of bacteraemia during urological 
procedures were studied. The two procedures that were chosen for study are 
two of the most common procedures performed in the urological practice. At the 
Leeds Teaching Hospitals Trust, around two hundred and fifty transurethral 
resections of the prostate (TURP) operations are performed yearly. Catheter 
manipulation is done routinely on a daily basis. Different methodologies (the 
‘gold standard’ culture method culture method and novel technologies in 
2molecular microbiology) were employed to assess for the presence of bacteria 
in blood.  The gold standard culture method has been used over many decades 
but it has its drawbacks, which are described in Chapter 2. This is the reason 
alternative options to the culture methods were explored.
1.3 Background to infections in urology
The urinary tract is a sterile environment.  Instrumentation of the urological tract 
in the sterile surroundings of an operating theatre should not lead to infective 
episodes if proper aseptic techniques are used. However, several studies have 
shown the development of UTIs and systemic symptoms after the 
instrumentation of the urological tract [1-3]. The existing literature does not 
provide any significant evidence for the presence of asymptomatic bacteraemia 
secondary to instrumentation of the urinary tract. However, the presence of 
bacteraemia has been demonstrated in patients with symptoms. The review of 
this literature is discussed in the next section. The scope of this study extends 
primarily to patients undergoing TURP and catheter manipulation, though 
bacteraemia has been associated with a whole range of urological procedures 
ranging from cystoscopies to kidney instrumentation and prostatic biopsy [4, 5].
The development of IE requires the prior presence of bacteraemia. IE can be 
caused by a variety of organisms, the main ones being staphylococci, 
streptococci and enterococci [6]. Evidence whether instrumentation of body 
cavities (not including the vascular system) can lead to IE is minimal and the 
literature concerning this is reviewed in Chapter 2. Antibiotic prophylaxis has 
been used in surgical practice in order to prevent peri-operative infection since 
the introduction of systemic antimicrobials [7]. However, there is no clear 
definition of the type of ‘infection’ that antibiotic prophylaxis prevents. Does 
antibiotics prophylaxis prevent asymptomatic bacteriuria, urinary tract infections, 
bacteraemia or sepsis?
In the early part of the last century, investigators started doing work on 
bacteraemia and urological manipulation. Prior to this, there was anecdotal 
evidence and isolated case series about episodes of rigors and deaths 
associated with urological instrumentation. As early as 1810 [8], Moffait 
described a case in which a patient suffered from rigors and fever following 
urethral dilatation for a chronic urethral stricture. The patient eventually 
succumbed to this episode. The cause of death was attributed to sepsis. In 
1832, Brodie linked urethral instrumentation (bougie-dilatation) to rigors, 
describing a patient who experienced rigors with repeated bougie-dilatation. He 
3went on to hypothesise that the rigors coincided with the passage of urine over 
the raw urethral mucosa, rather than coinciding with the actual surgery. In 1887, 
Halle reported bacteraemia in a patient with a urethral stricture and partial 
urinary retention (presumably high post micturition residual volume). The patient 
died six days later, and bacteraemia was detected from a blood sample taken 
several hours after death. Bertelsmann and Mau described a case of death 
secondary to staphylococcal endocarditis in 1902. The patient reportedly had 
two urethral dilatations, each associated with rigors prior to his death. The 
above cases are reported in the paper by Rodin et al. [8].  Subsequently, 
isolated cases of suspected infection related to urological instrumentation have 
been reported in the literature.
It was only in 1930 that the first structured study was done by Barrington and 
Wright to investigate the link between urological instrumentation (urethral 
dilatation) and bacteraemia. Thereafter, more investigators published their case 
series. Some of these studies are shown in Table 1 (below).
Barrington and Wright found bacteraemia in twelve out of twenty of their 
patients.  The patients had urethral surgery (mainly urethral dilatations) and 
blood cultures were taken six minutes after surgery.  If the patients had 
subsequent urethral dilatations, repeat cultures were then taken.  The study 
also demonstrated bacteraemia in two out eleven patients after micturition 
through the dilated ‘raw’ urethra.
In 1958, Slade commented on the incidence of infection and septicaemia 
following urological procedures [9].  He quoted figures from the Bristol Royal 
Infirmary whereby 5000 autopsies, done over twenty years, revealed four cases 
of infective endocarditis - all linked to previous urological instrumentation.  
Slade designed protocols with the aim of identifying bacteraemia following 
micturition through a recently surgically manipulated urethra.  Whilst he failed to 
demonstrate an effect, he did show that there was a high incidence of 
bacteraemia (ten out of thirty-eight patients) on catheter withdrawal following 
urological surgery in patients with bacteriuria.
4Authors Date Procedure No of patients
Positive 
Blood 
Cultures
Barrington 
&Wright 1930
Operation on urethra 
or later dilatation 20 12
Simple dilatation of 
stricture 3 1
Powers 1936 Dilatation of stricture 16 3
Bjorn (cited 
by Merritt) 1951
Trans-urethral 
resection of prostate 106 13
Slade 1958 Removal of catheter
28 infected 
urine 10
12 sterile urine Nil
Mitchell 
and others 1962
Dilatation 
of 
stricture
No prior 
urethral 
disinfection
28 infected 
urine 11
Prior 
urethral 
disinfection
30 infected 
urine 3
86 sterile urine Nil
Tulloch and 
others 1964 Dilatation of stricture
14 infected 
urine 5
Rodin and 
Murray 1966
Dilatation of stricture
15 infected 
urine 1
22 sterile urine Nil
Prostatic massage
39 (15 with 
chronic 
prostatitis)
Nil
Anterior urethroscopy 22 Nil
Table 1.  Early work on bacteraemia (adapted from Rodin  and Murray) [8].
The brief description of the historical facts above gives us an inkling that 
urological instrumentation may lead to bacteraemia and infective endocarditis.  
However, this is level 3 evidence at best and data that are more robust are 
required to assess the association between urological instrumentation and 
bacteraemia and the subsequent development of IE [10].
51.4 Structure of the Thesis
The thesis aims to address the issues related to urological instrumentation, 
bacteraemia and the development of IE. 
Chapter 1 sets the scene of the thesis. It briefly describes the aims and 
objectives of the study and gives a historical overview of iatrogenic infections in 
urological practice. Thereafter, a thorough review of the literature regarding the 
development of IE and its relevance in patients who have undergone urological 
procedures is described. The chapter examines the development of 
bacteraemia following urological procedures. This is reviewed in two separate 
sections: firstly, bacteraemia in patients undergoing TURP and secondly 
bacteraemia in patients undergoing catheter manipulation.
Chapter 2 depicts the methodology of the epidemiological study used to 
investigate the association of urological instrumentation and the development of 
IE. The chapter describes the results obtained in detail and the implications of 
these results.
Chapter 3 details the methods used to assess bacteraemia. The culture method 
is described briefly with the major emphasis on the novel molecular 
microbiological methods used. The different in vitro experiments carried out are 
described.
Chapter 4 highlights two prospective studies, recruiting patients having 
urological procedures (TURP and catheter manipulation) in order to determine 
the presence, nature and duration of bacteraemia. The analysis of the results is 
reported.
Chapter 5 is a detailed discussion and interpretation of the results obtained 
from the epidemiological study and the prospective studies.
Chapter 6 concludes the thesis by summarising the main findings, addressing 
the limitations of the work and making suggestions about future possibilities and 
areas of investigation.
1.5 Infective Endocarditis and Urology
1.5.1 Infective Endocarditis
1.5.1.1 Introduction
Infective endocarditis (IE) is an inflammation of the endocardium caused by 
pathogens: mainly bacterial or fungal. It is a notoriously hard disease to 
6diagnose and to treat. In recent years, IE has affected intracardiac implants like 
valvular prosthesis and pacemaker electrodes in addition to the native 
endocardium.
William Osler described IE as an entity in 1885 [11] at the Royal College of 
Physicians. The diagnosis and treatment of the disease have significantly 
improved since then, with the modern era of advanced diagnostic imaging and 
antimicrobial therapy. Although a rare disease, IE still carries a significant 
morbidity and mortality [12-15] despite improvement in antimicrobial therapy 
and surgical management, as well as improvements in the management of the 
complications. The mortality associated with IE has not improved over the last 
thirty years ranging between 20% and 30% with some pathogens causing a 
higher fatality rate than others [15, 16].
1.5.1.2 Epidemiology
An increase in incidence of IE has been noted since the 1980s, from one to two 
cases per million to 11 to 26 cases per million [17, 18], which has been 
attributed partly to an increase in diagnostic and therapeutic procedures done 
by health-care workers [14]. Most series quote an incidence between 2.3 and 
5.9 per 100 000 people, with more elderly than young people being affected 
[19, 20]. From a urological point of view, urology patients treated tend to be 
elderly and therefore have and inherent increased risk of developing IE.
This change in epidemiology has been investigated in France by Hoen et 
al. [21] who performed a population study on 26% of the French population, 
which included patients who first presented with a diagnosis of IE in 1999.
Figure 1. Incidence of Infective Endocarditis in Different Age Groups 
(from Hoen et al. [21])
Figure 1 shows that the majority of the patients were above 64 when they were 
first diagnosed with IE, which is similar to the age group of patients undergoing 
7urological instrumentation, the median of which is 61 years [22].  There is also 
an argument to suggest that this increased incidence can be linked to better 
diagnostic facilities available to modern medicine. In a series published by the 
Royal College of Physician Research Unit in 1984, 15% of the IE was attributed 
to organisms having gained access through the alimentary or genitourinary 
portals [17]. Men are more likely to suffer from IE with a male to female ratio of 
2:1, but the male preponderance is poorly understood [23]. Patients tend to 
present earlier owing to the easy access of medical facilities. This phenomenon 
artificially inflates the incidence of IE, especially in the third world countries. It is 
known that patients who present late tend to have a worse outcome. Therefore, 
many patients are diagnosed with IE, when previously they would have 
succumbed to the disease owing to lack of access of medical facilities.
Over the last decade, the profile of the disease has changed, with fewer cases 
associated with rheumatic fever especially in the developed world and more 
cases linked to medical and surgical interventions, the elderly population and 
patients with intracardiac devices or undergoing haemodialysis [16, 23]. From a 
urological point of view, the fact that the cohort of patients developing IE is 
becoming older is significant, as patients are more likely to have had 
instrumentation of their urological tract.
1.5.1.3 Risk factors
Epidemiological studies have shown that patients diagnosed with IE have a 
higher prevalence of diabetes mellitus and malignancy [24]. These conditions 
may be linked in the pathogenesis of IE, given that such patients are 
immunosuppressed. They also tend to be more prone to infections, which may 
seed the cardiac valves. Furthermore, these patients have a greater need for 
intravenous access with intravascular devices in situ for long periods. Over the 
next decades, the number of surgical interventions is expected to increase 
particular in the elderly population, and this may in turn lead to an increase in 
the incidence of IE.
1.5.1.4 Pathogenesis
The normal endocardium is resistant to colonisation by bacteria circulating in 
the bloodstream [25]. However, when the endocardium is disrupted, tissue 
factor activates the coagulation cascade and leads to formation of a thrombus 
through the deposition of platelets and fibrin [25]. The presence of this sterile 
thrombus predisposes the endocardium to colonisation by bacteria, leading to 
infective endocarditis [26].
8Endocardial disruption may occur by a variety of mechanisms [27]:
x intrinsic – e.g. high pressure turbulent blood flow;
x iatrogenic – e.g. intravenous catheters;
x inflammatory – e.g. rheumatoid heart disease;
x degenerative – e.g. in the geriatric population.
Events that induce bacteraemia have been noted in just 20% of cases of 
IE [15].  In the other 80% of cases, no causal event was found in the time-line 
prior to the onset of the disease. This suggests that prior bacteraemia was not 
detected, as it was not symptomatic. There is growing evidence that certain
factors, labelled the ‘missing link’ in the pathogenesis of IE play a significant 
role in the development of IE. Host factors like altered immune and 
inflammatory states and/or associated endothelial dysfunction have been 
identified as precursors to IE [28]. Inflammatory cytokines and adhesion 
molecules like the intercellular adhesion molecule-1 (ICAM-1), E-selectin and 
vascular cell adhesion molecule-1 (VCAM-1) are unregulated in endothelial 
cells of valves with IE [28].
ICAM-1 is an inflammatory cytokine, which self-perpetuates; it increases a 
monocyte chemoattractant protein, which in turn increases the levels of ICAM-1 
[29].  This inflammatory activation disrupts the endothelial barrier and makes it 
more prone to adherence of platelets and hence the activation of the 
coagulation cascade via the tissue factor (extrinsic) arm [28, 29]. This leads to a 
thrombus formation at the site on the endothelium, which in turn may become 
colonised by circulating bacteria in blood [26]. Infective endocarditis ensues.
Without an infecting pathogen, the above process leads to non-infective 
endocarditis. Non-infective endocarditis is a very well documented clinical 
entity, associated with systemic disease like lupus erythematosus 
(Libman-Sacks endocarditis), malignancy (marantic endocarditis) and acute 
rheumatic fever [30]. Therefore, it is clear that bacterial virulence factors are not 
the only players in leading to endothelial dysfunction, in some cases, 
inflammatory cytokines may play a role.
This inflammatory model has been tested on two groups of rabbits by Dankert 
et al. [31].  Rabbits in Group A were injected with Interleukin-Į D SUR-
inflammatory cytokine) using an intracardiac catheter. Group B was the control 
group and the intracardiac catheter was sited without injection of any reagent.  
The intracardiac catheters were then removed in both groups. Bacteria were 
then injected intravascularly. Their results showed that rabbits in Group A had 
9bacterial colonies on the endothelium. The rabbits in Group B showed no 
endocardial bacterial colonisation.  This observation can be compared with 
human patients in a state of chronic inflammation who suffers episode (s) of 
bacteraemia (e.g. critically ill patients in intensive care), who end up developing 
IE while being in an ‘inflammatory’ state.
Other factors have been linked to non-infective endocarditis. Haemodynamic 
stress and turbulence can lead to alterations in endothelial morphology, which 
makes it more prone to allow the formation of vegetations [32].  This 
mechanism is associated with the development of endocarditis in patients with 
cardiac valvular disease.  The higher pressures in the left side of the heart in 
patients with cardiovascular disease may explain the greater prevalence of 
left-sided endocarditis.
The pathogenesis of endocarditis, in some cases, appears to be linked to 
systemic inflammatory states and altered endothelial cell morphology. A study 
by Tonetti [33] demonstrated increased inflammatory markers (PAI-1, 
E-selectin, CRP, interleukin-6, neutrophils and Von Willebrand factor) in 
patients with chronic periodontitis. This mechanism has also been linked to the 
formation of atherosclerosis, with the initial step being endothelial damage.
1.5.1.5 Microbiology of Infective Endocarditis
The common organisms known to cause IE are Staphylococcus aureus, “oral 
streptococci”, coagulase-negative staphylococci and enterococci. Less common 
causes include: Streptococcus anginosus group, Abiotrophia species, 
E-haemolytic streptococci (Groups A, B, C, D and G), Pseudomonas 
aeruginosa, HACEK (Haemophilus aphrophilus, Actinobacillus 
actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens and
Kingella kingae), Neisseria gonorrhoeae, fungi, and Bartonella species. 
Polymicrobial infection is uncommon [15, 34, 35]. In the series of 582 episodes 
of IE studied by Bayliss in 1984, 27 of the episodes were caused by 
Streptococcus bovis 17 of the episodes were caused by enterococci, 14 by 
Streptococcus faecalis (now described as Enterococcus faecalis), 11 by 
Escherichia coli or other Gram-negative bacilli, and 6 by Streptococcus 
durans [17].
Bacteria that end up colonising the endocardium and endocardial thrombi are 
expected to be resistant to the bactericidal effect of blood, especially 
platelets [36]. However, a proportion of blood cultures taken from patients 
suffering from IE are negative for bacterial growth. This may sometimes 
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adversely affect the clinical management of the patient as antimicrobial therapy 
is started on an empirical basis, which may not be optimal therapy.
1.5.1.5.1 Enterococcus species
Enterococci are part of the normal intestinal microbiota of humans but can also 
cause serious infections when displaced from their normal locations [37]. The 
genus Enterococcus includes more than 17 species, but only a few cause 
clinical infections in humans [38]. Enterococcus species are facultative 
anaerobic organisms that can survive and grow in many environments. The 
most common species associated with humans are Enterococcus faecalis and 
Enterococcus faecium, accounting for more than 90% of clinical isolates [37]. 
Other enterococcal species known to cause human infection include 
Enterococcus avium, Enterococcus gallinarum, Enterococcus casseliflavus, 
Enterococcus durans, Enterococcus raffinosus and Enterococcus mundtii [39].
Enterococcus faecalis and other enterococci may also colonise the anterior 
urethra, the vagina, the cervix and the perineum [17]. It is known that IE can be 
caused by enterococcus species, mainly Enterococcus faecalis [50]. 
Enterococcal endocarditis is caused by genitourinary and gastrointestinal 
pathogens in 40-50% of cases [40].
1.5.1.6 Clinical Presentation
The clinical picture may be confusing in many cases but the diagnosis of 
infective endocarditis should be suspected in the face of unexplained, persistent 
fever. Fatigue, anorexia, and back pain are all associated with IE, with the 
classic cardinal symptoms being new onset or worsened heart murmur, night 
sweats and weight loss.  IE manifests in different ways, depending on [23]:
x the underlying cardiac pathology;
x the microbial cause;
x the complications;
x the underlying patient characteristics.
The clinical course of IE can be markedly different in different patients.  This 
often leads to a long latency between the onset of symptoms and a definitive 
diagnosis of IE, typically one month, which may in turn contribute to the high 
morbidity associated with the disease [15].
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The European Society of Cardiology (ESC) classifies IE as follows [34]:
IE according to localisation of the infection and presence of intracardiac 
material:
a. left-sided native valve endocarditis;
b. left-sided prosthetic valve endocarditis;
x early endocarditis (< 1 year after valve surgery);
x late endocarditis (> 1 year after valve surgery);
c. right-sided endocarditis;
d. device-related endocarditis.
IE according to mode of acquisition:
a. healthcare-associated endocarditis;
x nosocomial endocarditis;
x non-nosocomial endocarditis;
b. community-acquired endocarditis;
c. endocarditis associated with intravenous drug use.
Active IE – Fever and positive blood cultures, histopathological evidence 
of IE
Recurrence:
a. relapse;
b. re-infection.
The symptoms of early native valve endocarditis (NVE) are usually subtle and 
nonspecific. They include low-grade fever (absent in 3-15% of patients), 
anorexia, weight loss, influenza-like syndromes, polymyalgia-like syndromes, 
pleuritic pain, and abdominal symptoms (pain and vomiting) [34].
The textbook embolic and immunological signs and symptoms develop much 
further down the line, especially if no appropriate treatment has been given. 
Embolic manifestations occur in around 30% of cases [15]. In the contemporary 
management of IE, treatment is instituted early. This is the reason why it has 
now become rare to detect signs like Osler’s nodes (subcutaneous 
haemorrhagic nodules linked to immune complex vasculitis or septic embolism), 
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Janeway lesions (haemorrhage of the palms and soles caused by immune 
complexes) and Roth’s spots.
After the acute episode of IE, long-term complications may persist. These 
include [41]:
x congestive heart failure and other cardiac pathologies.  This is generally 
linked to the destruction of the chordate tendinae and/or cardiac valves. 
Eventually the ventricles fail;
x arterial embolisation leading to neurological damage.  As discussed 
above, these are rarely seen nowadays;
x renal insufficiency.  The mechanism is linked to the deposition of immune 
complexes in the glomeruli of the kidneys leading to glomerulonephritis. 
This can present with frank haematuria.
1.5.1.7 Diagnosis
1.5.1.7.1 Duke criteria
The Duke’s criteria were proposed in 1994 by Durack et al. from the Duke 
Endocarditis Service at the Duke School of Medicine in North Carolina [42]. The 
Duke’s criteria consist of a collection of major and minor criteria used to 
establish a diagnosis of endocarditis. A diagnosis can be reached in any of 
these three ways: two major criteria, one major and three minor criteria, or five 
minor criteria. The major criteria include:
x positive blood culture (two separate samples > 12 hours apart) with 
typical IE microorganism, defined as one of the following:
x viridans-group streptococci, S. bovis, or HACEK group, or
x community-acquired Staphylococcus aureus or enterococci, in the 
absence of a primary focus;
x microorganisms consistent with IE from persistently positive blood 
cultures;
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x evidence of endocardial involvement with positive echocardiogram 
defined as:
x oscillating intracardiac mass on valve or supporting 
structures, in the path of regurgitant jets, or on implanted 
material in the absence of an alternative anatomic 
explanation, or
x abscess, or
x new partial dehiscence of prosthetic valve or new valvular 
regurgitation (worsening or changing of pre-existing 
murmur is not sufficient).
The minor criteria include:
x predisposing factor: known cardiac lesion, recreational drug injection;
x fever > 38° C;
x evidence of embolism, pulmonary infarcts and haemorrhages (sub-ungal, 
conjunctival);
x immunological problems like glomerulonephritis, Osler’s nodes and 
Janeway lesions;
x positive blood culture (which does not meet a major criterion);
x positive echocardiogram (which does not meet a major criterion).
Since its introduction in 1994, the Duke’s criteria for the diagnosis of IE have 
been a useful tool to aid the diagnosis of IE.  Over the years, the Duke’s criteria 
have been modified to improve sensitivity. Li et al. from the same unit in North 
Carolina published modifications in 2000 [43]. However, the associated 
increase in sensitivity has come at a price. There has been a corresponding 
loss of specificity according to a meta-analysis of 3557 patients [15].
1.5.1.7.2 Modified Duke’s Criteria
Pathological criteria:
x positive histology or microbiology of pathological material obtained at 
autopsy or cardiac surgery;
x valve tissue, vegetation, embolic fragments or intracardiac abscess 
content.
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Major Criteria:
x two positive blood cultures showing typical organisms consistent with 
infective endocarditis, such as viridians streptococci and the HACEK 
group;
x persistent bacteraemia from two blood cultures taken > 12 hours apart or 
three or more positive blood cultures where the pathogen is less specific, 
such as Staphylococcus aureus and Coagulase-negative staphylococci;
x positive serology for Coxiella burnetti, Bartonella species, or Chlamydia 
psittaci;
x positive molecular assays for specific gene targets;
x positive echocardiogram showing oscillating structures, abscess 
formation, new valvular regurgitation or dehiscence of prosthetic valves.
Minor Criteria:
x predisposing heart disease;
x fever > 38° C;
x immunological phenomena such as glomerulonephritis, Osler’s nodes, 
Roth spots, or positive rheumatoid factor;
x microbiological evidence not fitting major criteria;
x elevated C reactive protein (CRP) or erythrocyte sedimentation rate 
(ESR);
x vascular phenomena such as major emboli, splenomegaly, clubbing, 
splinter haemorrhages, petechiae or purpura.
For a definitive diagnosis of infective endocarditis, the following rules must be 
obeyed:
x pathological criteria positive or
x two major criteria or
x one major criterion and two minor criteria or
x five minor criteria present.
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This is the set of rules generally used in clinical practice nowadays in 
conjunction with other non-specific parameters like:
x a raised white blood cell count (leucocytosis), with a left shift 
(an increased ratio of immature to mature neutrophils);
x a raised C-reactive protein (CRP);
x a raised erythrocyte sedimentation rate (ESR);
x a raised pro-calcitonin concentration.
1.5.1.8 Echocardiography
Echocardiography is the study of the heart and its related structures with the 
use of ultrasound waves. It is one of the cornerstones of the modified Duke’s 
criteria for the diagnosis of IE. The procedure can be carried out via two 
modalities [44]:
x Transthoracic Echocardiography (TTE). The probe is placed on the 
patient’s chest wall. It emits and picks up waves that are then transmitted 
to a computer. A computer is used to analyse the waves to deliver an 
image on the screen.
x Transoesophageal Echocardiography (TOE). This is a similar procedure 
as above, except that the probe is inserted through the mouth into the 
oesophagus. This allows the probe to be in closer contact to the heart 
and hence provides more accurate images [45]. Furthermore, owing to 
the position of the probe, the right side of the heart, not accurately 
visualised with TTE, is better visualised.
The images obtained through echocardiography provide a pictorial as well as a 
morphological characterisation of the heart and any associated lesions linked to 
IE.  Erbel et al. quote that TOE is generally more sensitive than TTE except for 
the right side of the heart [46].
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Important parameters noted on echocardiography are [47]:
x presence of vegetation (thrombus adherent to the endocardium which is 
colonised with bacteria);
x size of the vegetation (there is a correlation with complications and 
patient survival);
x degree of damage to the cardiac tissues (abscess, fistulae, perforations, 
damage to chordae tendinae, prosthesis dehiscence, and blood flow 
insufficiency on Doppler scanning);
x ventricular function. 
In patients confirmed with a diagnosis of IE, progression of the disease can be 
monitored with serial echocardiographic imaging.
1.5.1.9 Blood Cultures
Three sets of blood cultures (aerobic and anaerobic) should be taken, prior to 
the start of any antibiotic therapy. The blood cultures should be taken from 
adequately disinfected peripheral sites. In patients with IE, there is an 
assumption that bacteria are constantly being shed into the bloodstream from 
the vegetations. This leads to continuous bacteraemia, which correlates with the 
usual associated pyrexia. About 10-30% patients with IE have negative blood 
cultures, attributed most often to prior antibiotic treatment and/or a fastidious 
organism as the cause of infection [34]. Ultimately, the diagnosis of IE is based 
on sound clinical judgment. The Duke’s criteria only offer tools to help aid 
diagnosis.
1.5.1.10 Management
Many patients are started on empirical broad-spectrum antibiotics, pending 
results from blood cultures. Blood cultures have been the cornerstone of the 
microbiological diagnosis of IE. Once suitable sensitivities are obtained, patients 
can be switched to the optimal antibiotic regime. Patients who are unresponsive 
to medical management (supportive and antibiotic therapy) progress to surgical 
therapy.  This involves the removal of the infective focus and replacement of the 
infected valve.
1.5.1.11 Prognosis
If left untreated, IE is generally fatal. However, in the modern age of 
multidisciplinary management of complex conditions, IE is largely a treatable 
disease. Prognosis depends on the identity of the offending organism, the 
presence of an intracardiac prosthesis and the timeliness of treatment 
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(antimicrobial therapy and surgery). IE caused by viridans streptococci has a 
cure rate of up to 98% whilst fungal infections tend to be harder to treat with a 
success rate of only 50% [34]. If a prosthetic device is involved in the infection, 
the cure rate is lower. Patients who end up having surgical management of their 
infection tend to do less well, as the procedure comes with a mortality of up to 
30% [48].
1.5.2 Instrumentation and Infective Endocarditis
It has been hypothesised that IE may follow a transient bacteraemia caused by 
a surgical procedure involving the dental, alimentary, respiratory, dermatological 
and genitourinary tract [17, 49]. From a urology perspective, this relates to 
instrumentation of the urinary tract. Traditionally, antibiotic prophylaxis has been 
used with a view to either prevent bacteraemia or reduce its magnitude and 
duration. In urological practice, it is thought that enterococci are the 
predominant pathogens that lead to bacteraemia [49]. The rationale for using 
antibiotics prophylaxis in the urological practice is [47]:
x to minimise the infections (UTIs and sepsis) in the acute phase;
x to minimise long-term infections likes IE and infected prosthetics.
However, over the years, it has been proposed that IE can be caused by 
bacteraemia resulting from normal daily activities [50].  Moreover, not 
everybody having had an invasive medical procedure develops IE; some people 
have predisposing factors like underlying valvular pathology and congenital 
heart malformations [14, 17] with Bayliss reporting a 41% rate of cardiac valve 
abnormalities in his IE series [17]. The duration and amplitude of the 
bacteraemia have been proposed as important factors predisposing to IE [14, 
51]. Yardena et al. showed that 13 out of 212 episodes of IE were preceded by 
urological procedures [52].
However, it has never been shown whether instrumentation of the urinary tract 
is statistically associated with the development of IE. The use of antibiotic 
prophylaxis in procedures causing bacteraemia is controversial, as the scientific 
literature is inadequate to support or invalidate the practice. There has been no 
prospective, randomised trial in humans to that effect. Therefore, there is a 
need to design an epidemiological study to evaluate this link. 
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1.6 Bacteraemia and TURP
1.6.1 The Prostate and Bladder Outflow Obstruction
The prostate is a pelvic organ, which is traversed by the urethra. The prostate is 
made up of 70% glandular tissue and 30% fibromuscular tissue. Benign 
prostatic hyperplasia (BPH) is a condition that affects men as they grow older.  
The pathophysiology involves detrusor dysfunction and bladder outflow 
obstruction, and is defined histopathologically by the proliferation of epithelial 
and stromal cells in the peri-urethral zone of the prostate. Up to 70% of men 
above 60 years old have a degree of BPH [53].
Symptoms and bother make patients seek treatment for BPH. The management 
options ranges from medical treatment to surgical management. The surgical 
management options include open prostatectomy and trans-urethral 
prostatectomy (resection or vaporisation). Urinary tract infections (UTIs) were 
an indication for surgical management of BPH in earlier series, though in more 
contemporary series, surgical management is available for most patients with 
troubling symptoms, irrespective of the presence of UTIs [54].
1.6.2 Transurethral Resection of the Prostate (TURP)
The transurethral resection of the prostate (TURP) is a procedure introduced in 
the early part of the last century in the United States of America and has been 
popularised all over the world. TURP is normally performed under general or 
spinal anaesthesia and local and national guidelines advise antibiotic 
prophylaxis (single dose prior to the start of surgery) [55, 56]. If the patient is 
catheterised prior to the procedure, the catheter is removed. A resectoscope is 
inserted urethrally until the prostate is visualised. After a cystoscopy of the 
bladder, prostate resection begins and lasts between thirty to sixty minutes. 
After resection, the prostatic chips are removed and haemostasis is achieved. 
The patient is catheterised urethrally and the catheter remains in situ until the 
post-operative haematuria settles (usually 48 hours).
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Figure 2.  Diagrammatic view of a TURP [57]
The diagram shows the resection loop cutting through the prostate 
tissue.
TURP is a routine urological procedure, with around two hundred and fifty (250) 
such procedures performed at the Leeds Teaching Hospitals NHS Trust each 
year.
1.6.3 Infection and TURP
1.6.3.1 Bacteraemia and TURP: The mechanism
The normal urological tract is a sterile environment, except for the distal urethra, 
which is often colonised with organisms from the perineal area [58]. Therefore, 
instrumentation of the urinary tract in the sterile environment of the operating 
theatre should not lead to bacteraemia. However, bacteraemia has been 
demonstrated during TURP in several studies and this will be discussed in the 
next section. In this section, the issue of how bacteria gain access to the 
bloodstream during a TURP is discussed. The source of the bacteria has been 
shown to be from [59]:
x urine;
x the urethral meatus;
x the prostate gland;
x instruments and fluids used intraoperatively.
The urinary tract is a normally sterile site and operating theatres are clean 
environments: nevertheless, there are multiple potential sources of bacteria.  
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These may have access to the vascular system leading to the potential for 
bacteraemia during TURP:
1) During a TURP, prostate tissue is resected leading to exposed blood 
vessels. The natural host barrier is breached allowing easy access for 
bacteria to gain entry into the bloodstream. During the procedure, fluid is 
injected continuously through the resectoscope to aid visualisation during 
the resection of the prostate. This constant flow of fluid retrogradely, from 
the outside of the patient to inside of the bladder, may provide a route of 
entry for bacteria residing at the urethral meatus, on the surgical 
instruments or in irrigation fluid to gain access inside the urinary tract [60].
2) Bacteriuria is one of the main reasons for the development of bacteraemia 
during urological procedures [2, 61]. Bacteriuria in the peri-procedure period 
increases the incidence of developing bacteraemia [2] and a UTI (up to 68% 
in the absence of prophylactic antibiotics use [62]). For this reason, it is 
generally accepted that non-emergency urological instrumentation should 
be delayed until bacteriuria is cleared with antibiotic therapy. However, this 
is not always possible, especially in the presence of a foreign body (e.g. a 
urethral catheter) in the urological tract. Nevertheless, it has also been 
shown that two-thirds of post-operative bacteriuria are caused by different 
bacterial strains than pre-operative bacteriuria [58, 63].
3) The prostate. Prescott et al. demonstrate that out of 170 patients having 
prostate surgery, 46% patients had microbial growth from the prostate 
tissue obtained, with most of these patients (94%) having preoperative 
sterile urine [58]. The main organism cultured was ‘Staphylococcus albus’
(coagulase-negative staphylococci).  Although this may represent a 
contaminant, the methodology used suggests true bacterial growth within 
the prostate.  This defies the commonly accepted truth that the urinary tract 
is a sterile system. Other studies have also attributed post-operative 
bacteriuria and UTIs to pathogens residing in the prostate gland [64-66]. 
Studies have demonstrated bacterial colonisation of the prostate tissue, in 
spite of no evidence of bacteriuria [65]. Having a urethral catheter in situ
was associated with prostatic bacterial colonisation [67]. Therefore, if 
bacteria reside in the prostate with the patient being asymptomatic, 
breaching the prostate tissue can lead to an escape of those bacteria into 
the bloodstream [68]. 
Furthermore, patients undergoing a TURP operation have bladder outflow 
obstruction. In animal models, there is evidence that obstruction of the urinary 
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tract, however brief, can lead to bacteriuria and bacteraemia [69]. This may 
indicate that bacteraemia may be caused by the underlying urological pathology 
(bladder outflow obstruction) rather than the procedure [70].
1.6.3.2 Bacteraemia and TURP: The Incidence
The reported incidence of patients undergoing TURP with bacteraemia and 
without antibiotic prophylaxis varies widely (0-31%) decreasing to 1% with 
antibiotic prophylaxis [2, 68]. There is a wide range of reported bacteraemia 
incidences as the methodologies and patients groups used were very diverse. 
However, most published studies consider bacteraemia in clinically affected 
patients (e.g. pyrexial patients postoperatively). Only three studies looked at the 
incidence of bacteraemia in all patients undergoing TURP, irrespective of 
clinical symptoms. They are discussed further in Section 1.6.3.3.6. Therefore, it 
is hard to put a definite value on the incidence of bacteraemia during TURP. 
The most common organisms cultured in patients with perioperative 
bacteraemia are listed below, with Gram-negative bacteria being the most 
common [59, 66, 71, 72]: 
x Escherichia coli;
x Enterococcus faecalis (previously Streptococcus faecalis);
x coagulase-negative staphylococci (previously Staphylococcus albus);
x Proteus mirabilis;
x Klebsiella spp.;
x Pseudomonas aeruginosa.
1.6.3.3 Infection and TURP
As the literature is sparse concerning studies of asymptomatic bacteraemia in 
patients undergoing the TURP operation, it is worthwhile reviewing the literature 
regarding infection associated with TURP. Infections described following TURP 
include UTIs, peri-prosthetic abscess [73], sepsis, septic shock and infective 
endocarditis [74]. Tables 2-6 show the most commonly reported infective 
outcome variables in the literature.
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1.6.3.3.1 Bacteriuria
Reference Type of Study Pre-procedure urine
Number of 
patients
Antibiotic 
Prophylaxis
Rate of 
Bacteriuria (%) Main Organisms
Jackaman
et al. [69]
Retrospective 76% sterile 140 Not known 10 Not known
Mayer 
et al. [70]
Prospective, 
randomised
75-78% sterile 92 Given Bactrim: 17.0
Placebo: 20.5
Not known
Collste 
et al. [71]
Prospective 71% sterile 107 Not known Sterile urine: 32
Infected urine: 
100
Not known
Gordon 
et al. [72]
Prospective 100% sterile 122 Nil 28 Staphylococcus epidermidis
Botto 
et al. [73]
Prospective, 
randomised
Not known 176 Cefotaxime
Placebo
16.1
57.5
Not known
Grabe 
et al. [74]
Prospective, 
randomised
Not known 47
49
Cefotaxime
Placebo
48
63
Not known
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Reference Type of Study Pre-procedure urine
Number of 
patients
Antibiotic 
Prophylaxis
Rate of 
Bacteriuria (%) Main Organisms
Grabe 
et al. [71]
Prospective, 
randomised
60.9% sterile 179 Cefotaxime
Placebo
12.2
26.6
Escherichia coli
Enterobacter
sp.
Klebsiella oxytoca
Proteus mirabilis
Enterococcus faecalis
Staphylococcus epidermidis
Grabe 
et al. [81]
Prospective 
randomised
Bacteriuria
43% 
40% 
98
94
Cefotaxime
Placebo
18
42
Not known
Charton 
et al. [82]
Prospective, 
randomised
100% sterile 49
51
Antibiotics
Placebo
18.4
51.0
Not known
Fujita 
et al. [83]
Prospective 71.7% sterile 46 Cefotaxime 8.7 Not known
Okamura 
et al. [84]
Prospective Not known 54 Not known 30 Not known
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Reference Type of Study Pre-procedure urine
Number of 
patients Antibiotic Prophylaxis
Rate of 
Bacteriuria 
(%)
Main 
Organisms
Charton 
et al. [85]
Prospective, 
randomised
100% sterile 47
48
Netilmicin
Placebo
2
34
Not known
Taylor 
et al. [86]
Prospective, 
randomised
79.9% sterile 158
150
Temocillin
Placebo
33
87
Gram-
positive in 
treatment 
group
Adolfsson 
et al. [87]
Prospective, 
randomised
0% sterile 343 Trimethoprim+
sulfamethoxazole 
Norfloxacin 
21.9
21.7
Not known
Lepage 
et al. [88]
Prospective, 
randomised
100% sterile 200 Cefotiam
Cefazoline
16 Not known
Table 2. Studies reporting the incidence of bacteriuria following TURP
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Bacteriuria, the presence of bacteria in a urine sample, is the most commonly 
reported infective outcome following TURP.  Most studies define bacteriuria as 
> 104 colony forming units (cfu) per mL of urine. The rates vary depending on 
whether antibiotic prophylaxis was used, the sterility of the urine pre-procedure 
and which definition of bacteriuria has been used. There is a wide range of 
reported incidence of bacteriuria, as the patients, methods to assess bacteriuria 
and the reporting of results was heterogeneous. The literature supports the 
notion that sterile urine preoperatively leads to a lower risk of the patient 
developing bacteriuria post-operatively. Furthermore, if antibiotics are used as 
prophylaxis, the incidence of bacteriuria decreases further as shown above. 
However, it is debateable how important an infective outcome variable 
bacteriuria is and this will be discussed further in the section 5.3.3.2.
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1.6.3.3.2. Urinary Tract Infection (UTIs)
Reference Type of Study Pre-procedure urine Number of patients Antibiotic Prophylaxis Rate of UTIs (%)
Gibbons 
et al. [89]
Prospective 
randomised
All were sterile 100 Antibiotics
No antibiotics
Same in both 
groups
Shah 
et al. [90]
Prospective 
randomised
Not known 50
50
50
50
Placebo
Cephalexin
Co-trimoxazole
Carfecillin
28
8
16
28
Goldwasser
et al. [64]
Prospective 
randomised
Sterile 81 Sulfamethoxazole-
trimethoprim (10/7)
Sulfamethoxazole-
trimethoprim (1/7)
Nil
3.8
3.8
32
Ferrie 
et al. [91]
Prospective  
randomised
All were sterile 58 Cefuroxime
Placebo
3.4
6.8
Grabe 
et al. [80]
Prospective 
randomised
Not known 47
49
Cefotaxime
Placebo
2.1
10.2
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Reference Type of Study Pre-procedure urine Number of patients Antibiotic Prophylaxis Rate of UTIs (%)
Finkelstein 
et al. [92]
Prospective 
randomised
Not known 66
63
Ceftriaxone
Placebo
3.0
12.7
Grabe 
et al. [81]
Prospective 
randomised
Bacteriuria
43% 
40% 
98
94
Cefotaxime
Placebo
0
7.4
Joly-Guillou 
et al. [72]
Prospective 
randomised
All were sterile 87 Cefotaxime
Placebo
30
4
Dorflinger 
et al. [93]
Prospective, 
randomised
Not known 52
51
Sulbactam+
Ampicillin
Cefoxitin
8
4
Prokocimer 
et al. [94]
Prospective, 
randomised
All were sterile 90 Cefotaxime
Placebo
30
4
Fujita 
et al. [95]
Retrospective All were sterile 1251 Heterogeneous 17
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Reference Type of Study Pre-procedure urine Number of patients Antibiotic Prophylaxis Rate of UTIs (%)
Taylor 
et al. [86]
Prospective, 
randomised
All were sterile 235 Temocillin
Placebo
13
24
Stricker 
et al. [96]
Prospective, 
randomised
All were sterile 100 Ampicillin+
Gentamicin
Placebo
17
16
Desai 
et al. [97]
Prospective, 
randomised
Not known 40
40
Enoxacin
Placebo
8
38
Baert 
et al. [98]
Prospective, 
randomised
Not known 31
30
Fosfomycin trometamol
Placebo
0
20
Table 3. Studies reporting the incidence of UTIs following TURP
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A urinary tract infection (UTI) is defined as an inflammatory process caused by 
infectious agents in the urinary tract; it is associated with bacteriuria [93].  A 
patient should have at least one of the following symptoms or signs, with no 
other recognised cause to fulfil clinical criteria for a UTI:
x fever> 38° C in a patient aged \HDUVRIDJH
x lower urinary tract symptoms (urgency, frequency, dysuria, suprapubic 
tenderness, loin pain);
x a positive urine culture of  105 cfu/mL with no more than two species 
present.
This is a contemporary definition and many of the earlier studies investigating 
UTIs used very broad and heterogeneous definitions of a UTI. Owing to the 
various definitions of UTI, the literature reports a rate of UTI ranging from 0% to 
38% following a TURP. The literature also supports the use of antibiotic 
prophylaxis to reduce the rate of UTI post TURP as shown in Table 3 above.
1.6.3.3.3. Fever
Reference Type of 
Study
Pre-
procedure 
urine
Number 
of 
patients
Antibiotic Prophylaxis Rate of Fever (%)
Gibbons 
et al. [89]
Prospective 
randomised
100% 
Sterile
100 Antibiotics
No antibiotics
Same in both groups
Nielsen 
et al. [100]
Prospective 
randomised
100% 
sterile
110 Cefoxitin
Placebo
3.9
26.4
Olsen 
et al. [101]
Prospective 
randomised
0% sterile 22
20
Cefotaxime
Methenamine hippurate
4.5
45
Qvist 
et al. [102]
Prospective 
randomised
100% 
sterile
54
43
Cefotaxime
Placebo
13.3
18.6
Prescott 
et al. [58]
Prospective 
randomised
Not known 196 Cephalosporin
Antiseptic
0
1.7
Table 4. Studies reporting the incidence of fever following TURP
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Fever post TURP has been reported in a number of studies, with most studies 
using a temperature of > 38º C as the cut-off point.  Up to 45% of patients 
receiving no antibiotic prophylaxis during their TURP operation suffer fever and 
antibiotic prophylaxis decreases the incidence of fever.
1.6.3.3.4. Sepsis
Reference Type of Study Pre-
procedure 
urine
Number of 
patients
Antibiotic Prophylaxis Rate of Sepsis 
(%)
Schonebeck 
et al. [103]
Prospective, 
randomized
0% sterile 37
42
Cephalexin (10/7)
Methenamine hippurate 
(10/7)
5.4
16.7
Murphy 
et al. [104]
Retrospective Mixed 1604 Different 1.1 (18)
Grabe 
et al. [80]
Prospective, 
randomised
Not known 47
49
Cefotaxime
Placebo
4.2
4.1
Grabe 
et al. [81]
Prospective, 
randomised
Bacteriuria
43% 
40% 
98
94
Cefotaxime
Placebo
0
1.1
Shearman 
et al. [62]
Prospective, 
randomised
81% sterile 110 Ciprofloxacin
Placebo
1.8
9.1
Table 5. Studies reporting the incidence of sepsis following TURP
Sepsis is defined as the association of a non-specific systemic inflammatory 
response with evidence, or suspicion, of a microbial cause [105].  This 
contemporary definition originates from the early 1990s and has remained 
largely unchanged. However, prior to this, sepsis was defined very loosely. 
Therefore, comparing contemporary studies to historical studies may not 
necessarily be addressing the same issue. Sepsis incidence of up to 17% have 
been reported post TURP, with the presence of a sterile urine sample 
preoperatively decreasing the chance of developing sepsis post-operatively. 
31
1.6.3.3.5 Bacteraemia in symptomatic patients
Reference Type of 
Study
Pre-
procedure 
urine
Number 
of 
patients
Antibiotic 
Prophylaxis
Rate of 
Bacteraemia 
(%)
Gordon 
et al. [78]
Prospective All sterile 122 Nil 3.3
Botto 
et al. [79]
Prospective, 
randomised
Not known 176 Cefotaxime
Placebo
0
2.3
Charton 
et al. [85]
Prospective, 
randomised
All sterile 47
48
Netilmicin
Placebo
0
2.1
Table 6. Studies reporting bacteraemia rate post TURP
The above studies found a bacteraemia rate between 0 and 3.3% in patients 
who have symptoms of sepsis after TURP.  In these studies, blood cultures 
were taken in symptomatic patients diagnosed with sepsis after TURP, after 
they have had antibiotic prophylaxis intraoperatively. The incidence of 
bacteraemia was very low. 
1.6.3.3.6 Bacteraemia and TURP: Asymptomatic patients
The following studies have specifically looked at intra- and peri-operative 
bacteraemia associated with TURP, irrespective of symptoms. Neilsen et al. 
reported a transient bacteraemia incidence of 46% in patients undergoing 
TURP, without antibiotic prophylaxis. The recruitment process and 
microbiological methodologies were not clearly defined [70].
In the 1980s, Robinson et al. showed a 36% rate of perioperative bacteraemia 
in patients undergoing TURP without antibiotic prophylaxis. 5 mL of blood was 
collected from the antecubital fossa at fifteen minutes after the start of surgery, 
then on Day 1 and Day 2. The blood cultures were incubated up to 14 days and 
subcultured at Days 2, 7 and 14 post-operatively [59]. The rate of bacteraemia 
reflects the surgical practice as well as the microbiological armamentarium 
available at the time.
Ibrahim et al. conducted a randomised controlled trial of patients having TURP 
[106]. They collected one intraoperative blood sample (5 mL) for culture just 
32
before the end of the operation in a heterogeneous group of one hundred and 
sixty eight patients with sterile pre-operative urine. Of the one hundred and 
thirty patients who received no antibiotic prophylaxis, seven (5.4%) developed 
bacteraemia. None of the thirty-eight patients who received 1 g of IV cephradine 
developed intraoperative bacteraemia. This study claimed that intraoperative 
bacteraemia was not linked to postoperative infective complications like 
septicaemia or epididimo-orchitis. However, the study was designed to collect 
only one intraoperative blood sample for culture with no negative controls. 
Though this study showed that antibiotic prophylaxis reduced the incidence of 
intra-operative bacteraemia, it was not designed to show an association 
between intraoperative bacteraemia and post-operative infective complications.
The literature is deficient with respect to studies specifically designed to assess 
bacteraemia related to TURP. Most studies report bacteriuria, UTIs and fever 
post-TURP; if patients were suspected to have a bacteraemia clinically (e.g.
fever or rigors), blood cultures were then taken to determine the presence of 
bacteraemia. Thus, ‘symptomatic bacteraemia’ has been identified but not 
studied systematically. By reviewing the literature, it is clear that there is a need 
for a well-designed study to look at the incidence of bacteraemia associated 
with a TURP.
1.7 Bacteraemia and Catheter Manipulation
The development of bacteraemia at urethral catheter removal is a well-
documented event.  Urethral catheters get colonised with multiple 
microorganisms within 24 hours of insertion and this leads to a 5% increase in 
risk of bacteriuria per day that the catheter stays in situ [38, 107, 109]. 
Bacteraemia has been noted in 1-4% of catheterised patients with bacteriuria, 
with certain risk factors like immunosuppression and older age being significant 
contributory factors [110]. Urethral catheterisation may lead to bacteraemia 
[110], with 17% of nosocomial bacteraemia being associated with 
catheterisation [111]. Having a long-term urethral catheter is the leading cause 
of Gram-negative bacteraemia [112]. The following studies have specifically 
looked at bacteraemia associated with catheter change and removal.
Ibrahim et al. demonstrated bacteraemia in six out of one hundred and sixty 
eight patients (3.6%) undergoing catheter removal after a TURP [106]. A 5 mL 
volume of blood was taken for culture just after catheter removal in patients who 
did not receive any antibiotics prophylaxis for their catheter removal. None of 
the patients was symptomatic. However, this cohort of patients had a recent 
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TURP and this may be a confounding factor, assessing bacteraemia in a 
recently instrumented urological tract, rather than catheter removal per se.
Bregenzer et al. showed a 4.2% rate of bacteraemia in a geriatric cohort of 
patients undergoing catheter change [113]. Blood cultures were drawn before 
and at 5, 15, and 30 minutes after the catheter replacement. Preoperative urine 
cultures showed growth of one to five different microorganisms. Of four hundred 
and eighty blood cultured in one hundred and twenty patients, twenty-seven 
blood cultures (5.6%) were positive. However, the same species grew from 
blood and urine in only five patients, with no patients having any symptoms 
suggestive of systemic sepsis. This was a well-designed study.
Polastri et al. conducted a prospective study, recruiting thirty-three patients for 
urinary catheter change [114]. All patients had pre-procedure bacteriuria. 
Quantitative blood cultures (Isolator) were performed at two time points (during 
and shortly after urinary catheter removal and insertion). Two out of the forty-six 
blood cultures were positive and at a very low concentration; one patient had 
0.13 cfu/mL Enterococcus faecalis (known as Streptococcus faecalis at the 
time) in the blood sample taken 5 minutes after removal of the urinary catheter, 
and the patient had 0.1 cfu/mL Proteus mirabilis 5 minutes after reinsertion of a 
new urinary catheter. None of the patients were symptomatic. Although this 
study was small, it described low-level asymptomatic bacteraemia in relation to 
catheter manipulation for the first time.
Jewes et al. conducted a prospective study of one hundred and fifteen patients 
having one hundred and ninety-seven catheter changes in the community [115]. 
A pre-procedure urine sample and a 10 mL post-procedure blood sample were 
taken. Urine was cultured on CLED agar and the blood was incubated in broth 
for seven days and sub-cultured at Day 2 and Day 7 following inoculation. All 
patients had polymicrobial bacteriuria. Twenty episodes of bacteraemia, all 
asymptomatic were noted (10.2%), five of which were polymicrobial.
Again, it must be noted that there are very few studies designed specifically to 
determine the incidence of bacteraemia associated with catheter manipulation. 
Most studies are retrospective and report bacteraemia in patients with urinary 
catheters in situ, who present with fever and rigors. In 31 the patients who are 
asymptomatic, the level of bacteraemia described was very low. One surprising 
point that emerges from the literature is that bacteraemia and bacteriuria tend to 
show different isolates. There is the need for a well-designed study to assess 
the incidence of bacteraemia when catheters are manipulated and its 
association with bacteriuria.
1.8 Methodology to detect bacteraemia
The vascular system is a sterile closed system and the persistent presence of 
bacteria in blood is abnormal. ‘Bacteraemia’ is a term used to describe the 
presence of bacteria in blood; the number of bacteria per unit volume of blood is 
irrelevant in the definition of bacteraemia [116]. One viable bacterium is 
sufficient for bacteraemia to exist.
Blood is a potent medium for proliferation of bacteria, which are pathological to 
humans, as it is maintained at the optimal temperature and pH. The 
constituents of blood provide a ready source of energy for bacteria to reproduce 
[117]. However, blood is an integral part of the immune system that helps the 
body to fight bacterial proliferation [118]. Figure 3 below shows the basic 
immune functions of blood responsib
Figure 3. Immune pathways in blood 
In spite of this extensive mechanism to fight bacterial proliferation in blood, 
bacteraemia still occurs. There are several ways to detect bacteraemia in blood, 
with the traditional ‘sampling, incubation and culture’ being the gold standard. In 
order for a diagnostic test to be useful, it should have a high sensitivity, a high 
specificity and a high positive and negative predictive value [120].
Many other avenues have 
surrogate markers of host response to infection (acute
C-reactive protein, haematological products like neutrophil count, and other 
biomarkers including proteomic and genomic markers), PCR
techniques [120]. This chapter addresses the two methods used to detect 
bacteraemia, namely the gold standard incubation/culture and the PCR
molecular technique.
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1.8.1 Incubation and Culture
Incubation and culture is regarded as the gold standard technique to detect 
bacteraemia [121]. A standard protocol for the detection of bacteraemia 
involves the use of a blood culture system, which should [122]:
x include a culture medium as rich as possible to allow the recovery of very 
small numbers of a variety of fastidious organisms;
x neutralise antimicrobial substances, either natural blood components or 
antimicrobial agents;
x minimise contamination;
x allow the detection of bacteria within a reasonable time-frame.
Traditionally, after a specific period, the broth is inspected for its appearance. 
Microscopy and Gram staining are then performed on a sample of the broth. 
Broths suspected to be positive are sub-cultured on solid agar. If growth is 
noted, the growth environment (aerobic and/or anaerobic) and the 
morphological appearances of the colonies are reported. Gram staining and 
microscopy are the preliminary tests done on the bacterial colonies before 
proceeding to more specific biochemical and molecular tests. With the advent of 
automated systems, the culture bottles are handled slightly differently.
Blood culture systems range from ‘in house’ and commercial manual to fully 
automated systems. These systems rely on a variety of detection principles and 
cultural environments to detect bacteria [123]. Most systems utilise both aerobic 
and anaerobic bottles. The identification of bacteria is affected by a number of 
clinical factors (method of collection, the number and the timing of samples, the 
site(s) sampled and previous antimicrobial therapy) and technical factors (the 
volume of sample, the culture media, neutralisation of antimicrobial agents, 
incubation time and temperature, agitation of media and headspace 
atmosphere) [124]. Collection of blood is performed from a suitable 
venepuncture site, following disinfection of the skin.
The volume of blood collected for incubation plays an important role in the 
detection of bacteraemia, with an increased volume leading to an increased 
bacterial yield [125].  The culture media also play an important part in the 
isolation of bacteria with the ratio of the supplements in the broth, the volume of 
the broth, the headspace above the fluid broth and the presence of 
antimicrobial neutralising agents all affecting the outcome. The ratio of blood to 
broth is also important in determining the viability of the bacteria [124].
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The culture media is normally incubated at a temperature of 35° C to 37° C for 
five to seven days, though a longer incubation time is advocated if fastidious 
organisms are suspected [124]. The headspace of the culture bottles is an 
important variable in determining bacterial growth. Aerobic bottles normally 
have a combination of oxygen and carbon dioxide while anaerobic bottles have 
carbon dioxide and nitrogen. Agitation of the culture bottles during the 
incubation period has been shown to increase the yield and time to positivity for 
aerobic growth [126].
Subculture of culture bottles depends on whether an automated or a manual 
system is used for the incubation phase. In an automated system, the ‘positive’ 
bottles will be flagged up and these bottles are subcultured. Automatic systems 
flag up positive bottles by the measurement of a change in the components of 
the broth (for example, carbon dioxide production, increase in fluorescence) 
[127]. In a manual system, either all bottles are subcultured or bottles with signs 
of positivity (cloudiness) are subcultured. Subculturing all bottles increases the 
likelihood of detecting organisms like Neisseria spp. and Haemophilus 
influenza, which show little visible signs of growth in the incubated culture 
bottles [128].
1.8.2 Molecular Assays
Molecular methodology has revolutionised the field of virology over the last two 
decades. However, in the bacterial field, molecular microbiology is still, rather 
surprisingly, in its infancy. Broadly speaking, three types of strategies have 
been described [129]:
x pathogen-specific assays targeting species or genus-specific sequences;
x broad-range assays targeting conserved sequences in the bacterial 
genome, (panbacterial 16S and 23S rRNA genes);
x multiplex assays allowing the parallel detection of species or 
genus-specific targets of different pathogens potentially involved in a 
certain infection type.
Quantitative real-time PCR is a system where amplification and detection of 
amplified products happens in a single vessel.  Two strategies exist for real-time 
monitoring [130]:
x the use of fluorescent DNA-intercalating dyes, which bind 
non-specifically to double-stranded DNA generated during amplification;
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x the use of DNA probes with specific annealing within the target-amplified 
region.
The internal probes emit a fluorescent signal during each amplification cycle 
only in the presence of targeted sequences, with the signal intensity increasing 
in proportion to the amounts of amplified products generated. Real-time PCR 
allows for absolute and relative quantification of the target sequence. However, 
not all molecular methods require the amplification method or PCR [131]. Mass 
spectrometry (MS) uses the signatures of peptides and carbohydrates or the 
length, charge and base contents of the nucleic acids present for identification 
[132]. Matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS) is a contemporary technology for the routine 
identification of bacteria in clinical microbiology laboratories [133].
1.8.2.1 Bacterial DNA Isolation
To detect and identify the bacteria present in blood, it is imperative to separate 
the bacteria from the blood products [134]. This is because blood has an 
inhibitory effect on the different molecular steps [135]. Most methods of DNA 
isolation need to be carried out as soon as the sample is collected as DNA 
degradation is noted. Most methods require DNA isolation to take place within 
twenty-four hours of collection [134]. Once the bacterial DNA is isolated, it 
needs to be purified to a level that most PCR-inhibitory components are 
removed. The human genome results in significant signal to noise problems 
during PCR, which already has inherent limitations like the presence of Taq
DNA polymerase inhibitors [136]. Another factor that influences PCR is the ratio 
of bacterial DNA to background DNA, which in the case of blood relates to the 
human DNA from the blood products [137].
Possible interference in the detection of bacterial DNA can be attributed to 
human DNA as it has been shown that both have similar base codons and 
determinants, probably secondary to the evolution [138]. Furthermore, lateral 
translocation of genes from bacteria and human genome has also been 
demonstrated, which may increase the false positive rate during bacterial DNA 
PCR [139].
There are a number of commercially available kits for the isolation of bacterial 
DNA from blood, for example MolYsis, Molzym GmbH & Co. KG, Bremen and 
Pureprove, SIRS-Lab GmbH, Jena [134, 140]. Most protocols for the isolation of 
bacterial DNA have been shown to decrease the amount of human DNA 
significantly, when isolating bacterial DNA from human samples [141]. However, 
most of the protocols have limitations, reducing the bacterial yield at the end of 
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the process. All protocols consist of chaotropic conditions during the DNA 
degradation stage by DNase [142]. These conditions are very harsh and some 
bacteria with non-existent, thin or labile cell walls may be lost together with 
human DNA during this stage. This bacterial isolation process may be biased 
towards the detection of Gram-positive bacteria, owing to the presence of large 
amounts of peptidoglycan in their envelopes. The Pureprove technology is 
based on the selective binding of bacterial DNA to a human protein immobilised 
on sepharose. Though present more often in bacterial DNA than human DNA, 
the binding site is not ubiquitous in bacteria. This may lead to the washing away 
of bacterial DNA together with the human contaminants [141].
1.8.2.2 Bacterial DNA Amplification
Polymerase chain reaction (PCR) is a method that allows exponential 
amplification of short DNA sequences (usually 100 to 600 bases) within a longer 
double-stranded DNA molecule. PCR entails the use of a pair of primers, each 
about 20 nucleotides in length, which are complementary to a defined sequence 
on each of the two strands of the DNA. A DNA polymerase extends these 
primers, so that a copy is made of the designated sequence, which overlaps on 
extension [143]. After making one copy, the same primers can be used again, 
not only to make another copy of the input DNA strand but also of the short 
copy made in the first round of synthesis. This leads to exponential amplification 
[143].
Figure 4. The first four c
Since it is necessary to raise the temperature to separate the two strands of the 
double strand DNA in each round of the amplification process, a major step 
forward was the discovery of a thermo
polymerase), isolated from 
pools.  As a result, it is not necessary to add new polymerase in every round of 
amplification [143]. After several (around 20
PCR product is analysed. Chromatography and 16S rRNA sequence 
determination are the methods that are commonly used [
divided into 4 broad phases as shown in the graph below (Figure 5) [144].
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ycles of the polymerase chain reaction
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Figure 5.  A sigmoid curve showing a typical amplification
The four phases are described below:
Linear phase: During this phase, amplified fluorescence is still below 
background fluorescence. This normally lasts 10-15 amplification cycles.
Early-exponential phase: The cycle threshold (Ct) value lies in this phase, when 
amplified fluorescence exceeds background fluorescence. Usually, the 
fluorescence reaches at least 10 times the standard deviation of the baseline at 
this point [145].
Log-linear phase: During this phase, the polymerase chain reaction has 
reached optimal conditions, whereby the amplified products double after each 
cycle (assuming ideal efficiency of the process).
Plateau phase: During this phase, there are various limiting factors, which 
restrict the efficiency of the process. For example, the amount of primers to 
replicate the initial DNA has been used up.
1.8.2.2.1 Real-Time PCR
In real-time PCR, a positive reaction is detected by the accumulation of a 
fluorescent signal [144]. The cycle threshold (Ct) value is defined as the number 
of cycles required for the fluorescent signal to cross an arbitrary threshold, 
which can be defined automatically or manually. This arbitrary value is the value 
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at which the background fluorescence is exceeded. Ct values are inversely 
proportional to the amount of target nucleic acids present [144].
Real-time PCR has revolutionised the way in which data are collected during 
the PCR process. By collecting data at every single step of the process, 
real-time PCR has combined two previously separate steps (amplification and 
detection) into one; this constant output from the PCR process allows for the 
dynamic detection curve plotted above to be achieved [144]. In SYBR Green 
PCR, a dye that fluoresces maximally when bound to double-stranded DNA is 
used. However, DNA-binding dyes do not bind in a sequence-specific manner: 
therefore, there is always the chance of false positive reactions [145]. Real-time 
PCR has the added benefit of allowing quantification, without significant 
post-amplification manipulations. However, it is expensive and owing to its 
extreme sensitivity, proper experiment design is crucial to have the added 
benefit of high specificity. A melting curve is one of the parameters used in 
determining specificity [146].
1.8.2.3 Controls
In an experiment, a control is a known variable, which is included to provide a 
reference set of data that can be compared with the data obtained from the 
experimental variables [147]. An ideal control is a variable used to account for 
all the confounding factors except the variable being measured. To ensure that 
the change noted in the target variable is due to the reason being tested, a 
controlled experiment is run [148]. A control group is an additional and separate 
experiment, set up like the others with exactly the same conditions. The only 
difference is that test variable is changed [148]. Dependable controls are 
sometimes hard to develop. Without a control, it is impossible to be completely 
sure that changing the variable causes the observations seen. In molecular 
microbiology, controls are used in all the various steps from bacterial DNA 
extraction to sequence determination.
During the bacterial extraction process, extraction and purification controls are 
used. The controls required are [149]:
x sample-positive control. This control reflects the performance of the 
extraction process;
x sample-negative control. This control helps to control for 
cross-contamination during the extraction and purification process.
During the polymerase chain reaction, a number of controls are used to 
ascertain that bacterial DNA is amplified and detected [150].
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x PCR-positive control. This test includes a definite number of target 
sequence copies to make sure the assay is performing as specified This 
helps to normalise samples to account for sample-to-sample variation 
with regards to tissue mass or cell number;
x PCR-negative control. This control contains all the reagents except a 
target DNA. DNA free water is used instead of the eluate. This control 
helps to detect any exogenous DNA, which might have been introduced 
and carried over while pipetting the reagents;
x PCR internal control. Potential inhibition of the PCR process by blood 
components, which might have been carried over from the extraction and 
purification process is accounted for by this control.
The meticulous use of the same amount of PCR mastermix should be used for 
all the experiments in order to standardise the whole process further. Variation 
in this volume has been shown to deliver different PCR efficiencies though the 
starting concentration of DNA is the same [151]. As can be seen above, the 
whole process is fraught with problems at different stages. A tiny variation at the 
beginning of the process may end up being amplified to significant scales that 
the results are distorted. Below is a list of the other possible causes of 
variations that can happen from the initial step of DNA extraction to the final 
step of amplification and identification.
x PCR inhibitors like the reverse transcriptase enzyme or blood. These 
may affect the PCR kinetics [136];
x the structure and concentration of the target DNA [152];
x the quality and amount of PCR reagents [152];
x the conditions at which the PCR equipment operates. For example, a 
slight difference in temperature when measuring fluorescence can lead 
to a difference in the amount of DNA detected [152];
x human error is by far the most likely cause of variation. Running a 
standard curve during each reaction may improve this problem though it 
is very time and labour intensive [153].
The use of the same batch of suspensions and equipment as well as the use of 
a single investigator help minimise variation in the whole process [154]. 
Quantifying intra- and inter-assay variation gives a more accurate picture of the 
actual process.
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1.8.2.4 Identification of bacterial DNA
Once the bacterial DNA has been amplified, the amplimers can be identified by 
a number of methods. In this chapter, two main methods of identification are 
addressed.
1.8.2.4.1 Sequence determination
Nucleotide sequence determination has been a technology that was first 
described in 1975 by Sanger in the Croonian lectures at the Royal Society 
[155]. The technology was subsequently commercialised and made available to 
the global research community. Applied Biosystems (ABI) commercialised a 
number of instruments during the 1990s, with a gradually increasing amount of 
automation [156]. This made the sequence technology less labour and time 
intensive. Next generation sequencing (NGS) was introduced in the early part of 
this millennium and has since gained in popularity, mainly through its ability to 
bring down costs and increase the throughput.  This has permitted the 
determination of entire genome sequences. The second generation NGS can 
produce up to a billion bases in a single run (Illumina SOLiD). The leading 
technologies of the second generation NGS are [157]:
x Illumina, which uses solid phase amplification and sequences by 
synthesis and reads around 100 bases;
x Roche, which uses emulsion PCR technology and pyro-sequencing and 
reads around 400-500 bases;
x ABI makes use of emulsion PCR and ligation sequencing. It reads 
around 50 bases.
The third-generation NGS has shown considerable promise and circumvents 
one of the problems of previous technologies, by not using the PCR step.  
Previous generations of NGS use PCR, which can introduce base sequence 
errors owing to the differential amplification of bases. Therefore, by avoiding the 
PCR phase before identification, third generation NGS allows identification 
without amplification [158]. The main leading technologies of third generation 
NGS include [158]:
x Pacific Biosciences. This technology involves the incorporation of DNA 
polymerase with zero-mode wave guides, and then utilises a labelled 
nucleotide by diffusion. DNA detection happens with the detection of the 
labelled polymerase;
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x Oxford Nanopore Technologies. This technology utilises the 
incorporation of D-haemolysin with exonuclease. A current is used for 
DNA detection;
x Visi Gen Biotechnologies incorporating labelled nucleotide to modified 
quantum polymerase, which releases energy from a fluorescent labelled 
base. DNA is identified by light emission;
x Ion Torrent uses a semiconductor technology and sequencing detection 
happens by the release of hydrogen ions during the elongation of the 
nucleotide chain.
In-depth details of the sequencing determination processes mentioned above is 
outside the scope of this thesis.
1.8.2.4.2 Mass Spectrometry (MS)
MS is still a novel technology for the detection and identification of bacteria. The 
basic principle of MS involves the detection of mass to charge ratio of 
compounds [159]. At present, no system is available for the detection of
bacteraemia using MS [160]. However, matrix-assisted laser desorption 
ionisation (MALDI) time-of-flight (TOF) MS is a relatively recent technology. It 
utilises the molecular fingerprinting of bacteria, whereby bacteria can be 
detected by virtue of the different molecular masses of the nucleic acids 
fragments that constitute them. It has been successfully used in the quick 
identification of bacteria from colonies [161].
1.8.3 Culture method versus Molecular method
Both the culture and the molecular methods have their advantages and 
disadvantages. One of the common factors to determine positivity in both 
methods used for the detection of bacteraemia is the volume of blood used. The 
higher the volume of blood used, the greater the likelihood of detecting bacteria, 
whether the method used is bacterial growth or bacterial DNA amplification 
[162]. Another important factor is the time from blood sampling to the time the 
sample is processed (incubation or bacterial DNA extraction). The sooner 
processing starts, the higher the positivity rate [163].
One of the advantages of the culture method is it allows the determination of 
antibiotic susceptibility, which has yet to be reliably reproduced using the 
molecular methodology [164]. However, the culture method has it 
disadvantages. It allows detection of only viable bacteria that can be cultured 
[165]. Therefore, it does not detect the presence of dead bacteria or viable but 
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non-cultivable pathogens. In the instance when antimicrobial therapy has been 
started prior to sampling, viable bacteria may not be present in blood, although 
dead bacteria may be present [166]. Furthermore, fastidious organisms that 
require very specific conditions to grow may not be detected by the culture 
method [130]. Once growth is detected in the culture bottle after 24 to 48 hours 
of incubation, the final identification of the organism by phenotypic 
characteristics adds a significant time to the processing time. Therefore, the 
culture method is a process that can be slow to provide definitive results [167].
On the other hand, the molecular method has its own disadvantages. Firstly, the 
setup is prone to contamination and antimicrobial susceptibility is not possible 
(thought antimicrobial resistance can be determined by detecting the presence 
of targeted genes) [168]. However, it detects ‘DNAemia’ rather than 
bacteraemia, which allows detection of dead bacteria in the patients undergoing 
antimicrobial therapy [169]. Furthermore, it is possible to quantify the DNA load 
and, by inference, quantify the bacterial load [170]. And most significantly, there 
is no prolonged incubation phase in the molecular processing of the samples, 
making the molecular method a faster method than the culture method, though 
it can be more labour-intensive and considerably more expensive when the set-
up costs are taken into account [168].
1.9 Conclusions
IE is a condition associated with significant morbidity and mortality.  There is 
some evidence that IE can be caused iatrogenically. However, there is no 
evidence that urological instrumentation leads of the development of IE. The 
presence of bacteria in the vascular system is essential in the development of 
IE. There is evidence that instrumentation of the urinary tract can lead to 
symptomatic bacteraemia. However, the true incidence of bacteraemia, 
symptomatic or asymptomatic, associated with urological instrumentation is 
unknown. Therefore, at present, it is not possible to determine whether 
urological instrumentation leads to IE though there is low-level evidence 
suggesting this association.
This study aims to explore different methods to detect bacteraemia. It is 
abundantly clear from the literature that for a large proportion of septic 
episodes, an infective pathogen is not identified. Therefore, there is a need to 
devise a method with high sensitivity and specificity. Results reported in this 
thesis show that appropriate methods were used to determine the incidence of 
bacteraemia in patients having TURP and catheter manipulation, two of the 
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most common urological procedures in modern urology. To determine whether 
instrumentation of the urinary tract precedes the development of infective 
endocarditis, a novel approach case-control study was used.
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Chapter 2: An association between urological instrumentation 
and infective endocarditis
2.1 Introduction
Designing a study to investigate IE is a difficult prospect owing to its low 
incidence [171]. This is why little is known about the associated risk factors that 
can lead to the development of IE. Allocating a matched control group for a 
case-control study can be problematic from a study-design point of view. A 
particular difficulty is selection of patients in the control group with the same 
predisposing cardiac risk factors as the case group [172]. A study was designed 
to evaluate the iatrogenic risk factors associated with the development of IE. 
The null hypothesis that instrumentation of body cavities (the upper and lower 
gastrointestinal tract and the urinary tract) is not a risk factor for the 
development of IE was tested. Owing to the difficulty associated with designing 
such a study, a novel approach to the traditional case-control design was used. 
The objective was to identify any association between instrumentation and the 
subsequent development of IE.
2.2 Methods
2.2.1 Justification of Approach
Ethical approval for the study was granted by the Yorkshire and Humber 
Research Ethics Committee - Bradford (reference 11/YH/0093). Owing to the 
relative rarity of IE, It was decided that a retrospective approach was the best 
way to obtain a large cohort of patients. A case-control design was chosen as 
an appropriate method to analyse risk in an observational epidemiological study 
[172]. The novel approach to the case-control design used was to select both 
the ‘case’ and ‘control’ group patients from a population of patients with IE. The 
outcome measure was IE caused by selected pathogens. A number of possible 
causative exposures were identified and their rates calculated. In this 
investigation, the main causative exposures being investigated were 
instrumentation (urological, upper and lower gastrointestinal).
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The IE patients were divided into four distinct patient groups based on the 
microbiological aetiology of the disease.  The four groups were:
x Group A: patients with enterococcal endocarditis
x Group B: patients with coagulase-negative staphylococcal 
(CoNS) endocarditis
x Group C: patients with Streptococcus bovis group endocarditis
x Group D: patients with oral streptococcal endocarditis
Therefore, when Group A (the case group) was being evaluated; Group B, C 
and D were used as controls (the control group).  This approach (assigning 
case and control groups) was applied to the three other groups.
Case Group Control Groups
A B, C and D
B A, C and D
C A, B and D
D B, C and D
Table 7. Table showing the cases and the controls used
This approach to the case-control design, which only included patients who had 
suffered an episode of IE, bypassed the problem in previous case-control 
studies of selecting a suitable control group of patients at risk of IE [173- 175]. 
This is because all patients in this study have developed IE and therefore have 
predisposing factors to the development of IE. The study design utilises the fact 
that the normal human microbiota is specific to an anatomical site. Oral 
streptococci colonise the oral cavity [176, 177] but are rarely cultured from the 
skin, faeces or urinary tract [178]. The natural habitat of Streptococcus bovis 
group organisms is the bowel, and can be found in 5-16% of stool samples of 
healthy individuals [179]. However, they are not part of the normal oral microbial 
flora and rarely cause urinary tract infections [180, 181]. Enterococci are part of 
the normal microbiota of the lower gastrointestinal tract, with a mean of 105-107
organisms per gram of human stool [182]. However, enterococci can colonise 
the mouth, particularly in patients with poor oral health [183] and are a common 
cause of urinary tract infection [184]. Coagulase-negative staphylococci are 
members of the normal human skin microbiota and mucous membranes [185]. 
They are associated with hospital-acquired infections, usually related to medical 
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devices and community-acquired urinary tract infections e.g. caused by 
Staphylococcus saprophyticus [185]. It is highly unlikely that IE caused by 
bacteria of the Streptococcus bovis group could result from a dental procedure 
because these bacteria reside in the bowel and are not found in the mouth. 
Similarly, it is highly unlikely that oral streptococcal IE would result from of a 
lower gastrointestinal procedure. The source of the organism for enterococcal 
endocarditis is likely to be urological. Coagulase-negative staphylococcal IE is 
believed to come from the skin arising from vascular access device infections or 
valve surgery [185, 186].
2.2.2 Population
Adult patients treated for IE at the Leeds Teaching Hospitals NHS Trust (LTHT) 
between 1st January 2001 and 31st December 2010 from the following groups of 
organisms (1) enterococci (2) coagulase-negative staphylococci (3) 
Streptococcus bovis group and (4) oral streptococci were included. IE was 
diagnosed according to the Duke criteria [43]. LTHT comprises two large 
(> 1000 bed) teaching hospitals, which serve the population of Leeds 
(approximately 600 000 people) as well as receiving referrals from surrounding 
hospitals. IE patients included in this analysis came from Leeds and the 
surrounding locations.
Patients managed by the Leeds Endocarditis Service are routinely asked about 
potential risk factors for endocarditis in addition to other clinically relevant 
questions and the data entered onto an audit database. Fully anonymised data 
extracts from this database were used for statistical analysis. This is a 
retrospective study utilising fully anonymised, routinely collected clinical data 
that will not influence the individuals concerned; therefore, patient consent has 
not been sought.
2.2.3 Study design
An unmatched case-control design was been used to compare the rate of 
different types of procedure in each group of endocarditis cases. Each group 
was been compared to the three other groups of patients to investigate any 
difference in the predisposing factors.
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Study 1 Study 2 Study 3 Study 4
Cases
A
(enterococcal 
IE)
B
(CoNS IE)
C
(Streptococcus
bovis IE)
D
(oral 
streptococcal IE)
Controls B, C & D A, C & D A, B & D A, B &C
Suspected 
iatrogenic 
exposure
urological 
instrumentation
superficial skin 
instrumentation
lower 
gastrointestinal 
instrumentation
oral 
instrumentation
Table 8. The case-control study design
2.2.4 Variables
Data were collected from the Leeds Teaching Hospitals Endocarditis Service 
database, patient case notes, the hospital results server and the Patient 
Pathway Management (PPM) system. In the first instance, the IE database was 
cross-referenced with patient logbooks, routinely maintained by Dr Jonathan 
Sandoe (JS, Consultant Microbiologist), who performs the routine endocarditis 
ward rounds. This process helped resolve any issue with incomplete data. If 
incomplete data was identified, the PPM system was accessed to search for the 
missing data (whenever possible). Data on enterococcal bacteriuria were 
acquired from the hospital results server. The principal investigator (AM) was 
blinded with respect to the four groups of patients) for this step. The principal 
investigator was, therefore, not aware data on bacteriuria was being collected 
for which group of patients. All data was stored on an Excel spreadsheet. The 
following data were collected:
x age of patient;
x sex of patient;
x the valve affected by IE (Aortic, Mitral, Tricuspid or Pulmonary);
x the Duke criteria for the IE episode;
x the organism responsible for the IE episode;
x the presence of enterococcal bacteriuria with one year of the episode of 
IE;
x the presence of enterococcal bacteriuria at hospital presentation of the 
IE episode;
x urological instrumentation within one year of the development of IE;
x any upper GI instrumentation within one year of the development of IE;
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x any lower GI instrumentation within one year of the development of IE;
x the presence of an intracardiac prosthetic device (cardiac valvular 
replacement or intracardiac pacemaker wire) at presentation;
x the use of intravenous drugs;
x any documented valvular heart disease (congenital or acquired);
x the need for haemodialysis preceding the IE episode.
The identity of the causative bacterial pathogen was collected in order to 
ascribe the patients to the different ‘case’ groups. The urological procedures 
included every per-urethra, endoscopic procedure excluding urethral 
catheterisation and urodynamic studies. Cystoscopy, endoscopic resection of 
the prostate (TURP), endoscopic resection of bladder tumour (TURBT) and 
ureterorenoscopy were included. Upper gastrointestinal procedures included 
oesophagogastroduodenoscopy (OGD) and endoscopic retrograde 
cholangiopancreatography (ERCP). Lower gastrointestinal procedures included 
sigmoidoscopy and colonoscopy. Antimicrobial prophylaxis (IV gentamicin 
2 mg/kg single dose) is routine practice at the Leeds Teaching Hospitals NHS 
Trust for all the per-urethra urological procedures included in this study except 
cystoscopy. Patients undergoing upper and lower GI procedures did not receive 
routine antibiotic prophylaxis, except for ERCP (ciprofloxacin 750 mg single oral 
dose).
2.3 Results
2.3.1 Demographics
Table 9 below describes the number of units of observations obtained per 
variable assessed. All data were available for analysis regarding 
instrumentation. There were some missing data for the other variables. This 
issue is further discussed in Section 2.3.2.3.
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Variables observed N=384 (%)
Age of Patient 384 (100)
Enterococcal bacteriuria (within 1 year) 248 (64.6)
Enterococcal bacteriuria (at presentation) 248 (64.6)
Intravenous Drug User 323 (84.1)
Congenital Cardiac Anomaly 324 (84.4)
Acquired Cardiac Disease 325 (84.6)
Intracardiac Prosthesis 325 (84.6)
Haemodyalysis Patient 323 (84.1)
Upper GI Instrumentation 384 (100)
Lower GI Instrumentation 384 (100)
Urological Instrumentation 384 (100)
Table 9. The nature and number of available data for analysis
Variables Group A
N=111 
(28.9%)
Group B
N=86 
(22.4%)
Group C
N=36 
(9.4%)
Group D
N=151 
(39.3%)
Total
N=384 (100%)
Age>60 79 (28.8) 56 (34.9) 29 (19.4) 59 (60.9) 223 (41.9)
Male sex 80 (72.1) 56 (65.1) 21 (58.3) 122 (81.3) 279 (72.8)
Lower GI 
Instrumentation
5 (4.5) 3 (3.5) 1 (2.8) 5 (3.3) 14 (3.6)
Upper GI 
Instrumentation
5 (4.5) 6 (7.0) 2 (5.6) 4 (2.6) 17 (4.4)
Urological 
Instrumentation
24 (21.6) 4 (4.7) 2 (5.6) 4 (2.6) 34 (8.9)
Enterococcal bacteriuria 
(within 1 year)
3 (2.7)
Enterococcal bacteriuria 
(at presentation)
6 (5.4)
IVDU 6 (6.7) 2 (2.5) 0 (0) 7 (5.6) 15 (4.7)
Congenital cardiac 
anomaly
2 (2.2) 5 (6.3) 1 (3.6) 26 (20.6) 34 (10.5)
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Variables Group A
N=111 
(28.9%)
Group B
N=86 
(22.4%)
Group C
N=36 
(9.4%)
Group D
N=151 
(39.3%)
Total
N=384 (100%)
Acquired cardiac 
anomaly
39 (43.3) 40 (50.6) 14 (48.3) 41 (32.5) 134 (41.4)
Intracardiac prosthetic 
device
33 (36.7) 42 (53.2) 7 (24.1) 31 (24.6) 113 (34.9)
Haemodyalysis 4 (4.4) 10 (12.7) 1 (3.6) 3 (2.4) 18 (5.6)
V
alve
Aortic 61 (55.0) 43 (50.0) 18 (50.0) 75 (49.7) 197 (51.3)
Mitral 40 (36.0) 25 (29.1) 19 (52.8) 64 (42.4) 148 (38.5)
Pulmonary 2 (1.8) 0 (0) 0(0) 7 (4.6) 9 (2.3)
Tricuspid 2 (1.8) 9 (10.5) 0 (0) 7 (4.6) 18 (4.7)
Native valve IE 66 (59.5) 37 (43.0) 27 (75.0) 120 (79.5) 250 (65.1)
Prosthetic 
valve IE
Early 15 (13.5) 21 (24.4) 5 (13.9) 4 (2.6) 45 (11.7)
Late 16 (14.4) 7 (8.1) 4 (11.1) 17 (11.3) 44 (11.5)
Pacemaker lead IE 2 (1.8) 11 (12.8) 0 (0) 2 (1.3) 15 (3.9)
Table 10. Demographics of patients included in the case control study of 
investigating the association of IE and risk factors
Greyed out boxes indicate no data collected.
Three hundred and eighty-four (384) patients were included in this study. Table 
10 shows the basic demographics and patient characteristics; 58% of all 
patients were above 60 years old, with the oral streptococcal IE group having 
the lowest proportion of patients over 60 years old. The age density histogram 
in Figure 6 shows the distribution of the patients per age group. The line 
superimposed on the bar graph shows that there is a sharp rise in patients 
diagnosed with IE after the age of 50. 
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Figure 6. Histogram of age of patients.
Overall, there was a male predominance (72.8% of all patients). The highest 
proportion of female patients was in Group C. Urological or gastrointestinal 
procedures were relatively uncommon in the total cohort but over 20% of 
patients in the enterococcal IE group had undergone a urological procedure in 
the 12 months prior to presentation. Forty-one percent (41%) of patients had an 
acquired cardiac abnormality (stenosis or regurgitation) whilst only 10% of the 
patients were born with a congenital cardiac abnormality. Over a third of the 
patients had previous cardiac valvular surgery; 53.2% of the patients in Group B 
had an intracardiac prosthetic device. A minority of patients were intravenous 
drug users (4.7%) or were dependent on haemodyalysis (5.6%). Most IE 
episodes affected native cardiac valves (65%), with the aortic valve most 
commonly affected.
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Figure 7. Pie Chart showing the proportion of patients in in the four different 
groups of patients with IE.
The pie charts above visually demonstrate the proportion of patients per group. 
The oral streptococcal group was the largest ‘case’ group with the control group 
being twice its size. The Streptococcus bovis group was the smallest ‘case’ 
group with the ‘control’ group being ten-fold larger.
2.3.2 Statistical analysis
Bradford-Hill criteria were used to investigate the association between the 
development of IE and the possible risk-factors [187]. The main principles of the 
Bradford-Hill rule of association stipulate that an association (between 
instrumentation and the development of IE) can be regarded as causative if:
1. the strength of the association between instrumentation and the 
development of IE is significant enough (p values);
2. the association of instrumentation is repeatedly noted in the group of 
patients developing IE (consistency);
3. the association of instrumentation is specific to a particular group of 
patients developing IE. This is accounted for by linking the development of 
IE by a particular organism to the natural habitat of the said organism in 
the human body;
4. there is a temporal relationship between the development of IE and 
instrumentation. It is unlikely that the development of IE would be the 
cause of instrumentation in the group of patients;
Enterococcus faecalisCoNS
Streptococcus bovisOral streptococcus
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5. an increase in the number of episodes of instrumentation results in an 
increase in the incidence of IE in the patient group (biological gradient)
6. the plausibility that IE is the result of instrumentation. This is further 
verified in the second part of the study, which investigates the 
development of bacteraemia secondary to instrumentation of the 
urological tract. This bacteraemia in turn may lead to the development of 
IE.
The data were cleaned up and any discrepancies in the source data were 
updated by checking the patient pathway manager (PPM) electronic database. 
It was ascertained that the data from the IE database corroborated with the data 
available from the patient pathway management system, which tracks the 
patient journey through the different departments in the hospital. In case of 
discrepancy from the two data source, the PPM data was used as the actual 
data. Data missing from the IE database were actively searched for on the PPM 
database and the IE database updated accordingly. 
The data were converted to binary variables (0: absent and 1: present). The 
software programs used were IBM SPSS Statistics, Version 19.0.0 and 
R-Studio, Version 0.95.265. Missing data were replaced using the multiple 
imputations method using SPSS Statistics. Univariate and multivariate analysis 
were performed using SPSS (Version 19.0.0, IBM Company, Chicago, USA). A 
logistic regression model was used for the multivariate analysis. Missing data 
patterns were identified and a multiple imputation method was used to complete 
the data set.
2.3.2.1 Preliminary Analysis
The variables included in the initial analysis shown in Table 11. Basic statistical 
analysis was done using a 2 by 2 cross table to investigate a possible 
association between the development of IE and the different variables.
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Variable (Exposure) Outcome
Urological Instrumentation within 1 year 0 or 1
Upper GI Instrumentation within 1 year 0 or 1
Lower GI instrumentation within 1 year 0 or 1
Age>60 0 or 1
Age Continuous
Sex (male) 0 or 1
Intravenous drug user (IVDU) 0 or 1
Haemodyalysis 0 or 1
Congenital cardiac anomaly 0 or 1
Acquired cardiac anomaly 0 or 1
Intracardiac prosthesis (valve, pacemaker) 0 or 1
Enterococcal bacteriuria at presentation 0 or 1
Enterococcal bacteriuria within 1 year 0 or 1
Table 11. Variables used to investigate an association with the development 
of IE
The detailed analyses from the univariate statistical tests performed for patients 
with enterococcal IE are shown in Tables 12-23. Each variable with a suspected 
association with the development of enterococcal IE was assessed.
Enterococcal IE
Total0 1
Sex of 
Patient
Female Count 73 31 104
% within Sex of Patient 70.2% 29.8% 100.0%
Male Count 200 80 280
% within Sex of Patient 71.4% 28.6% 100.0%
Total Count 273 111 384
% within Sex of Patient 71.1% 28.9% 100.0%
Value
95% Confidence Interval
Lower Upper
Odds Ratio for Sex of Patient (Female / Male) 0.94 0.58 1.53
Table 12. Risk Estimate (sex and enterococcal IE)
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The sex of the patient did not appear to be an important variable in determining 
whether a patient developed enterococcal IE or one of the three other types of 
IE (OR: 0.94, CI: 058-1.53).
Table 13. Risk estimate (enterococcal bacteriuria within a year of presentation 
and enterococcal IE)
The number of patients with enterococcal bacteriuria identified within one year 
of presentation of their enterococcal IE episode was too few to perform any 
meaningful statistical test.
Enterococcal 
IE
Total0 1
Enterococcal 
Bacteriuria 
(within 1 
year)
0 Count 137 108 245
% within Enterococcal Bacteriuria (within 1 
year)
55.9% 44.1% 100.0
%
1 Count 0 3 3
% within Enterococcal Bacteriuria (within 1 
year)
.0% 100.0
%
100.0
%
Total Count 137 111 248
% within Enterococcal Bacteriuria (within 1 
year)
55.2% 44.8% 100.0
%
Value
95% Confidence Interval
Lower Upper
For cohort Enterococcal IE = 1 0.44 0.38 0.51
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Enterococcal IE
Total0 1
Enterococcal 
Bacteriuria 
(at presentation)
0 Count 135 105 240
% within Enterococcal Bacteriuria 
(at presentation)
56.2% 43.8% 100.0%
1 Count 2 6 8
% within Enterococcal Bacteriuria 
(at presentation)
25.0% 75.0% 100.0%
Total
Count 137 111 248
% within Enterococcal Bacteriuria 
(at presentation)
55.2% 44.8% 100.0%
Value
95% Confidence Interval
Lower Upper
Odds Ratio for Enterococcal bacteriuria (at 
presentation) (0 / 1)
3.86 0.76 19.5
Table 14. Risk estimate (enterococcal bacteriuria at presentation and 
enterococcal IE)
Again, the number of patients presenting with bacteriuria on admission for their 
IE episode is very small though statistical analysis gives an impression that 
there is an association with the presence of enterococcal IE (OR: 3.86, CI: 0.76-
19.5).
Enterococcal IE
Total0 1
Urological 
Instrumentation
0 Count 264 87 351
% within Urological Instrumentation 75.2% 24.8% 100.0%
1 Count 10 24 34
% within Urological Instrumentation 29.4% 70.6% 100.0%
Total Count 274 111 385
% within Urological Instrumentation 71.2% 28.8% 100.0%
Value
95% Confidence Interval
Lower Upper
Odds Ratio for Urological Instrumentation (0 / 1) 7.28 3.35 15.8
Table 15. Risk estimate (urological instrumentation and enterococcal IE)
The odds ratio of 7.28 (CI: 3.35-15.8) suggests that patients who have had 
urological instrumentation are seven times more likely to develop enterococcal 
IE as opposed to the three other types of IE investigated.
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Enterococcal IE
Total0 1
Lower GI 
Instrumentation
0 Count 264 106 370
% within Lower GI Instrumentation 71.4% 28.6% 100.0%
1 Count 10 5 15
% within Lower GI Instrumentation 66.7% 33.3% 100.0%
Total
Count 274 111 385
% within Lower GI Instrumentation 71.2% 28.8% 100.0%
Value
95% Confidence Interval
Lower Upper
Odds Ratio for Lower GI Instrumentation (0 / 1) 1.25 0.41 3.73
Table 16. Risk estimate (lower GI instrumentation and enterococcal IE)
Univariate analysis did not reveal any association between lower 
gastrointestinal instrumentation and the subsequent development of 
enterococcal IE.
Enterococcal IE
Total0 1
Upper GI 
Instrumentation
0 Count 261 106 367
% within Upper GI Instrumentation 71.1% 28.9% 100.0%
1 Count 13 5 18
% within Upper GI Instrumentation 72.2% 27.8% 100.0%
Total Count 274 111 385
% within Upper GI Instrumentation 71.2% 28.8% 100.0%
Value
95% Confidence Interval
Lower Upper
Odds Ratio for Upper GI 
Instrumentation (0 / 1)
0.95 0.33 2.72
Table 17. Risk estimate (Upper GI instrumentation and enterococcal IE)
Again, univariate analysis shows no statistical association between upper 
gastrointestinal instrumentation and the development of enterococcal IE.
It was decided to investigate whether older patients were more likely to develop 
enterococcal IE as opposed to the three other kinds of IE. A threshold of 60 
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years was used to divide the patient cohort into two approximately equal groups 
(the median age for the whole cohort: 60.2 years)
Enterococcal IE
Total0 1
Age>60
0 Count 129 32 161
% within Age>60 80.1% 19.9% 100.0%
1 Count 145 79 224
% within Age>60 64.7% 35.3% 100.0%
Total
Count 274 111 385
% within Age>60 71.2% 28.8% 100.0%
Value
95% Confidence Interval
Lower Upper
Odds Ratio for Age>60 (0 / 1) 2.20 1.37 3.53
Table 18. Risk estimate (age>60 and enterococcal IE)
An association between the development of enterococcal IE and the patient’s 
age being greater than 60 was noted with an OR: 2.20, CI 1.37-3.53.
Enterococcal IE
Total0 1
Intravenous 
Drug User
0
Count 224 84 308
% within Intravenous Drug User 72.7% 27.3% 100.0%
1
Count 9 6 15
% within Intravenous Drug User 60.0% 40.0% 100.0%
Total Count 233 90 323
% within Intravenous Drug User 72.1% 27.9% 100.0%
Value
95% Confidence Interval
Lower Upper
Odds Ratio for Intravenous Drug User 
(0 / 1)
1.78 0.61 5.15
Table 19. Risk estimate (intravenous drug user and enterococcal IE)
Univariate analysis did not reveal any statistical association between being an 
intravenous drug user and the subsequent development of enterococcal IE.
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Enterococcal IE
Total0 1
Congenital 
Cardiac 
Anomaly
0
Count 202 88 290
% within Congenital Cardiac Anomaly 69.7% 30.3% 100.0%
1
Count 32 2 34
% within Congenital Cardiac Anomaly 94.1% 5.9% 100.0%
Total
Count 234 90 324
% within Congenital Cardiac Anomaly 72.2% 27.8% 100.0%
Value
95% Confidence Interval
Lower Upper
Odds Ratio for Congenital Cardiac Anomaly 
(0 / 1)
0.14 0.03 0.61
Table 20. Risk estimate (congenital cardiac anomaly and enterococcal IE)
Univariate analysis showed that enterococcal IE was less likely to develop in 
patients a congenital cardiac anomaly.
Enterococcal IE
Total0 1
Acquired 
Cardiac 
Disease
0
Count 139 51 190
% within Acquired Cardiac Disease 73.2% 26.8% 100.0%
1
Count 96 39 135
% within Acquired Cardiac Disease 71.1% 28.9% 100.0%
Total
Count 235 90 325
% within Acquired Cardiac Disease 72.3% 27.7% 100.0%
Value
95% Confidence Interval
Lower Upper
Odds Ratio for Acquired Cardiac Disease
(0 / 1)
1.11 0.68 1.81
Table 21. Risk estimate (acquired cardiac anomaly and enterococcal IE)
Acquired cardiac anomaly did not have any bearing on the subsequent 
development of enterococcal IE.
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Enterococcal IE
Total0 1
Intracardiac 
Prosthesis
0
Count 154 57 211
% within Intracardiac Prosthesis 73.0% 27.0% 100.0%
1
Count 81 33 114
% within Intracardiac Prosthesis 71.1% 28.9% 100.0%
Total
Count 235 90 325
% within Intracardiac Prosthesis 72.3% 27.7% 100.0%
Value
95% Confidence Interval
Lower Upper
Odds Ratio for Intracardiac Prosthesis (0 / 1) 1.10 0.66 1.83
Table 22. Risk estimate (intracardiac prosthesis and enterococcal IE)
Univariate analysis did not demonstrate any association between the presence 
of an intracardiac device and the development of enterococcal IE.
Enterococcal IE
Total0 1
Haemodyalysis 
Patient
0 Count 219 86 305
% within Haemodyalysis Patient 71.8% 28.2% 100.0%
1 Count 14 4 18
% within Haemodyalysis Patient 77.8% 22.2% 100.0%
Total
Count 233 90 323
% within Haemodyalysis Patient 72.1% 27.9% 100.0%
Value
95% Confidence Interval
Lower Upper
Odds Ratio for Haemodialysis Patient (0 / 1) 0.73 0.23 2.27
Table 23. Risk estimate (haemodyalysis and enterococcal IE)
There was no statistical association between the development of enterococcal 
IE and the patient having haemodyalysis.
In conclusion, univariate analysis showed that enterococcal IE was associated 
with urological instrumentation and increasing age, whilst no statistical 
association was found between the other suspected risk factors. Then, the 
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same univariate analysis was carried out for the three other groups and the 
results are shown in Table 24.
Enterococcal IE 
group
CoNS
IE group
Streptococcus 
bovis IE group
Oral 
streptococcal IE 
group
Variable
Odds 
Ratio 
95% 
Confidence 
Interval 
Odds 
Ratio 
95% 
Confidence 
Interval 
Odds 
Ratio 
95% 
Confidence 
Interval 
Odds 
Ratio 
95% 
Confidence 
Interval 
S
ex 0.94 0.58-1.54 0.62 0.37-1.03 0.48 0.24-0.97 2.10 1.28-3.43
A
ge >60
2.20 1.37-3.53 1.46 0.88-2.40 3.27 1.40-7.67 0.27 0.17-0.49
E
nterococcal 
B
acteriuria (at 
presentation)
3.86 0.76-19.5
E
nterococcal 
B
acteriuria 
(w
ithin 1 year)
0.44 0.38-0.51
IVD
U 1.78 0.61-5.15 0.46 0.10-2.10 0.91 0.88-0.94 1.39 0.49-3.93
C
ongenital 
cardiac 
anom
aly 0.14 0.03-0.61 0.50 0.19-1.35 0.30 0.04-2.24 6.18 2.70-14.1
A
cquired 
cardiac 
anom
aly 1.11 0.68-1.81 1.63 0.98-2.72 1.35 0.63-2.90 0.54 0.34-0.86
Intracardiac 
prosthesis
1.10 0.66-1.83 2.74 1.63-4.62 0.56 0.23-1.36 0.46 0.28-0.80
H
aem
odyalysis
0.73 0.23-2.27 4.28 1.63-11.3 0.61 0.08-4.73 0.30 0.09-1.06
U
pper G
I 
P
rocedures
0.95 0.33-2.72 1.79 0.65-4.93 1.22 0.27-5.55 0.43 0.14-1.33
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Enterococcal IE 
group
CoNS
IE group
Streptococcus 
bovis IE group
Oral 
streptococcal IE 
group
Variable
Odds 
Ratio 
95% 
Confidence 
Interval
Odds 
Ratio 
95% 
Confidence 
Interval 
Odds 
Ratio 
95% 
Confidence 
Interval 
Odds 
Ratio 
95% 
Confidence 
Interval 
Low
er G
I 
P
rocedures
1.25 0.41-3.73 0.86 0.24-3.14 0.68 0.09-5.36 0.77 0.26-2.29
U
rological 
P
rocedures
7.28 3.35-15.8 0.44 0.15-1.28 0.58 0.13-2.54 0.19 0.06-0.54
Table 24. Univariate analysis evaluating the risk factors in the development of 
IE.  Data on enterococcal bacteriuria was collected for the 
enterococcal IE group only. The ‘greyed out’ boxes indicate that no 
data was available.
Patients with enterococcal IE were significantly more likely to be over 60 years 
of age (OR: 2.20) and to have undergone urological procedures (OR: 7.28) 
compared with patients in the other three IE groups. There was an association 
between the presence of enterococcal bacteriuria, at the time of the hospital 
admission when the IE episode was diagnosed, and enterococcal IE. The 
detailed analyses are described in more details above. The presence of an 
intracardiac prosthesis and being haemodyalysis dependent were associated 
(OR 2.74 and 4.28 respectively) with the development of CoNS IE compared to 
IE caused by the other pathogen groups. Increasing age was also associated 
with Streptococcus bovis group IE, whereas being male and having a 
congenital cardiac anomaly made patients more likely to develop oral 
streptococcal IE rather than the three other types of IE. Upper and lower 
gastrointestinal procedures were not associated with any of the four different 
types of IE.
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To strengthen the statistical analysis, unnecessary details were dropped 
(removed from the analysis). The following data were dropped: 
x the timing of urological, upper and lower GI instrumentation was 
documented as ‘within 1 year’, ‘within 6 month’ and ‘within 3 month’ of 
the subsequent development of IE. All the instrumentation was 
documented as 0 or 1, irrespective of the timing of the said exposure;
x age was initially considered as a binary data (Age > 60, Age  60) for the 
F2 crosstabs 2 by 2 analysis. In subsequent analysis (logistic regression), 
age was used as a continuous variable;
x upper and lower gastrointestinal instrumentation was no included in 
further analyses as univariate analyses revealed no statistical 
association with the subsequent development of IE.
2.3.2.2 Logistic regression model
A binomial logistic regression statistical model was used to evaluate the 
association between the development of the four disease possibilities and the 
variables deemed significant from the univariate analyses. The variables not 
deemed significant (based on the 2 by 2 F2 test) were not included to avoid 
confounding the effects of the included variables on the final outcome. 
Multivariate analysis using a logistic regression model was performed using 
SPSS (Version 19.0.0, IBM Company, Chicago, USA).
2.3.2.3 Missing data
Missing data were completed using a multiple imputations method, resulting in 
seven data sets (the original data set, five imputed data sets and one pooled 
data set). Imputations were carried out using the whole data set originally 
available. The standard imputation protocol inbuilt in SPSS was used to 
complete the data set. Table 25 below shows the patterns of missing data. 
Sensitivity analysis was undertaken to investigate if a bias might have arisen 
from some of the data being incomplete [188]. No evidence for bias was found. 
Sensitivity analysis yielded the same conclusions as the analysis on the 
incomplete data; the fitted values and their confidence intervals were not 
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substantially changed as shown by the results based on the original data and 
the pooled data after multiple imputations.
N
Missing Patterns
U
pper G
I
instrum
entation
Low
er G
I 
instrum
entation
U
rological 
instrum
entation
Sex
A
ge
Intracardiac 
prosthetic device
A
cquired cardiac 
anom
aly
C
ongenital 
cardiac anom
aly
H
aem
odyalysis
IVD
U
C
om
plete if ...
314 314
70 X X X X X 384
Table 25. Patterns of missing data
Three hundred and fourteen out of the 384 entries had a complete dataset, with 
70 entries having missing data. All the entries had a complete data set for the 
following variables:
x upper GI instrumentation;
x lower GI instrumentation;
x urological instrumentation;
x sex;
x age.
This was made possible as three different data sources were crosschecked to 
gather the data:
x the endocarditis spreadsheet;
x the patient pathway management (PPM) system;
x the hospital results database.
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As the hospital notes of patients were not accessed, it was not possible to 
gather all the data with respect to cardiac history, haemodyalysis and 
intravenous drug usage.
2.3.2.4 Multivariate Analysis
Multivariate analysis was performed on the initial data set, the five imputed data 
sets and the final pooled data set. The tables below show the results from the 
initial data set and the pooled data set for each of the four groups of patients.
Table 26. Multivariate analysis on the data for patients with enterococcal IE 
group.  Bold rows indicate variables that achieved statistical 
significance.
Table 26 shows the results of the multivariate analysis on the data relating to 
patients diagnosed with enterococcal IE. The analysis indicates that urological 
Variable
Model 
Coefficient
Standard 
Error
p-value Odds Ratio
95% CI for 
Odds Ratio
Lower Upper
Original 
data
Age 0.03 0.01 0.005 1.03 1.01 1.05
Sex 0.32 0.30 0.300 1.37 0.76 2.49
IVDU 1.90 0.69 0.006 6.69 1.72 26.1
Congenital Cardiac Anomaly -0.78 0.82 0.343 0.46 0.09 2.30
Acquired Cardiac Anomaly -0.17 0.37 0.642 0.84 0.41 1.73
Intracardiac prosthetic device 0.25 0.38 0.505 1.28 0.62 2.68
Haemodialysis -0.43 0.64 0.499 0.65 0.19 2.27
Urological Procedures 2.11 0.43 0.000 8.21 3.54 19.05
Constant -3.26 0.76 0.000 0.04
Pooled
Imputed 
data
Age 0.03 0.01 0.007 1.03 1.01 1.05
Sex 0.35 0.31 0.251 1.42 0.78 2.58
IVDU 1.74 0.68 0.011 5.72 1.50 21.77
Congenital Cardiac Anomaly -0.86 0.82 0.297 0.43 0.09 2.12
Acquired Cardiac Anomaly -0.25 0.37 0.499 0.78 0.38 1.60
Intracardiac prosthetic device 0.31 0.37 0.407 1.36 0.66 2.84
Haemodialysis -0.45 0.64 0.480 0.64 0.18 2.23
Urological Procedures 2.15 0.43 0.000 8.56 3.69 19.85
Constant -3.18 0.75 0.000 0.04 0.01 0.18
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procedures, within the one year preceding the diagnosis, were statistically 
associated with the development of enterococcal IE (OR: 8.21, CI: 3.54-19.05, 
p < 0.05). Enterococcal IE was also associated with increasing age (OR: 1.03, 
CI: 1.01–1.05, p < 0.05) and the patient being an intravenous drug user (OR: 
6.69, CI: 1.72–26.1, p < 0.05).
Variable
Model 
coefficient
Standard 
Error
p-value
Odds 
Ratio
95% CI for 
Odds Ratio
Lower Upper
Original 
data
Age -0.01 0.01 0.231 0.99 0.97 1.01
Sex 0.16 0.30 0.606 1.17 0.65 2.10
IVDU -0.90 0.86 0.297 0.41 0.08 2.21
Congenital Cardiac Anomaly -1.22 0.66 0.064 0.30 0.08 1.07
Acquired Cardiac Anomaly -.257 0.38 0.504 0.77 0.36 1.64
Intracardiac Prosthetic Device 1.46 0.39 0.000 4.28 2.00 9.16
Haemodialysis 1.96 0.54 0.000 7.06 2.48 20.1
Urological Procedures -0.98 0.59 0.096 0.38 0.12 1.19
Constant -0.86 0.65 0.188 0.423
Pooled 
Imputed 
Data
Age -0.01 0.01 0.241 0.99 0.97 1.01
Sex 0.17 0.30 0.564 1.19 0.66 2.15
IVDU -0.91 0.86 0.292 0.40 0.08 2.18
Congenital Cardiac Anomaly -1.24 0.65 0.059 0.29 0.08 1.05
Acquired Cardiac Anomaly -0.28 0.38 0.468 0.76 0.36 1.60
Intracardiac Prosthetic Device 1.47 0.39 0.000 4.34 2.04 9.23
Haemodialysis 1.96 0.54 0.000 7.06 2.48 20.1
Urological Procedures -0.98 0.59 0.094 0.38 0.12 1.15
Constant -0.88 0.65 0.178 0.42 0.12 1.49
Table 27. Multivariate analysis on the data for patients with CoNS IE group. 
Bold rows indicate variables that achieved statistical significance.
The analysis shows that CoNS IE was associated with the presence of an 
intracardiac prosthetic device (OR: 4.28, CI: 2.00–9.16, p < 0.05) and 
haemodialysis (OR: 7.06, CI: 2.48–20.1, p < 0.05).
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Variables
Model 
coefficient
Standard 
Error
p-value
Odds 
Ratio
95% CI for 
Odds Ratio
Lower Upper
Original 
data
Age 0.05 0.017 0.008 1.05 1.01 1.08
Sex 0.85 0.438 0.052 2.34 0.99 5.53
IVDU -17.2 10245 0.999 0.00 0.00 Infinity
Congenital Cardiac Anomaly 0.18 1.16 0.876 1.20 0.12 11.6
Acquired Cardiac Anomaly 0.45 0.51 0.380 1.56 0.58 4.22
Intracardiac prosthetic Device -1.42 0.58 0.015 0.24 0.08 0.76
Haemodyalysis -0.87 1.09 0.423 0.42 0.05 3.52
Urological Procedures -0.73 0.80 0.362 0.48 0.10 2.31
Constant -5.47 1.290 0.000 0.00
Pooled 
Imputed 
Data
Age 0.05 0.02 0.003 1.05 1.02 1.09
Sex 0.83 0.44 0.059 2.29 0.97 5.42
IVDU -6.25 6465 0.999 0.00 0.00 Infinity
Congenital Cardiac Anomaly 0.30 1.16 0.797 1.35 0.14 13.2
Acquired Cardiac Anomaly 0.57 0.50 0.250 1.77 0.67 4.68
Intracardiac prosthetic Device -1.52 0.58 0.008 0.22 0.07 0.68
Haemodyalysis -0.87 1.09 0.425 0.42 0.05 3.54
Urological Procedures -0.74 0.80 0.352 0.48 .010 2.27
Constant -5.85 1.31 0.000 0.00 0.00 0.04
Table 28. Multivariate analysis on the data for patients with Streptococcus 
bovis IE group.  Bold rows indicate variables that achieved 
statistical significance.
The results from the multivariable analysis show that Streptococcus bovis group 
IE was associated with increasing age (OR: 1.05, CI: 1.01–1.10, p < 0.05). An 
intracardiac prosthetic device appeared to be protective to the development of 
Streptococcus bovis IE with respect to the three other types of IE (OR: 0.24, CI: 
0.08–0.76, p < 0.05).
71
Variables
Model 
Coefficient
Standard 
Error
p-value
Odds 
Ratio
95% CI for Odds 
Ratio
Lower Upper
Original 
data
Age -0.03 0.01 0.001 0.97 0.96 0.99
Sex -0.80 0.30 0.009 0.45 0.25 0.82
IVDU -1.05 0.63 0.098 0.35 0.10 1.21
Congenital cardiac anomaly 0.82 0.54 0.128 2.26 0.79 6.47
Acquired Cardiac Anomaly 0.11 0.34 0.739 1.12 0.57 2.19
Intracardiac Prosthetic 
Device
-0.93 0.35 0.009 0.40 0.20 0.79
Haemodyalysis -1.41 0.68 0.038 0.24 0.06 0.92
Urological Procedures -1.70 0.57 0.003 0.18 0.06 0.56
Constant 1.96 0.60 0.001 7.12
Pooled 
Imputed 
Data
Age -0.03 0.01 0.001 0.97 0.95 0.99
Sex -0.85 0.31 0.006 0.43 0.23 0.78
IVDU -1.14 0.63 0.071 0.32 0.09 1.10
Congenital cardiac anomaly 0.79 0.53 0.137 2.21 0.78 6.29
Acquired Cardiac Anomaly 0.11 0.34 0.740 1.12 0.58 2.17
Intracardiac Prosthetic 
Device
-0.91 0.35 0.009 0.40 0.20 0.80
Haemodyalysis -1.41 0.68 0.038 0.24 0.06 0.93
Urological Procedures -1.73 0.57 0.002 0.18 0.06 0.54
Constant 2.07 0.60 0.001 7.92 2.42 25.9
Table 29. Multivariate analysis on the data for patients with oral streptococcal 
IE group.  Bold rows indicate variables that achieved statistical 
significance.
Table 29 shows that age, intracardiac prosthetic device, male sex, 
haemodialysis and urological procedures seem to have a protective effect 
against developing oral streptococcal IE. These results can be interpreted in the 
light that the ‘case’ group (oral streptococcal IE) was being compared of the 
three other ‘control groups’ (A, B and C). Therefore, one can deduce that older 
and male patients having urological procedures and dialysis are more likely to 
be in the control group than in the oral streptococcal group.
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Table 30. Diagrammatic representation showing the association between the 
development of the four different types of IE and the variables 
investigated
Table 30 is a diagrammatic representation of the different associations between 
the development of IE and the variables investigated. The key results are:
x this study shows that there is a strong association between urological 
instrumentation and the development of IE caused by enterococci (Group 
A). There is also an association between increasing age and IV drug 
usage and the development of IE caused by enterococci;
x staphylococcal IE is associated with prosthetic devices (haemodialysis 
lines and intracardiac prosthetic devices);
x Streptococcus bovis group IE is associated with increasing age;
x there does not seem to be a positive association between the 
development of oral streptococcal IE and the variables collected in this 
study.
2.4 Discussion
Endocarditis prophylaxis guidelines from the National Institute of Health and 
Clinical Excellence (NICE) no longer recommend antibiotic prophylaxis for 
routine urological and gastrointestinal procedures on the basis of a lack of 
evidence of a link between these procedures and IE [189]. Other national or 
international guideline development groups have taken a similar stand 
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[23, 190-198]. Infective endocarditis appears to be increasing in incidence in 
England [199], but the reasons for this can only be speculated upon [200].  The 
authors speculate that an ageing population, with more risk factors for the 
development of IE may in part explain the increase in incidence of IE. The 
increase in incidence appears to be independent of a huge reduction in 
prescriptions for antimicrobial prophylaxis by dental practitioners [199] but NICE 
recommendations remain controversial and many clinicians continue to 
prescribe IE prophylaxis for a variety of conditions. NICE included just three 
case–control studies that analysed the risk of developing IE after various 
procedures; two of these included gastrointestinal procedures and one 
procedure studied dental procedures. There has been no case–control study 
investigating urological investigations and subsequent development of IE.
This is, therefore, the first case–control study that has focussed on preceding 
urological and gastrointestinal investigations and development of IE. It is also 
the first case–control study to include only patients who have suffered from IE, 
thereby removing the problems of selecting an appropriate control group of ‘at 
risk’ patients. The validity of this approach is supported by the fact that the 
analysis confirms several findings that are already known such as the 
association between increasing age or IVDU and the development of 
enterococcal IE [201-203]; the association between CoNS IE and dependence 
upon haemodialysis (which can be explained by the ease of access of skin 
microbiota to the vascular system via the vascular catheters often used for 
haemodialysis [204-206]); and the well-known association between presence of 
an intracardiac prosthetic device and CoNS IE [23]. Increasing age and the 
development of Streptococcus bovis group IE has also been reported [207], 
which may be explained by the fact that Streptococcus bovis IE has been linked 
with bowel malignancy, with the incidence of the latter increasing with age [208, 
209]. It was speculated that patients with bowel symptoms and gastrointestinal 
neoplasia might be more likely to have gastrointestinal procedures and 
Streptococcus bovis group IE, in a similar manner to urological procedures and 
enterococcal IE, but this was not demonstrated in the analysis.
This study also demonstrates that patients diagnosed with enterococcal IE were 
more likely to have enterococcal bacteriuria at the time of presentation 
compared with the other patients diagnosed with IE, though statistical 
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significance was not achieved (OR: 3.86, CI: 0.76–19.5). This may be due to 
the relatively small number of patients with enterococcal IE who actually had 
documented enterococcal bacteriuria. This association between enterococcal 
bacteraemia and bacteriuria may be a similar phenomenon to Staphylococcus 
aureus bacteraemia and bacteriuria whereby bacteria in the blood can appear 
in the urine as a result of glomerular filtration [210]. The former hypothesis 
reinforces the theory that patients with enterococcal IE who undergo urological 
procedures have underlying urological pathology, which predisposes them to 
bacteriuria and subsequent bacteraemia. Another possible explanation for the 
association between the development of IE and prior urological procedures 
revolves around the inflammatory response mediated by the body during a 
procedure [33, 211]. This may explain why bacteraemia linked to iatrogenic 
procedures, which are associated with a state of inflammation, might have a 
higher likelihood of leading to infective endocarditis than bacteraemia 
secondary to mundane daily activities. However, there is no conclusive 
evidence of this hypothesis.
2.4.1 Interpretations
This study supports the NICE, American Heart Association (AHA) and 
European Society of Cardiology (ESC) recommendations not to give 
antimicrobial prophylaxis for gastrointestinal procedures. It does, however, 
demonstrate a statistical association between urological procedures and the 
development of enterococcal IE, which raises questions about the role of 
urological investigations in the development of enterococcal IE and the need for 
more information about the infective risks of such procedures. Similar to 
arguments relating to dentistry and IE, two possible explanations are proposed: 
1) urological procedures can cause an enterococcal bacteraemia, which (rarely) 
results in IE; or 2) patients with urological pathology are predisposed to 
enterococcal urinary tract infection (or colonisation) and spontaneous 
enterococcal bacteraemias, which may result in IE. The lack of consistent 
findings of previous enterococcal bacteriuria in enterococcal IE patients, 
suggests asymptomatic infection or colonisation may be involved.
2.4.2 Limitations
This is a retrospective study from a single hospital trust, but it should be noted 
that patients came from two large teaching hospitals as well from the 
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surrounding area. Although the cohort of patients may have been biased 
towards more complex cases, this will have applied to all cases of IE in the 
analysis. A retrospective, case–control design will always be subject to potential 
bias but a prospective randomised study would be impractical owing to the 
relative rarity of enterococcal IE. The case–control study design that has been 
used has overcome concerns about the validity of the control group, in terms of 
comparable risk of developing IE. By including only patients with IE, patients in 
both the ‘case’ and ‘control’ groups had risk factors for developing IE. This 
design has limitations: only cases caused by selected groups of pathogens 
were included. These groups were chosen because their natural habitats are 
well recognised and anatomically confined; Staphylococcus aureus was not 
included because of the wide variety of body sites that may be colonised or 
infected with the organism. The validity of this methodology is supported by the 
fact that the analysis confirms a number of previously reported associations.
The majority patients undergoing urological procedures included in this study 
will have received antibiotics prophylaxis as described in the Methods section 
though it was not possible to record the compliance with antimicrobial 
prophylaxis regimens reliably. It is noteworthy that these regimens do not have 
activity against enterococci. There were some missing data, but inclusion of a 
multiple imputations method and re-analysis of the data did not alter the 
findings. A sensitivity analysis based on completed datasets was undertaken; 
this showed no evidence of bias and consequently this sensitivity has provided 
greater confidence in the findings.
2.4.3 Generalisability
Further studies are required to evaluate the presence of bacteraemia during 
urological procedures, and cardiac valvular bacterial seeding pre- and post-
procedure, in patients with underlying urological pathology. An understanding of 
the incidence of bacteraemia during daily activities like urination would help 
guide further research so that more focussed recommendations about antibiotic 
prophylaxis could then be made.
2.5 Conclusions
This is the first case-control study to examine urological procedures as a risk 
factor in the development of IE. An association between urological procedures 
and enterococcal IE has been found. This study has also not demonstrated any 
association between gastrointestinal procedures and the development of IE. 
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The association between enterococcal IE and urological procedures raises 
questions about the pathogenesis of enterococcal IE. Can enterococcal IE 
result from bacteraemia caused by the procedure or are patients who undergo 
urological procedures more likely to have an underlying urological pathology 
that causes repeated bacteraemias in the period preceding the procedures? 
Both mechanisms may lead to the bacterial seeding of cardiac valves, but 
would warrant different approaches to prophylaxis.
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Chapter 3: Methods to detect bacteraemia
3.1 Introduction
This chapter describes the different methods used to detect, identify and 
quantify bacteria and bacteraemia.  The process of determining the optimal 
methods for assessing bacteraemia in the context of this study is described.  
The main technologies used were:
x incubation and culture of blood;
x extraction of bacterial DNA from blood;
o amplification of bacterial DNA by PCR;
o identification of bacterial DNA by sequencing and mass-
spectrometry technology (PLEX-ID).
The evolution of the methodologies used to refine the final methodology used 
for the clinical trial (Chapter 4) is described in this chapter.
3.2 Methods
3.2.1 In Vitro Studies
The aim of the in vitro studies was to evaluate a number of techniques to 
identify the most appropriate for use in the detection of bacteraemia during the 
prospective clinical study (Chapter 4).  As low-level bacteraemias were 
expected from the study patients, an assay that is able to detect low levels of 
bacteria in blood consistently was required.  Different methods to quantify the 
number of bacteria in blood were explored, to evaluate whether it was possible 
to measure the bacterial load in the patients recruited in the study.
3.2.2 Development of an assay to detect low level bacteraemias
Different techniques can be used to detect bacteria in blood.  The schematic 
diagram below shows the basic pathways.  In the hospital setting, the ‘culture 
method’ arm is traditionally used to detect and identify bacteraemia.  However, 
this method becomes unreliable if the patient has been given antibiotic therapy 
prior to collection of the blood for culture [212].  Furthermore, some bacteria are 
unreliably detected using this method, especially if the incubation time is short 
[213].  The ‘molecular method’ offers the potential benefit of additional 
sensitivity as well as the possibility to detect fastidious bacteria, even 
setting whereby the patients have received prior antibiotics therapy [212].
Figure 8. Methods to detect bacteraemia
A broad-range PCR method to detect and identify low levels of bacteria in blood 
has been designed and validated.  The use of broad
bacteria from positive culture bottles is widely reported [214].  Furthermore, 
broad-range PCR has also been shown to be an effective method in 
determining the nature of the pathogen in joint infection and culture negative IE 
[130].  However, the use of broad
detect bacteraemia is fraught with complications relating to contamination of the 
DNA sample [214].  At each of the steps involved in the molecular method 
(broadly DNA extraction, DNA amplifi
contamination may occur leading to false positive results.  Furthermore, at each 
step, the loss of bacterial DNA material can occur
results.
3.2.2.1 Incubation and Culture
In the first instance, the author needed to become accustomed to the basic 
principles of incubation and plating bacterial colonies.  Basic techniques like 
Gram staining and microscopy to identify the biochemical properties of various 
commonly encountered h
number of commercially available biochemical identification kits was explored.  
Culture
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Detection
Identification
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Thereafter, the Miles & Misra bacterial quantification method to determine the 
number of viable bacteria in broth was used [215].  Blood was seeded with 
bacteria to attempt to quantify the number of viable bacteria present using the 
Miles & Misra method of bacterial quantification.
3.2.2.2 Samples
Three of the most common organisms involved in infection in urological practice 
are Escherichia coli, Enterococcus faecalis and Staphylococcus epidermidis 
[55].  Therefore, it was decided that in vitro experiments would mainly involve 
these three organisms.
In the first instance, inocula of the organisms in Table 31 were acquired from 
the organism bank at the Leeds Teaching Hospitals NHS Trust.  All the above 
organisms were plated on Columbia blood agar (CBA) and cysteine lactose 
electrolyte deficient (CLED) plates.  All the organisms were incubated at 37° C 
in air.  The plates were read after 24 hours.  Growth was noted on all the plates.  
Each organism was inoculated in a tube of glycerol broth and stored in a freezer 
at around -70° C to -80° C.  This set of tubes was used as the organism bank 
for subsequent experiments.
Gram stained preparations of all the organisms were examined according to the 
standard operating protocol from the Health Protection Agency, now Public 
Health England.  The results are tabulated below.
80
Table 31. Organisms acquired from the organism bank (GP: Gram-positive, 
GN: Gram-negative)
The next step was for the author to become familiar with the analytical profile 
index (API) protocols by BioMerieux SA, Marcy-l'Etoile, France.  These are 
bacterial identification systems, developed in the 1970s, that allow for rapid 
identification of bacteria to species level.  The kits include strips that contain up 
to 20 miniature cupules in which biochemical reactions are tested.  Dilute 
bacterial suspensions are inoculated in each slot cupule of the API strip, which 
is then incubated appropriately, Following suitable incubation and the addition 
of certain reagents when appropriate, the results are read and noted on a 
scoring sheet.  This uses an octal scoring system to provide a unique number 
between 0 and 7 for each set of three tests.  APIweb™ is a software product 
containing all of the API databases that allows for an automated interpretation 
of API strip results [216].
The strips that were used were:
API® Gram-negative Identification:
• API 20E – 18-24 hour identification of Enterobacteriaceae and 
other non-fastidious gram negative bacteria;
• API Rapid 20E – 4-hour identification of Enterobacteriaceae;
ORGANISM Microscopy and Gram Stain
Enterococcus faecalis GP coccus
Escherichia coli GN rod
Extended spectrum E-lactamase Escherichia coli GN rod
Haemophilus influenzae GN rod
Klebsiella edwardsii GN rod
Pseudomonas aeruginosa GN rod
Staphylococcus epidermidis GP coccus
Staphylococcus aureus GP coccus
Meticillin-resistant Staphylococcus aureus GP coccus
Streptococcus penumoniae GP coccus
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• API 20NE – 24 to 48-hour identification of Gram-negative 
non-Enterobacteriacae.
API® Gram-positive Identification:
• API Staph – Overnight identification of clinical staphylococci and 
micrococci;
• RAPIDEC® Staph – 2-hour identification of the commonly 
occurring staphylococci;
• API 20 Strep – 4 or 24-hour identification of streptococci and 
enterococci API®.  
Anaerobe Identification:
• API 20A® – 24-hour identification of anaerobes;
• Rapid ID 32A – 4-hour identification of anaerobes.
This process allowed insight in the different biochemical reactions available for 
the identification of bacteria to species level.  However, owing to the funding 
restrictions, a decision was made not to continue using these methods.
3.3 Experiment 1 – Quantification of bacteria
An experiment to be able to quantify the number of bacterial colonies from a 
broth suspension was designed.
3.3.1 Method
The first step was to measure 900 ȝ/ VWHULOH ZDWHU LQ WHQ VWHULOH WXEHV  7KH
tubes were labelled A-J.  Tube A was inoculated with Enterococcus faecalis.  A 
100 ȝ/YROXPHRIWKHFRQWHQWVIURP7XEH$ZDVSLSHWWHGLQWR7XEH% ȝ/RI
the contents of Tube B was pipetted into Tube C and so on, until multiple ten 
ten-fold serial dilutions of the initial inoculum were obtained.  Volumes of 200 ȝ/
from each tube were plated on CLED plates, which were then incubated at 
37° C in air for 24 hours.
3.3.2 Results
All the bacterial growth on the CBA plates for any of the Tubes A-J was 
confluent and viable counts could thus not be made.  The above experiment 
was repeated but, instead, only 20 ȝ/VDPSOHYROXPHVZHUHXVHGLQFXEDWHGRQ
CLED agar for 24 hours in air at 37° C.  The results are shown in Table 32 
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below.  Tube E was used to calculate the number of bacterial cfu present in the 
initial broth suspension.
The mean count in Tube E was
(33 + 41 + 39 + 32 + 42 + 38) / 6 = 37.5 cfu/mL
Therefore, the bacterial count in the initial suspension was
(37.5 / 20 x 1000) x 104 = 1.9 x 107 cfu/mL
Tube
Count on 
Plate 1
Count on 
Plate 2
Count on 
Plate 3
Count on 
Plate 4
Count on 
Plate 5
Count on 
Plate 6
A
(original)
Confluent Confluent Confluent Confluent Confluent Confluent
B 
(x 10-1)
Confluent Confluent Confluent Confluent Confluent Confluent
C
(x 10-2)
Confluent Confluent Confluent Confluent Confluent Confluent
D
(x 10-3)
Confluent Confluent Confluent Confluent Confluent Confluent
E
(x 10-4)
33 41 39 32 42 38
F
(x 10-5)
<20 <20 <20 <20 <20 <20
G
(x 10-6)
Not
detected
Not
detected
Not
detected
Not
detected
Not
detected
Not
detected
H
(x 10-7)
Not
detected
Not
detected
Not
detected
Not
detected
Not
detected
Not
detected
Table 32. Quantification of Enterococcus faecalis
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Figure 9. CLED plate showing the results of a Miles and Misra dilution series 
to determine viable bacterial counts
3.4 Experiment 2 – Quantification of bacteria from incubated 
broth
The next experiment was to quantify the number of bacteria in an incubated 
broth.
3.4.1 Method
Two brain heart infusion (BHI) broth tubes (10 ml), labelled Tube X and Y, were 
inoculated with Enterococcus faecalis.  Both tubes were incubated at 37° C in 
air.  After 6 hours of incubation, Tube X was taken out of the incubator and 
serially diluted tenfold with sterile water to obtain eight successive suspensions 
(A-H).  The eight suspensions were plated on CLED plates in 20 ȝ/YROXPHVWR
allow quantification.  The plates were incubated at 37° C in air and read at 
24 hours.  Tube Y was incubated for 18 hours and the above process repeated.
3.4.2 Results
Tubes X, A, B, C and D yielded confluent bacterial growth making it impossible 
to count the number of bacterial colonies.  Tubes F, G and H grew less than 
20 cfu.  Therefore, Tube E was used for quantification purposes.
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The mean count in Tube E was
[(33 + 33 + 27 + 34 + 33 + 36) / 6] / 20 x 100 = 1.8 x 103 cfu/mL
Therefore, the mean count in the initial suspension was
= 1.8 x 103 x 105 = 1.8 x 108 cfu/mL
The mean count in Tube Y was
9.8 x 108 cfu/mL
Experiment 2 was repeated three times with the three common organisms 
encountered in urology (Enterococcus faecalis, Escherichia coli and
Staphylococcus epidermidis).  The bacterial growth curve below shows that the 
stationary phase is reached after 5 to 6 hours of incubation.
Figure 10. A typical bacterial growth curve 
3.5 Experiment 3 – Quantification of bacteria from blood
The next step was to quantify the number of bacteria in blood.  Whole research 
blood was ordered from the NHS Blood and Transplant Service for the following 
experiments.
3.5.1 Method
Enterococcus faecalis was inoculated in BHI broths (bottles containing 10 ml
each), which were incubated at 37° C in air for 6 hours.  The initial suspension 
was serially diluted tenfold with sterile molecular grade water to obtain eight 
different suspensions (Tubes A-G).
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The following tubes of blood spiked with bacteria were obtained:
4 mL of Tube B + 4 mL of Blood = Tube X
4 mL of Tube D + 4 mL of Blood = Tube Y
4 mL of molecular grade water + 4 mL of Blood = Tube Z
Six inocula of 20 ȝ/RI WKHVXVSHQVLRQVIURP7XEH;<DQG=ZHUHSODWHGRQ
CLED and incubated for 24 hours in air at 37° C.  Tube E and F were then 
serially diluted tenfold using blood to obtain eight diluted blood suspensions 
from each initial tube.  Six inocula of 20 ȝ/HDFKRIWKHVXVSHQVLRQVIURP7XEH
X, Y and Z were plated on CLED and incubated for 24 hours in air at 37° C.  
The suspensions (in six 20 ȝ/YROXPHVZHUHSODWHGIRUTXDQWLILFDWLRQSXUSRVHV
3.5.2 Results
The results are shows in the Table 33 below.
Plates Quantitation Plates Quantitation
Tube X Confluent Tube Y Confluent
Tube X x 10-1 Confluent Tube Y x 10-1 Confluent
Tube X x 10-2 Confluent Tube Y x 10-2 Confluent
Tube X x 10-3 Confluent Tube Y x 10-3 Confluent
Tube X x 10-4 Confluent Tube Y x 10-4 (22+34+27+52+22+32)/6
=31.5 cfu
Tube X x 10-5 Confluent Tube Y x 10-5 Too few
Tube X x 10-6 (19+29+28+26+26+32)/6
=26.2 cfu
Tube Y x 10-6 No growth
Tube X x 10-7 Too few Tube Y x 10-7 No growth
Tube E x 10-8 No growth Tube Y x 10-8 No growth
Tube Z No growth
Table 33. Suspensions plated in 6 x 20 ȝ/YROXPHVIRUquantification
BHI Broth tubes inoculated with 
Enterococcus faecalis
Tubes incubated at 37o
At 6 hours, tenfold serial dilutions were 
done 
3 ml blood spiked with Enterococcus 
faecalis from broth tubes A1 and A2 to 
obtain tubes S1 and S2
S1 and S2 processed as per 
SepsiTestTM protocol
At 37 C in air in a stationary position
1 ml of  A1 and A2 were incubated for
1 hour
20 µL of A1 and A2 were  plated on  
CLED agar  (D1 and D2 respectively) 
and repeated six times
The plates D1 and D2 were incubated in 
a stationary position at 37 C in air and 
read at 18 hours.
The colony count was noted and the 
numbers of bacteria per ml in Tubes  A1 
and A2 calculated
Ct values of  A1 and A2 were obtained 
and the quantification of bacteria in A1 
and A2 calculated
86
Therefore, the numbers of Enterococcus 
faecalis in the spiked blood samples were:
Sample X = (26.2/20) x 1000 x 10
1.3 x 109 cfu/mL
Sample Y = (31.5/20) x 1000 x 10
2.9 x 107 cfu/mL
Experiment 3 showed that quantification
possible from blood spiked with 
Enterococcus faecalis.
3.6 Experiment 4 – Molecular 
microbiological method to detect 
bacteraemia
Experiment 4 was designed to evaluate the 
use of molecular methods to detect 
bacteraemia.  SepsiTest™ by Molzym was 
used to detect bacterial DNA.  Sepsi
a kit developed by Molzym GmbH & Co.  KG
Bremen, Germany, with a protocol to identify 
bacteria from blood.  SepsiTest™
on the real-time PCR detection and 
sequence identification of organisms.  This 
molecular method provides the first results of 
positivity after only four hours.  In pos
cases, sequence analysis of the amplimers 
results in the readout of the species.  
SepsiTest™ requires 1 mL of blood and can 
detect three hundred and forty
human pathogens.
Figure 11.  Algorithm for Experiment 4
C  in air
6 =
4 =
was 
Test™ is 
, 
is based 
itive 
-five (345) 
3.6.1 Method – Part 1
The following consumables were required for the experiment:
• 12 mL (4
• green-top blood bottles (containing lithium heparin) from Becton 
Dickinson (BD), UK
• BHI Broth tubes
• Dilution bijoux bottles
• Distilled water
• CLED and CBA a
• Molzym SepsiTest™ kit
Two BHI broth tubes were each inoculated with one 1
Enterococcus faecalis
labelled A1 and A2.  A third BHI broth was labelled A3.  This tube was not 
inoculated with any organism.
Figure 12. Serial dilutions of A1
A1, A2 and A3 were thoroughly shaken and were then incubated in a stationary 
position at 37° C for four
the incubator, shaken, placed on the 
A1
•Starting unknown concentration of A1
A1- 10-1
•1 ml of A1 was added to 9 mL of distilled water
A1 - 10-2
•1 ml of the previous solution was added to 9 mL of distilled water
A1 - 10-3
•1 ml of the previous solution was added to 9 mL of distilled water
A1 - 104
•1 ml of the previous solution was added to 9 mL of distilled water
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mL x 3) of fresh human blood
x 2
gar plates
mm colony of 
grown on a CLED agar plate.  The two tubes were 
hours.  At 4 hours, A1, A2 and A3 were taken out of 
laboratory bench and observed.
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3.6.2 Results – Part 1
Tubes Appearance
A1 Cloudy
A2 Cloudy
A3 Clear
Table 34. Appearance of BHI broths tubes after 4 hours of incubation At 37° C
Cloudiness in the broths indicated bacterial proliferation.  Tube A1 was used for 
further experiments.  Tubes A2 (as Tube A1 was deemed adequate for the 
further experiments) and A3 were discarded.
3.6.3 Method – Part 2
The contents of Tube A1 were serially diluted tenfold using sterile 20 mL bijoux 
tubes as per the algorithm in Figure 12.  Three green-top tubes were labelled B, 
C and D and 4 mL of blood was added to each tube.  A 4 mL volume of the 
second (A1-10-2) and fourth dilution (A1-10-4) were pipetted in Tubes B and C 
respectively.  A 4 mL volume of distilled water was pipetted to Tube D.
Three CLED agar plates and three CBA agar plates were labelled.  The six 
plates were divided into twelve segments each.  In each segment of plates 
B-CBA and B-CLED, 20 ȝ/RIWKHVXVSHQVLRQIURP7XEH B was pipetted.  This 
procedure was repeated for suspensions in Tubes C and D until all six plates 
were inoculated with their corresponding suspensions.  The plates were 
incubated for 18 hours at 37° C in air.
3.6.4 Results – Part 2
All the segments on plates B-CLED, B-CBA, C-CLED and C-CBA were 
confluent.  There was no growth on the bacteria-free control plates.
3.6.5 Methods – Part 3
As all the bacterial growth was confluent and precluded quantification, Tube B 
was diluted serially as follows.
Figure 13. Serial dilutions of Tube B
Four CLED and four CBA agar plates were divided into six segments each as 
described above.  Samples from tubes X1, X2, X3 and X4 were plated on the 
both CBA and CLED as follows.
Figure 14. Algorithm for plating the diluted suspensions of Tube
The eight plates obtained were labelled.  
and was diluted serially as shown in Figure
Figure 15. Serial dilutions of Tube
Four CLED and four CBA agar plates were divided into six segments each as 
described above.  Samples from Y2, Y3, Y4 and Y5 were plated on the both 
CBA and CLED agar as follows.  The eight plates thus obtained were labelled.  
The sixteen plates were incubat
were read by counting the number of
CBA plates.
X0
• Neat cell suspension
X1
• 100 µL of X0 is added
X2
• 500 µL of X1 is added
X3
• 200 µL of X1 is added
X4
• 100 µL of X1 is added
20 µL of X1 was 
pipetted in a 
segment of a 
CLED plate
Y0 •Starting cell suspension
Y1 •100 µL of Y0 is added
Y2 •100 µL of Y1 is added
Y3 •100 µL of Y2 is added
Y4 •500 µL of Y3 is added
Y5 •200 µL of Y3 is added
Y6 •100 µL of Y3 is added
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Tube C was handled slightly differently 
15 below.
C
ed for 18 hours at 37° C.  Plates X1
cfu per 20 ȝ/LQRFXODQWVRQWKH&/('DQG
to 900 µL of distilled water (1 in 10 dilution)
to 500 µL of distilled water (1 in 20 dilution)
to 800 µL of distilled water (1 in 50 dilution)
to 900 µL of distilled water (1 in 100 dilution)
This was 
repeated for the 
other 5 segments 
of the CLED 
plate
The two previous 
processes were 
repeated on a 
CBA plate.
The three 
previous 
processes were 
repeated for X2, 
X3 and X4.
to 900µL of distilled water (1 in 10 dilution)
to 900µL of distilled water (1 in 100 dilution)
to 100µL of distilled water (1 in 200 dilution)
to 500µL of distilled water (1 in 400 dilution)
to 800µL of distilled water (1 in 800 dilution)
to 900µL of distilled water (1 in 4000 dilution)
B
-4 and Y2- 5 
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3.6.6 Results – Part 3
The results are shown in Table 35 below.
CLED Plate CBA Plate
X1-CLED X1-CBA
Count per 
segment
54 59 47 55 N N 48 58 56 44 N N
X2-CLED X2-CBA
Count per 
segment
29 29 30 39 28 26 21 32 20 18 27 31
X3-CLED X3-CBA
Count per 
segment
F F F F F F F F F F F F
X4-CLED X4-CBA
Count per 
segment
F F F F F F F F F F F F
Table 35. Quantification on plates X1-4 
F = too few to count; N = not inoculated; T = too many to count
The results for plates Y are shown below.
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CLED Plate CBA Plate
Y2-CLED Y2-CBA
Count per 
segment
T T T T N N T T T T N N
Y3-CLED Y3-CBA
Count per 
segment
26 31 28 26 37 24 39 35 28 32 33 37
Y4-CLED Y4-CBA
Count per 
segment
9 13 10 13 8 9 9 15 9 13 14 11
Y5-CLED Y5-CBA
Count per 
segment
F F F F F F F F F F F F
Table 36. Quantification on plates Y2-5
F = too few to count; N = not inoculated; T = too many to count
The mean bacterial counts and the concentrations of the initial suspensions are 
shown in Table 37 below.
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Plate
CLED CBA
Average 
Count/CFU
Number of bacteria 
in the initial 
suspension /ml
Average 
Count/CFU
Number of bacteria 
in the initial 
suspension/ml
X1
(1/10)
53.75 2.69 x 108 51.5 2.57 x 108
X2
(1/20)
30.2 3.02 x 108 24.8 2.48 x 108
Y3
(1/200)
28.7 2.87 x 108 34 3.40 x 108
Y4
(1/400)
10.3 2.57 x 108 11.8 2.95 x 108
Table 37. Mean counts and bacterial concentrations.
Therefore, the mean number of bacteria per mL in suspension B (X0) =
{(2.69+2.57+3.02+2.48)/4} x 108 = 2.69 x 108 cfu/mL
and, the mean number of bacteria per mL in suspension C (Y0) =
{(2.87+3.40+2.57+2.95)/4} x 108 = 2.94 x 108 cfu/mL
3.6.7 Methods – Part 4
Once the growth and quantification methods were performed using the 
traditional culture methods described above, samples B, C and D were also 
used to identify and quantify the bacteraemia present using SepsiTest™.  The 
three samples (B, C and D) were processed in duplicates.  The SepsiTest™
methodology was used and the samples in Table 37 above were amplified 
using the MxPro-Mx3000P thermocycler from Stratagene.  Owing to time 
constraints, the process was run over three separate days as follows.
x Day 1: Step 1-7 for bacterial DNA extraction.  The samples were then
stored at -15° C;
x Day 2: Step 8-18 for the completion of the DNA extraction.  The samples 
were stored at -15° C;
x Day 3: DNA amplification using the thermal profile advised by the 
SepsiTest™ manual.
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3.6.8 Results – Part 4
The results of the molecular experiments good amplification of the bacterial 
DNA was noted with Ct values as low as nineteen cycles noted.  Sharp and 
narrow melting curves were noted at temperatures between 88-92° C.
Sample Contents Ct Values
NC Negative Control (Bacteria Mastermix + DNA free water) 22.98
IC-B1 Internal Control (IC Mastermix + B1 DNA) 26.51
IC-B2 Internal Control (IC Mastermix + B2 DNA) 26.52
IC-C1 Internal Control (IC Mastermix + C1 DNA) 26.01
IC-C2 Internal Control (IC Mastermix + C2 DNA) 27.91
IC-D1 Internal Control (IC Mastermix + D1 DNA) 28.63
IC-D2 Internal Control (IC Mastermix + D2 DNA) 25.75
IC-Water Internal Control (IC Mastermix + DNA-free water) 27.17
B1 Bacteria Mastermix + B1 DNA 26.27
B2 Bacteria Mastermix + B2 DNA 25.31
C1 Bacteria Mastermix + C1 DNA 25.90
C2 Bacteria Mastermix + C2 DNA 19.72
D1 Bacteria Mastermix + D1 DNA 23.34
D2 Bacteria Mastermix + D2 DNA 23.55
P1 Bacteria Mastermix + P1 DNA 22.84
P2 Bacteria Mastermix + P2 DNA 29.28
Table 38. Samples processed by the SepsiTest™ method and their Ct values
Table 38 above shows the Ct values of the samples processed using the 
SepsiTest™ method.  Experiment 4 showed that it was possible to quantify the 
number of bacteria using the culture method.  The molecular method was able 
to detect the bacteria in blood and further work was required to evaluate 
whether quantification using the molecular method was possible.
3.7 Experiment 5 
Experiment 5 was designed to evaluate whether it was possible to quantify 
low-level bacteraemia using the Sepsi
Enterococcus faecalis 
3.7.1 Method
Three tubes of BHI broths, containing 10 ml of broth each, were labelled A, B 
and C.  Tube A was inoculated with two 1
faecalis.  Tube B was inoculated with twenty 1
faecalis.  Tube C was not inoculated with any organism.  Tubes A, B and C 
were incubated for 6
cloudy, Tube B was very cloudy and Tube C was clear.  Suspension B was 
used for further tests.  Tube B was re
shown in Figure 18 below.
Figure 16. Dilutions of the BHI broth from Tube B
A 200 ȝ/ YROXPH RI VXVSHQVLRQ < ZDV SLSHWWHG LQWR 
blood to produce suspension PY and subsequent tenfold dilutions were 
performed as shown in Figure 19 below.  
Figure 17. Serial dilutions of spiked blood
The following suspensions were used for molecular processing:
Y1 •100 µL of Y is added
Y2 •100 µL of Y1 is added
Y3 •100 µL of Y2 is added
Y4 •100 µL of Y3 is added
Y5 •100 µL of Y4 is added
Y6 •100 µL of Y5 is added
Y7 •100 µL of Y6 is added
PY1 • 200 µL of Y is added to 1800 µL of blood (1/10 dilution)
PY2 • 200 µL of PY1 is added to 1800 µL of blood (1/100 dilution)
PY3 • 200 µL of PY2 is added to 1800 µL of blood (1/1000 dilution)
PY4 • 200 µL of PY3 is added to 1800 µL of blood (1/10000 dilution)
PY5 • 200 µL of PY4 is added to 1800 µL of blood (1/100000 dilution)
PY6 • 200 µL of PY5 is added to 1800 µL of blood (1/1000000 dilution)
PY7 • 200 µL of PY6 is added to 1800 µL of blood (1/10000000 dilution)
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- SepsiTest™
Test™ kit.  The organism used was 
from a previous plate growth. 
mm colony of the 
mm colonies of the 
hours at 37° C in air.  At 6 hours, Tube A was mildly 
-labelled as Y and serially diluted as 
mL of bacteria
to 900 µL of molecular water (1/10 dilution)
to 900 µL of molecular water (1/100 dilution)
to 900 µL of molecular water (1/1000 dilution)
to 900 µL of molecular water (1/10000 dilution
to 900 µL of molecular water (1/100000 dilution)
to 900 µL of molecular water (1/1000000 dilution)
to 900 µL of molecular water (1/10000000 dilution)
Enterococcus 
Enterococcus 
-free 
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x PY, PY1, PY2, PY3, PY4, PY5, PY6, PY7 and C, with C being 2 mL of 
blood without any inoculant.
For the Miles and Misra method of quantification, the following suspensions 
were used:
x Y1, Y2, Y3, Y4, Y5, Y6 and Y7.
Bacterial DNA from the nine samples (C, PY, PY1, PY2, PY3, PY4, PY5, PY6 
and PY7) was extracted in duplicates using the SepsiTest™ protocol.  The 
extracted bacterial DNA was, in turn, amplified in triplicate using the 
SepsiTest™ protocol.  This process resulted in forty-eight separate samples 
and Ct values were obtained for the forty-eight samples.  A 20 ȝ/ YROXPH RI
each of Y1-7 were plated on CBA Agar plates in sextuplicate and incubated for 
18 hours at 37° C in air to allow quantification.
3.7.2 Results
The concentrations of the eight starting suspensions were calculated and 
tabulated, using the Miles and Misra quantification method.
Suspension Number of cfu/ml
Y 8.25 x 108
Y1 8.25 x 107
Y2 8.25 x 106
Y3 8.25 x 105
Y4 8.25 x 104
Y5 8.25 x 103
Y6 8.25 x 102
Y7 8.25 x 101
Table 39. Quantification using the culture method
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The SepsiTest™ method yielded the following Ct values (Table 40).
Initial  
Suspension
Duplicates after 
extraction
x Triplicate after 
PCR Ct values
C
&Į
&Į-A 25.63
&Į-B 26.51
&Į-C 29.00
&ȕ
&ȕ-A 26.31
&ȕ-B 28.69
&ȕ-C 27.79
Y
<Į
<Į-A 12.87
<Į-B 14.23
<Į-C 13.85
<ȕ
<ȕ-A 12.65
<ȕ-B 13.26
<ȕ-C 13.60
Y1
<Į
<Į-A 14.72
<Į-B 15.36
<Į-C 15.81
<ȕ
<ȕ-A 14.87
<ȕ-B 15.54
<ȕ-C 15.55
Y2
<Į
<Į-A 20.47
<Į-B 20.04
<Į-C 19.72
<ȕ
<ȕ-A 22.27
<ȕ-B 23.53
<ȕ-C 26.83
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Initial  
Suspension
Duplicates after 
extraction
Triplicate after 
PCR
Ct values
Y3
<Į
<Į-A 23.13
<Į-B 23.31
<Į-C 24.11
<ȕ
<ȕ-A 21.42
<ȕ-B 22.05
<ȕ-C 22.78
Y4
<Į
<Į-A 26.09
<Į-B 25.93
<Į-C 26.58
<ȕ
<ȕ-A 26.77
<ȕ-B 26.44
<ȕ-C Failed well
Y5
<Į
<Į-A 29.01
<Į-B 28.46
<Į-C 27.40
<ȕ
<ȕ-A 27.62
<ȕ-B 28.27
<ȕ-C 27.81
Y6
<Į
<Į-A 28.37
<Į-B 29.96
<Į-C 27.32
<ȕ
<ȕ-A 28.37
<ȕ-B 34.04
<ȕ-C 27.37
Initial  
Suspension
Duplicates after 
Y7
Table 40. Ct values using the Sepsi
amplification
The results obtained from the Miles and Misra and the Sepsi
were used to construct a standard curve, which was used for bacterial 
quantification.  The standard curve was plotted with the x
Log10 (number of bacteria) and the y
purpose of this experiment, 
able to identify and quantify 
value for the control sample, C
plotted for the five samples with mean 
Figure 18. Standard curve for 
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extraction
Triplicate after 
PCR
C
<Į
<Į-A 28.04
<Į-B 35.88
<Į-C 27.37
<ȕ
<ȕ-A 27.84
<ȕ-B 27.38
<ȕ-C 35.70
Test™ method of bacterial DNA 
T
-axis being the Ct values obtained.  For the 
Ct values above 27 were considered too high to be 
Enterococcus faecalis reliably, as the mean 
, was 27.3.  Therefore, the standar
Ct values of 27 or less (Figure 20).
Enterococcus faecalis using Sepsitest™
4 6 8 10
Log10 (Number of colonies) 
t values
est™ methods 
-axis being 
Ct
d curve was 
  
Ct Value 1
Ct Value 2
Ct Value 3
Ct Value 4
Ct Value 5
Ct Value 6
The molecular method used was not sensitive enough to detect low levels of 
bacteria in the blood samples.  Levels greater than 10
detected using this broad
the literature [8].  However, a more sensitive method was required, that was 
able to detect bacteraemia of
3.8 Experiment 6 –
Experiment 5 was repeated using a different molecular microbiological kit.  The 
kit used for bacterial DNA extraction from blood was the MolYsis Complete 
1 mL protocol.  DNA amplification was done usi
protocol using the in-house short 16S primers.
3.8.1 Method
The methods used in Experiment 5 were repeated using a different molecular 
kit (MolYsis Complete 1 mL).
3.8.2 Results
The standard curve obtained is shown below (Figure 
Figure 19. Standard Curve for 
Complete5 protocol
The standard curve allowed 
104 cfu/mL but no improvement
3.9 Experiment 7 –
This experiment was designed to be able to improve the detection and 
quantification of bacteria in blood using molecular methods, particular when the 
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4 cfu/mL could be reliably 
-range PCR method, in line with reported studies in 
< 104 cfu/mL
MolYsis Complete 1 mL protocol
ng an in-house amplification 
19).
Enterococcus faecalis using the 1
quantification of Enterococcus faecalis 
was possible.
MolYsis Complete5
4 6 8 10
10 (Number of colonies) 
mL MolYsis 
down to 
Y-Values
100
number of bacteria present in blood was low.  One of the problems encountered 
in previous experiments was the inability to detect low-level bacteraemia.  
Therefore, a decision was made to use larger volumes of blood for the 
molecular processing.  The kit identified was MolYsis Complete5 by Molzym 
GmbH & Co. KG, Bremen, Germany.
The SepsiTest™ bacterial DNA extraction protocol processed 1 mL of blood 
and yielded 100 ȝ/RI HOXDWH XVHG IRU DPSOLILFDWLRQ  7KHVDPH FRQFHQWUDWLRQ
gradient was possible using 1 mL of blood and the MolYsis Complete kit.  Both 
these protocols allowed quantification to 104 cfu/mL but no better.  MolYsis 
Complete5 uses 5 mL of blood instead of 1 mL of blood and yields 100 ȝ/RI
eluate as in the previous methods.  Therefore, in theory, five times more 
bacterial DNA was harnessed by the MolYsis Complete5 method, improving 
sensitivity and the ability to detect low levels bacteraemia.
3.9.1 Method
The organisms used were Enterococcus faecalis (A), Escherichia coli (B) and 
Staphylococcus epidermidis (C).  The colonies were obtained from previous 
plate growth.  Seven tubes of BHI broth (each containing 10 ml of broth) were 
labelled A1, A2, B1, B2, C1, C2 and D.  Tube A1 was inoculated with two 1 mm 
colony of Enterococcus faecalis.  Tube A2 was inoculated with twenty 1 mm 
colony of Enterococcus faecalis.  Tube B1 was inoculated with two 1 mm colony 
of Escherichia coli.  Tube B2 was inoculated with twenty 1 mm colony of 
Escherichia coli.  Tube C1 was inoculated with two 1 mm colony of 
Staphylococcus epidermidis.  Tube C2 was inoculated with twenty 1 mm colony 
of the Staphylococcus epidermidis.  Tube D was not inoculated with any 
organism.  The seven tubes were incubated for 6 hours at 37° C in air.
3.9.2 Results
At 6 hours, Tube A1 was mildly cloudy, Tube A2 was very cloudy, Tube B1 was 
mildly cloudy, Tube B2 was very cloudy, Tube C1 was very cloudy, Tube C2 
was cloudy and Tube D was clear.  Therefore, suspensions A2, B2, C2 and D 
were used for further tests.
3.9.3 Method
Tube A2 was relabelled as X, B2 as Y, and C2 as Z.  Suspension X was serially 
diluted as per the algorithm below (Figure 22) and this process was repeated 
with suspensions Y and Z.
Figure 20. Dilution of sample X
A 1 mL volume of X was pipetted into 9
suspension PX.  A 5
Falcon™ tube; the remaining 5
15 mL Falcon™ WXEH7KHWXEHVZHUHODEHOOHG3;ĮDQG3;ȕ
of X1 was pipetted into 9
PX1 was divided into two 15
VXVSHQVLRQ DQG ODEHOOHG 3;Į DQG 3;ȕ UHVSHFWLYHO\  7KLV SURFHVV ZDV
repeated with X1-X7, Y
blood was also divided into tubes labelled C
samples were obtained for DNA extraction (Table 41).  Bacterial DNA was 
extracted from the following samples using the Molzym MolYsis Complete5 
protocol.  The eluates obtained were stored at 
Samples with bacterae
3;Į 3;Į 3;Į
3;ȕ 3;ȕ 3;ȕ
3<Į 3<Į 3<Į
3<ȕ 3<ȕ 3<ȕ
3=Į 3=Į 3=Į
3=ȕ 3=ȕ 3=ȕ
&Į &ȕ
Table 41. Spiked blood samples for bacterial DNA extraction
X was serially diluted tenfold as per the algorithm below.  This process was 
repeated for samples Y and Z.
X1 •200 µL of X is added
X2 •200 µL of X1 is added
X3 •200 µL of X2 is added
X4 •200 µL of X3 is added
X5 •200 µL of X4 is added
X6 •200 µL of X5 is added
X7 •200 µL of X6 is added
101
mL bacteria-free blood to produce 
mL volume of suspension PX was pipetted into a 15
mL of suspension PX was pipetted in another 
A 
mL bacteria-free blood to produce PX1.  The 10
mL Falcon™ tubes, each containing 5
-Y7 and Z-Z7.  A 10 mL volume of fresh ‘unseeded’ 
ĮDQG&ȕ7KHUHIRUHWKHIROORZLQJ
-70° C.
mia
3;Į 3;Į 3;Į 3;Į 3;Į
3;ȕ 3;ȕ 3;ȕ 3;ȕ 3;ȕ
3<Į 3<Į 3<Į 3<Į 3<Į
3<ȕ 3<ȕ 3<ȕ 3<ȕ 3<ȕ
3=Į 3=Į 3=Į 3=Į 3=Į
3=ȕ 3=ȕ 3=ȕ 3=ȕ 3=ȕ
to 1800 µL of molecular water (1/10 dilution)
to 1800 µL of molecular water (1/100 dilution)
to1800 µL of molecular water (1/1000 dilution)
to 1800 µL of molecular water (1/10,000 dilution)
to 1800 µL of molecular water (1/100,000 dilution)
to 1800 µL of molecular water (1/1,000,000 dilution)
to 1800 µL of molecular water (1/10,000,000 dilution)
mL 
1 mL volume 
mL of 
mL of 
Figure 21. Dilutions of the initial sample
The following samples (Table 42) were obtained.  
the samples was plated on CBA Agar plates in triplicate and incubated for 
18 hours at 37° C.  The plates were used for bacterial 
Miles and Misra method.  Sa
X AX
Y AY
Z AZ
D
Table 42. Samples for Miles and Misra 
Viable counts were obtained in Samples AXf, AYc and AZb.  All the other 
samples had either too many or too few to quantify.  Bacterial 
using the Miles and Misra method was as shown in Table 43 below.
Samples CFU Counts on plate
AXf 152-150
AYc 41-41
AZb 190-186
Table 43. Bacterial count using the Miles and Misra method
AX •100 µL of X is added to 900 µL of distilled water ( 1/10 dilution)
AXa •100 µL of AX is added to 900 µL of distilled water (1/100 dilution)
AXb •100 µL of AXa is added to 900 µL of distilled water (1/1,000 dilution)
AXc •100 µL of AXb is added to 900 µL of distilled water (1/10,000 dilution)
AXd •200 µL of AXc is added to 800 µL of distilled water (1/50,000 dilution)
AXe •500 µL of AXc is added to 500 µL of distilled water (1/20,000 dilution)
AXf •100 µL of AXc is added to 900 µL of distilled water (1/100,000 dilution)
102
A 20 ȝ/volume 
quantification
mple D was a control sample.
SAMPLES
AXa AXb AXc AXd AXe
AYa AYb AYc AYd AYe
AZa AZb AZc AZd AZe
quantification
Mean count
Concentration of initial 
suspension (cfu/ml)
-142 148.0 X: 7.4 x 10
-40 40.7 Y:  2.0 x 10
-195 190.3 Z: 9.5 x 10
of each of 
using the 
AXf
AYf
AZf
quantification
8
7
6
103
Experiment 7 above was repeated to obtain further bacterial eluates.  The 
samples were labelled F (Enterococcus faecalis), G (Escherichia coli) and 
H (Staphylococcus epidermidis).  The concentrations of the different 
suspensions are as follow:
Concentration of Enterococcus faecalis: 1.32 x 108 cfu/mL
Concentration of Escherichia coli: 1.59 x 107 cfu/mL
Concentration of Staphylococcus epidermidis: 1.78 x 107 cfu/mL
The samples in Table 44 below were available for bacterial DNA extraction and 
amplification.
104
Enterococcus 
faecalis
Concentration
(Miles& 
Misra cfu/ml)
Escherichia 
coli
Concentration
(Miles & 
Misra cfu/ml)
Staphylococcus 
epidermidis
Concentration
(Miles & 
Misra cfu/ml)
3;Į
7.4 x 107
3<Į
2.0 x 106
3=Į
9.5 x 105
3;ȕ 3<ȕ 3=ȕ
3)Į
1.3 x 107
3*Į
1.6 x 106
3+Į
1.8 x 106
3)ȕ 3*ȕ 3+ȕ
3;Į
7.4 x 106
3<Į
2.0 x 105
3=Į
9.5 x 104
3;ȕ 3<ȕ 3=ȕ
3)Į
1.3 x 106
3*Į
1.6 x 105
3+Į
1.8 x 105
3)ȕ 3*ȕ 3+ȕ
3;Į
7.4 x 105
3<Į
2.0 x 104
3=Į
9.5 x 103
3;ȕ 3<ȕ 3=ȕ
3)Į
1.3 x 105
3*Į
1.6 x 104
3+Į
1.8 x 104
3)ȕ 3*ȕ 3+ȕ
3;Į
7.4 x 104
3<Į
2.0 x 103
3=Į
9.5 x 102
3;ȕ 3<ȕ 3=ȕ
3)Į
1.3 x 104
3*Į
1.6 x 103
3+Į
1.8 x 103
3)ȕ 3*ȕ 3+ȕ
3;Į
7.4 x 103
3<Į
2.0 x 102
3=Į
9.5 x 101
3;ȕ 3<ȕ 3=ȕ
3)Į
1.3 x 103
3*Į
1.6 x 102
3+Į
1.8 x 102
3)ȕ 3*ȕ 3+ȕ
3;Į
7.4 x 102
3<Į
2.0 x 101
3=Į
10
3;ȕ 3<ȕ 3=ȕ
3)Į
13 x 102
3*Į
16
3+Į
18
3)ȕ 3*ȕ 3+ȕ
3;Į
74
3<Į
2
3=Į
1
3;ȕ 3<ȕ 3=ȕ
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Enterococcus 
faecalis
Concentration
(Miles& 
Misra cfu/ml)
Escherichia 
coli
Concentration
(Miles & 
Misra cfu/ml)
Staphylococcus 
epidermidis
Concentration
(Miles & 
Misra cfu/ml)
3)Į
13
3*Į
1
3+Į
2
3)ȕ 3*ȕ 3+ȕ
3;Į
7
3<Į
Nil
3=Į
Nil
3;ȕ 3<ȕ 3=ȕ
3)Į
1
3*Į 3+Į
3)ȕ 3*ȕ 3+ȕ
Table 44. Samples available for amplification with the concentration of 
bacteria
All the samples in Table 44 above were stored at -70° C for further molecular 
processing.
3.10 Experiment 8 – Polymerase Chain Reaction
All the samples from Table 44 above were amplified in triplicate using the PCR 
protocol used in the Department (Appendix 4).
3.10.1 Results
The results from the Enterococcus faecalis samples are tabulated below.
106
Sample
Concentration 
(CFU/ml)
Ct values
Ct values for 
unspiked 
Blood
Ct values for NTC
X-A
7.4x107
14.81 15.42 15.32 29.63 27.91
X-B 11.98 12.17 12.16 29.36
X1-A
7.4x106
15.09 15.31 15.15 25.98 25.18
X1-B 13.76 13.46 13.88
X2-A
7.4x105
18.06 20.35 21.64 29.35 33.66
X2-B 19.84 18.73 19.92
X3-A
7.4x104
24.16 23.83 23.77 30.72 30.57
X3-B 20.12 22.06 22.17 29.03
X4-A
7.4x103
28.54 26.63 25.85 27.99 27.57
X4-B 24.60 26.22 25.62 28.40
X5-A
7.4x102
25.72 26.23 26.43 29.56 25.20
26.63 26.66 26.17 30.09
X5-B
27.89 27.84 26.54 29.68
27.65 27.61 27.58 26.81
X6-A
7.4x101
30.77 27.82 29.98 29.98 29.98
X6-B 29.25 30.76 31.28
X7-A
7
26.50 28.64 27.23 28.59 29.65
X7-B 28.15 29.91 28.78
Table 45. Ct values for the Enterococcus faecalis samples from the first 
extraction experiment (shading represent Ct values within three 
cycles of the Ct value of the negative control)
Samples having Ct values within three cycles of the negative control (unspiked 
blood) were not used for further analysis in plotting the standard curve.  This 
strict criterion allowed the subsequent use of the standard curve to be more 
accurate.  Figure 24 below shows the 
three cycles of the negative controls.
Figure 22. Standard Curve for X samples
The above analysis was repeated for the F samples (
The results and the resulting standard curve are shown 
Sample
Concentration 
(CFU/ml)
F-A
1.32X107
F-B
F1-A
1.32X106
F1-B
F2-A
1.32X105
F2-B
F3-A
1.32X104
F3-B
F4-A
1.32X103
F4-B
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standard curve using Ct values not within 
Enterococcus faecalis
below.
Ct values Ct values for Blood
13.21 13.90 13.77 29.47
10.47 10.17 10.32
13.31 13.13 13.19
13.35 13.54 13.06 30.00
18.92 18.40 18.43 27.83
18.01 18.27 17.81
20.85 21.58 21.28 29.64
22.69 22.89 22.84
24.34 25.28 25.64 28.22
25.57 24.69 25.94
4 6 8 10
Ct Values 1
Ct Values 2
Ct Values 3
Ct Values 4
Ct Values 5
Ct Values 6
Average Ct values
).  
Ct values for NTC
29.96
32.65
28.75
26.85
39.36
29.38
Sample
Concentration 
(CFU/ml)
F5-A
1.32X102
F5-B
F6-A
1.32X101
F6-B
F7-A
1
F7-B
Table 46. Ct values for the 
extraction experiment (shading represent C
cycles of the C
Figure 23. Standard curve for 
samples
Using values from both the Z and the F samples for 
standard curve below was obtained (Figure 26):
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108
Ct values Ct values for Blood
27.81 29.02 26.95 30.55
28.41 27.41 28.52
28.83 27.68 29.89 28.50
28.74 29.16 29.38
29.11 30.77 31.62 32.11
31.00 24.51 30.41
Enterococcus faecalis samples from the second 
t values within three 
t value of the negative control)
Enterococcus faecalis using values from F 
Enterococcus faecalis
4 6 8
(Number of colonies) 
Ct Values 1
Ct Values 2
Ct Values 3
Ct Values 4
Ct Values 5
Ct Values 6
Average Ct values
Ct values for NTC
31.89
30.17
35.07
, the 
Figure 24. Standard curve for 
F samples
The standard curves above shows that the m
allowed reliable detection and 
bacteraemia of an order of 
were reliably detected but not reliably quantified as the C
to 102 cfu/mL samples were within three cycles of the negative
above analysis was repeated for the 
epidermidis samples obtained from Experiment 7.  The results are shown 
below.
Sample
Concentration 
(CFU/ml)
Y-A
2.0 x 106
Y-B
Y1-A
2.0 x 105
Y1-B
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Enterococcus faecalis using values from X and 
olecular method that was used 
quantification of Enterococcus f
103 cfu/mL.  Samples containing 102 cfu
t values 
Escherichia coli and the Staphylococcus 
Ct values
Ct values for 
Blood
22.69 22.50 22.94 27.41
23.39 23.36 23.53
25.08 25.58 25.61
26.90 27.95 28.09 29.34
4 6 8 10
10 (Number of colonies) 
Ct Values 1
Ct Values 2
Ct Values 3
Ct Values 4
Ct Values 5
Ct Values 6
aecalis
/mL bacteria 
corresponding 
control.  The 
Ct values for 
NTC
29.65
37.23
110
Sample
Concentration 
(CFU/ml)
Ct values
Ct values for 
Blood
Ct values for 
NTC
Y2-A
2.0 x 104
30.29 29.89 30.37 33.84 31.84
Y2-B 29.58 31.19 30.54 31.26
Y3-A
2.0 x 103
27.17 29.74 30.48 32.62 28.90
Y3-B 29.95 30.00 30.49 30.78
Y4-A
2.0 x 102
29.85 28.69 28.46
Y4-B 29.63 32.51 31.29 33.33
Y5-A
2.0 x 101
28.20 31.16 30.29 32.81 35.43
Y5-B 27.57 31.86 33.82
Y6-A
2
30.52 31.03 31.25 26.08 27.00
Y6-B 30.83 29.89 32.20
Y7-A
Nil
31.92 31.78 30.12 29.23 29.32
Y7-B 29.09 28.82 30.97
Table 47. Ct values of Y samples (shading represent Ct values within three 
cycles of the Ct value of the negative control)
The Ct values of the Y samples above were used to construct a standard curve 
to allow quantification based on Ct values.  Ct values of samples within three 
cycles of the negative controls were disregarded in the construction of the 
standard curve.
Figure 25. Standard Curve for Y samples
Sample
Concentration 
(CFU/ml)
G-A
1.59x106
G-B
G1-A
1.59x105
G1-B
G2-A
1.59x104
G2-B
G3-A
1.59x103
G3-B
G4-A
1.59x102
G4-B
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Ct values
Ct values for 
Blood
10.71 10.61 10.57 31.17
13.09 13.17 13.03
16.09 15.88 15.43 30.04
15.31 15.44 15.57
19.82 19.70 19.54
19.46 18.95 19.16 27.09
25.05 25.29 25.42 30.92
26.25 26.79 26.55
26.91 26.91 26.26 30.78
27.27 27.24 27.06
4 6 8
10 (Number of colonies) 
Ct Values 1
Ct Values 2
Ct Values 3
Ct Values 4
Ct Values 5
Ct Values 6
Ct values for 
NTC
31.79
30.19
32.75
32.45
31.01
29.50
31.09
30.78
Sample
Concentration 
(CFU/ml)
G5-A
1.59x101
G5-B
G6-A
2
G6-B
G7-A
Nil
G7-B
Table 48. Ct values of G samples (shading represent C
cycles of the C
Figure 26. Standard curve for G samples
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Ct values
Ct values for 
Blood
28.40 27.75 28.38 28.97
28.95 28.62 28.99
31.69 31.43 32.41 32.05
29.25 31.57 30.83
32.77 31.99 29.83 29.22
32.32 29.77 30.53
t values within three 
t value of the negative control)
4 6 8
10 (Number of colonies) 
Ct Values 1
Ct Values 2
Ct Values 3
Ct Values 4
Ct Values 5
Ct Values 6
Ct values for 
NTC
30.48
31.62
33.79
Figure 27. Standard curve for 
samples
Sample
Concentration 
(CFU/ml)
Z-A
9.5 x 105
Z-B
Z1-A
9.5 x 104
Z1-B
Z2-A
9.5 x 103
Z2-B
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Escherichia coli using values from Y and G 
Ct values
Ct values for 
Blood
22.69 22.50 22.94 27.41
23.39 23.36 23.53
25.08 25.58 25.61
26.90 27.95 28.09 29.34
30.29 29.89 30.37 33.84
29.58 31.19 30.54
4 6 8
10 (Number of colonies) 
Ct Values 1
Ct Values 2
Ct Values 3
Ct Values 4
Ct Values 5
Ct Values 6
Ct values 
for NTC
29.65
37.23
31.84
31.26
Sample
Concentration 
(CFU/ml)
Z3-A
9.5 x 102
Z3-B
Z4-A
9.5 x 101
Z4-B
Z5-A
10
Z5-B
Z6-A
Z6-B
Z7-A
Z7-B
Table 49. Ct values of Z samples (shading represent C
cycles of the C
Figure 28. Standard curve for 
samples
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Ct values
Ct values for 
Blood
27.17 29.74 30.48 32.62
29.95 30.00 30.49
29.85 28.69 28.46
29.63 32.51 31.29
28.20 31.16 30.29 32.81
27.57 31.86 33.82
30.52 31.03 31.25 26.08
30.83 29.89 32.20
31.92 31.78 30.12 29.23
29.09 28.82 30.97
t values within three 
t value of the negative control)
Staphylococcus epidermidis using values from Z 
4 6 8
10 (Number of colonies) 
Ct Values 1
Ct Values 2
Ct Values 3
Ct Values 4
Ct Values 5
Ct Values 6
Ct values 
for NTC
28.90
30.78
33.33
35.43
27.00
29.32
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Sample
Concentration 
(CFU/ml)
Ct values
Ct values for 
Blood
Ct values for 
NTC
H-A
1.8 x 106
13.03 12.81 12.97 28.92 28.33
H-B 11.48 12.15 11.82 30.20
H1-A
1.78 x 105
14.31 14.70 13.99
H1-B 14.47 13.93 13.73
H2-A
1.78 x 104
17.47 17.51 17.19
H2-B 17.14 18.04 17.67
H3-A
1.78 x 103
22.66 22.38 22.66
H3-B 21.82 22.56 22.90
H4-A
1.78 x 102
26.06 27.60 25.71
H4-B 26.38 25.79 26.13
H5-A
1.78 x 101
29.97 28.52 30.01
H5-B 29.11 29.33 26.01
H6-A
2
25.82 25.07 23.69
H6-B 30.00 29.51 23.57
H7-A
Nil
24.90 30.22 22.78
H7-B 25.51 28.74 27.92
Table 50. Ct values of H samples (shading represent Ct values within three 
cycles of the Ct value of the negative control)
Figure 29. Standard curve 
samples
Figure 30. Standard curve for 
and H samples
Experiment 8 has demonstrated that it is possible to detect and quantify t
three most prevalent ‘urological bacteria’ from blood reliably and consistently, 
using molecular microbiological methods.  Furthermore, there was at least three 
cycles of amplification between the detection of a 
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negative controls.  Therefore, it is possible to use this assay (used under the 
above conditions) for the detection of 103 cfu/mL or more bacteraemia, in 
patients with suspected urological infections.
3.11 Experiment 9 – The Plex-ID
The final experiment described was to evaluate the use of the Plex-ID in the 
detection and quantification of bacterial DNA obtained via extraction from blood.  
The samples used were the Enterococcus faecalis (X and F), Escherichia coli 
(Y and G) Staphylococcus epidermidis (Z and H) samples obtained in 
Experiment 7.  Ibis Biosciences, now part of Abbott Molecular, developed the 
IbisT5000, based on a technology known as the triangulation identification for 
the genetic evaluations of risks (TIGER).  This research programme was 
mandated by the biodefense agencies in the USA [9].  The commercialised 
version of the IbisT5000 is the Plex-ID, marketed by Abbott Molecular.  It is a 
nearly fully automated system, which uses PCR ESI-MS technology to detect 
amplified nucleic acids from bacteria.  A computerised triangulation of the 
nucleic acid detected allows the detection of the organisms present, down to 
species level, in the Plex-ID databases.  A broad-range PCR is used on the 
DNA extracts which targets ribosomal and genes expressing housekeeping 
proteins.  The PCR uses multiple primers and allows hybridisation during the 
first cycles.  The Plex-ID allows a degree of quantification based on the peak 
heights of the mass spectra [10] and provides information on typing, virulence 
and resistance.  However, in-depth discussion of this technology is not within 
the scope of this thesis.
Figure 31. Diagrammatic representation of the Plex
3.11.1 Results
Tables 51-56 below shows the results obtained processing samples, X, Y, Z, F, 
G and H as per the standard protocol
compared with the quantification
well as the Ct values obtained from the broad
(Experiments 7 and 8).  All the samples 
system.  Bacteraemia down to the level of
quantified.
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-ID technology
for the Plex-ID.  The results were 
obtained from the Miles and Misra method as 
-range PCR experiments 
were identified correctly by the Plex
< 10 cfu/mL were detected and 
-ID 
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Enterococcus faecalis (Extraction 1)
Sample Miles & Misra Concentration (CFU/ml) Ct values Plex-ID value
X-A
7.4x107
14.81 15.42 15.32 194
X-B 11.98 12.17 12.16 -
X1-A
7.4x106
15.09 15.31 15.15 200
X1-B 13.76 13.46 13.88 -
X2-A
7.4x105
18.06 20.35 21.64 311
X2-B 19.84 18.73 19.92
X3-A
7.4x104
24.16 23.83 23.77 210
X3-B 20.12 22.06 22.17 181
X4-A
7.4x103
28.54 26.63 25.85 217
X4-B 24.60 26.22 25.62 195
X5-A
7.4x102
25.72 26.23 26.43
172
26.63 26.66 26.17
X5-B
27.89 27.84 26.54
119
27.65 27.61 27.58
X6-A
7.4x101
30.77 27.82 29.98 5
X6-B 29.25 30.76 31.28 17
X7-A
7.4
26.50 28.64 27.23 4
X7-B 28.15 29.91 28.78 -
Table 51. Comparison between conventional methods and molecular method 
(shading represent Ct values within three cycles of the Ct value of 
the negative control)
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Enterococcus faecalis (Extraction 2)
Sample Miles & Misra Concentration (CFU/ml) Ct values Plex-ID value
F-A
1.3x107
13.21 13.90 13.77 -
F-B 10.47 10.17 10.32 -
F1-A
1.3x106
13.31 13.13 13.19 -
F1-B 13.35 13.54 13.06 -
F2-A
1.3x105
18.92 18.40 18.43 -
F2-B 18.01 18.27 17.81 -
F3-A
1.3x104
20.85 21.58 21.28 229
F3-B 22.69 22.89 22.84 230
F4-A
1.3x103
24.34 25.28 25.64 197
F4-B 25.57 24.69 25.94 376
F5-A
1.3x102
27.81 29.02 26.95 149
F5-B 28.41 27.41 28.52 68
F6-A
13
28.83 27.68 29.89 22
F6-B 28.74 29.16 29.38 10
F7-A
1
29.11 30.77 31.62 19
F7-B 31.00 24.51 30.41 4
Table 52. Comparison between conventional methods and molecular 
methods (shading represents Ct values within three cycles of the Ct 
value of the negative control)
121
Escherichia coli (Extraction 1)
Sample Miles & Misra Concentration (CFU/ml) Ct values Plex-ID value
Y-A
2x106
22.69 22.50 22.94 195
Y-B 23.39 23.36 23.53 -
Y1-A
2x105
25.08 25.58 25.61 187
Y1-B 26.90 27.95 28.09 -
Y2-A
2x104
30.29 29.89 30.37 191
Y2-B 29.58 31.19 30.54 171
Y3-A
2x103
27.17 29.74 30.48 187
Y3-B 29.95 30.00 30.49 180
Y4-A
2x102
29.85 28.69 28.46 186
Y4-B 29.63 32.51 31.29 -
Y5-A
20
28.20 31.16 30.29 -
Y5-B 27.57 31.86 33.82 -
Y6-A
2
30.52 31.03 31.25 10
Y6-B 30.83 29.89 32.20 -
Y7-A
-
31.92 31.78 30.12 13
Y7-B 29.09 28.82 30.97 -
Table 53. Comparison between conventional methods and molecular 
methods (shading represents Ct values within three cycles of the Ct 
value of the negative control).
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Escherichia coli (Extraction 2)
Sample Miles & Misra Concentration (CFU/ml) Ct values Plex-ID value
G-A
1.6x106
10.71 10.61 10.57 -
G-B 13.09 13.17 13.03 -
G1-A
1.6x105
16.09 15.88 15.43 -
G1-B 15.31 15.44 15.57 -
G2-A
1.6x104
19.82 19.70 19.54 -
G2-B 19.46 18.95 19.16 -
G3-A
1.6x103
25.05 25.29 25.42 160
G3-B 26.25 26.79 26.55 -
G4-A
1.6x102
26.91 26.91 26.26 116
G4-B 27.27 27.24 27.06 -
G5-A
16
28.40 27.75 28.38 42
G5-B 28.95 28.62 28.99 -
G6-A
2
31.69 31.43 32.41 7
G6-B 29.25 31.57 30.83 -
G7-A
-
32.77 31.99 29.83 3
G7-B 32.32 29.77 30.53 -
Table 54. Comparison between conventional methods and molecular 
methods (shading represents Ct values within three cycles of the Ct 
value of the negative control).
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Staphylococcus epidermidis (Extraction 1)
Sample Miles & Misra Concentration (CFU/ml) Ct values Plex-ID value
Z-A
9.5x105
22.69 22.50 22.94 -
Z-B 23.39 23.36 23.53 -
Z1-A
9.5x104
25.08 25.58 25.61 -
Z1-B 26.90 27.95 28.09 -
Z2-A
9.5x103
30.29 29.89 30.37 13
Z2-B 29.58 31.19 30.54 -
Z3-A
9.5x102
27.17 29.74 30.48 4
Z3-B 29.95 30.00 30.49
Z4-A
95
29.85 28.69 28.46 -
Z4-B 29.63 32.51 31.29 -
Z5-A
10
28.20 31.16 30.29 -
Z5-B 27.57 31.86 33.82 -
Z6-A
1
30.52 31.03 31.25 -
Z6-B 30.83 29.89 32.20 -
Z7-A
1
31.92 31.78 30.12 -
Z7-B 29.09 28.82 30.97 -
Table 55. Comparison between conventional methods and molecular 
methods (shading represents Ct values within three cycles of the Ct 
value of the negative control)
Staphylococcus Epidermidis (Extraction 2)
Sample Miles & Misra Concentration (CFU/ml) Ct values Plex-ID value
H-A
1.8x106
13.03 12.81 12.97 -
H-B 11.48 12.15 11.82 -
H1-A
1.8x105
14.31 14.70 13.99 -
H1-B 14.47 13.93 13.73 -
H2-A
1.8x104
17.47 17.51 17.19
H2-B 17.14 18.04 17.67 -
H3-A
1.8x103
22.66 22.38 22.66 193
H3-B 21.82 22.56 22.90
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Sample Miles & Misra Concentration (CFU/ml) Ct values Plex-ID value
H4-A
1.8x102
26.06 27.60 25.71 203
H4-B 26.38 25.79 26.13 -
H5-A
18
29.97 28.52 30.01 99
H5-B 29.11 29.33 26.01 -
H6-A
2
25.82 25.07 23.69 30
H6-B 30.00 29.51 23.57 -
H7-A
-
24.90 30.22 22.78 21
H7-B 25.51 28.74 27.92 -
Table 56. Comparison between conventional methods and molecular 
methods (shading represents Ct values within three cycles of the Ct 
value of the negative control)
The results from Experiment 9 above demonstrate an alternative, novel 
molecular microbiological technology that can detect and quantify low-level 
bacteraemia reliably and consistently.  The Plex-ID technology, like other 
molecular technologies, is more labour-intensive than the conventional culture 
and Miles and Misra method.
3.12 Conclusions
The experiments carried out and reported in this chapter have shown that it is 
possible to detect, quantify and identify bacteraemia by different methods.  The 
traditional incubation and culture method allowed the detection of bacteria using 
conventional methods.  The molecular techniques detected bacterial DNA.  The 
broad-range PCR method that was optimised allowed the detection and 
quantification of bacteria to a level of 103 cfu/mL.  The Plex-ID method allowed 
detection and quantification to a level of < 10 cfu/mL, which is a major 
improvement on the broad-range PCR methods described in the initial 
experiments.  Identification was integrated in the Plex-ID method whereas 
further sequence analysis was required for the broad-range PCR methods.  
Experimenting and validating sequencing methodology for the detection of 
bacterial DNA was not within the remit of this thesis.
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Chapter 4: Bacteraemia during TURP and Catheter
Manipulation
4.1 Introduction
The literature suggests that bacteraemia does occur during urological 
procedures [14, 219-221]. However, most studies report bacteraemia in patients 
who become symptomatic after urological instrumentation. An absolute figure 
for the presence of bacteraemia during urological procedures is not reported in 
the literature. Therefore, the aim of the work presented in this chapter was to 
determine the incidence, amplitude, timing and causative organisms of 
bacteraemia occurring during urological procedures, using the methods 
described in Chapter 3. The significance of asymptomatic bacteraemia is not 
known but is discussed further in Chapter 5.
4.2 Ethics
Ethics approval was obtained from the Leeds West Research Ethics Committee 
(REC) (REC number: 10/H1307/5). Research and Development approval was 
obtained from the Leeds Teaching Hospitals NHS Trust Research and 
Development (R&D) department (R&D number: UR09/9173). The trial was also 
registered on the International Standard Randomised Controlled Trial 
Number (ISRCTN) Register (ISRCTN89902973).
4.3 The pilot study: is it feasible to recruit urology patients in a 
study to detect bacteraemia?
4.3.1 Introduction
To determine the feasibility of a prospective study to recruit patients having 
urological procedures, a pilot study was designed and run. Patients having 
transurethral resection of the prostate (TURP), extracorporeal shockwave 
lithotripsy (ESWL) and catheter manipulation were recruited and blood samples 
were obtained from the recruited patients. The three procedures above were 
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identified as they were commonly carried out in the urological department at the 
Leeds Teaching Hospitals Trust.
In the first instance, in the catheter manipulation group, it was decided to 
include patients having only catheter change rather than catheter removal. This 
was done in order to avoid recruiting patients who had been catheterised for a 
short period, where bacteraemia is rarely reported [222].
4.3.2 Methods
4.3.2.1 Identification of the participants and processing of samples
A urology research nurse identified patients. The inclusion criteria were adult 
patients attending the Leeds Teaching Hospital NHS Trust (LTHT) for TURP, 
catheter manipulation and ESWL. The research nurse approached and invited 
the patient to take part in the study. If a patient showed interest in taking part in 
the study, they were put in touch with the principal investigator (the author). 
Patient consent was obtained and allocated a unique identification number. 
Blood samples were obtained according to the schedules shown in Table 57. 
Samples were set up for culture according to the method described in 
Chapter 3. Blood culture isolates were processed by Gram stain and were 
identified according to the methods in Section 4.3.3.2. For the purpose of the 
pilot study, the blood samples obtained were processed using only the culture 
method, as the molecular methodologies had not been developed at the time 
this study was carried out. Demographic and clinical data were collected using a 
pro forma (Appendix 7).
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4.3.2.2 Timing of blood samples
For the purpose of the pilot study, blood was acquired at the following time 
points for the TURP group of patients:
A B C D E F G
Time 
Point
Pre-
procedure
Start of 
procedure
5 minutes 
into 
procedure
15-20 
minutes into 
procedure
End of 
procedure
10 
minutes 
following 
procedure
20 
minutes 
following 
procedure
Table 57. Schedule for timing of blood sampling in the pilot study of 
bacteraemia during TURP
For the catheter-change group, time-points C and D were excluded owing to the 
duration of the procedure.
4.3.3 Results
4.3.3.1 Demographics of the patients recruited
Table 58 shows the basic demographics of the patients recruited in the pilot 
study.
Procedure
TURP
N=11
Catheter 
change
N=5
ESWL
N=5
Male sex (%) 11 (100) 3 (60) 4 (80)
Mean age ± SD (years) 71.3 ± 10.2 60.0 ± 15.5 41.0 ± 14.8
Mean weight ± SD (kg) 81 ± 15.5 83.6 ± 11.3 69.9 ± 14.1
Urine dipstick Negative (%) 11 (100) 4 (80) 5 (100)
Within 2 weeks 
of the procedure
Antibiotics Therapy (%) 0 (0) 1 (20) 1 (20)
Instrumentation (%) 0 (0) 0 (0) 0 (0)
Symptomatic UTIs (%) 1 (9.1) 0 (0) 0 (0)
Immunosuppressant (%) 0 (0) 1 (20) 0 (0)
Diabetes Mellitus (%) 0 (0) 1 (20) 0 (0)
Procedure
Smoking (%)
Co-existing Infection (%)
Recent hospital stay (%)
Mean length of stay ± SD (days)
Recurrent UTIs (%)
Urinary stones (%)
Catheter-in-
Mean length of catheterisation ± SD (days)
Cardiac History (%)
Endocarditis (%)
Prosthetic device – cardiac and non
Organ transplant (%)
Table 58. Demographics of patients recruited in the pilot study of patients 
undergoing TURP, catheter change and ESWL
Figure 32 below shows the patients recruited as part of the pilot study.
Figure 32. The number of patients recruited during the pilot study
Pilot 
Study
TURP
Catheter 
Change
ESWL
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TURP
N=11
Catheter 
change
N=5
2 (18.1) 1 (20)
3 (27.3) 2 (20)
5 (45.4) 0 (0)
15.6 ± 12.0 n/a
0 (0) 1 (20)
1 (9.1) 1 (20)
situ (%) 7 (63.6) 5 (100)
84 ± 118 92±24
1 (9.1) 0 (0)
0 (0) 0 (0)
-cardiac (%) 1 (9.1) 0 (0)
0 (0) 0 (0)
13 patients 
approached
11 patients 
recruited
6 patients 
approached
5 patients 
recruited
7 patients 
approached
5 patients 
recruited
ESWL
N=5
2 (40)
0 (0)
0 (0)
n/a
1 (20)
5 (100)
0 (0)
84 ± 118
0 (0)
0 (0)
0 (0)
0 (0)
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4.3.3.2 Results of the sampling pilot study in patients having TURP
The samples acquired for the TURP group are shown in Table 59 below.
RECRUIT A B C D E F G
TURP001 ¥ X X X X X X
TURP002 ¥ ¥ ¥ ¥ ¥ ¥ ¥
TURP003 ¥ ¥ ¥ ¥ ¥ X X
TURP004 X X X X X X X
TURP005 ¥ ¥ ¥ ¥ ¥ ¥ X
TURP006 X X X X X X X
TURP007 ¥ ¥ ¥ ¥ ¥ ¥ ¥
TURP008 ¥ ¥ ¥ ¥ ¥ ¥ ¥
TURP009 X X X X X X X
TURP010 ¥ ¥ ¥ X X X X
TURP011 X X X X X X X
Table 59. Blood samples obtained from TURP patients
A complete set of blood samples was not obtained from all the participants. The 
reasons for the failure to complete the recruiting protocol are given in Table 60 
(over the page).
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Recruit Reason for failure
TURP001 The cannula fell out and was not re-sited
TURP003 The cannula failed to bleed for time-points F and G
TURP004 Patient was cancelled owing to lack of space on the theatre list
TURP 005 The cannula failed to bleed at time-point G
TURP006 Failure owing to logistics in operating theatre: unable to get samples
TURP009 The cannula failed to bleed
TURP010 The cannula fell out after time-point C
TURP 011 The cannula failed to bleed
Table 60. The reasons for the failure of the recruitment process during the 
TURP pilot study
Thirty-seven out of a maximum seventy-seven samples (48.1%) were obtained. 
Cannula failure was the most common reason for the inability to obtain the 
blood samples as shown in Table 60 above.
4.3.3.3 Results of sampling pilot study in patients having catheter change
The samples obtained for the catheter-change group are shown in Table 61 
(over the page). Patients who had a urethral catheter change were annotated 
with the letter U (e.g. CATH003-U) and the patients having a suprapubic 
catheter change were annotated with S (e.g. CATH001-S).
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RECRUIT A B C D E F G
CATH001-S ¥ ¥ ¥ ¥ ¥ ¥ ¥
CATH002-S ¥ ¥ X X ¥ ¥ ¥
CATH003-S ¥ ¥ X X ¥ ¥ X
CATH004-U X X X X X X X
CATH005-U ¥ ¥ ¥ X ¥ ¥ ¥
Table 61. Samples from catheter change patients
The reasons for the failure to complete the recruiting protocol are given in Table
62.
Recruit Reason for failure
Cath003-S The cannula failed to bleed at time-point G
Cath004-U Failure to gain venous access with participant
Table 62. The reasons for the failure of the recruitment process during the 
catheter change pilot study
The same issue arose for the catheter change participants (cannula failure) to 
explain the inability to acquire the complete set of blood samples.
4.3.3.4 Results of the sampling pilot study in patients having ESWL
The samples obtained from the ESWL patients are shown in the Table 63.
RECRUIT A B C D E F G
ESWL001 ¥ ¥ X X X X X
ESWL002 ¥ ¥ ¥ ¥ ¥ ¥ X
ESWL003 ¥ X X X X X X
ESWL004 ¥ ¥ ¥ ¥ ¥ ¥ ¥
ESWL005 ¥ ¥ ¥ ¥ ¥ ¥ ¥
Table 63. Samples from ESWL patients
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The reasons for the failure to complete the recruiting protocol are given below.
Recruit Reason for failure
ESWL001 The cannula fell out after time-point B
ESWL002 The cannula failed to bleed after time-point F
ESWL003 The cannula failed to bleed after time-point A
Table 64. The reasons for the failure of the recruitment process during the 
ESWL pilot study
4.3.3.5 Evidence of bacteraemia in the pilot study for TURP, catheter 
change and ESWL patients
Five positive samples were obtained in the pilot study and further investigations 
were carried out to allow identification of the bacteria found in the sample. The 
results are tabulated below (Table 65).
Gram-Staining Oxidase Test Catalase Test Identification by PCR
Control Samples
S. aureus Positive Coccus X ¥
P. aeruginosa Negative Rod ¥ ¥
Test Samples
TURP003 C GN Rod ¥ ¥VORZ P. aeruginosa
TURP005 B GN Rod X ¥ Enterobacter sp.
TURP007 C GN Rod ¥ ¥ P. aeruginosa
TURP007 D GN Rod ¥ ¥ P. aeruginosa
TURP007 G GN Rod ¥ ¥ P. aeruginosa
Table 65. Bacteraemia detected in the pilot study of patients having TURP
4.3.4 Conclusions of the pilot study
All the bacteraemias detected were in the patients undergoing TURP. Table 65 
shows the organisms detected in the five patients with bacteraemia.
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Pseudomonas aeruginosa was the most common organism detected in the pilot 
study. The pilot study showed a good recruitment rate. However, a few issues 
were noted which were improved in the prospective study. This is discussed in 
Sections 4.3.4.1-6.
4.3.4.1 Patient contact
It was deemed too time consuming for the urology research nurse to seek 
patients and approach them actively. Therefore, it was decided that the treating 
clinician would make the first approach with the patient and briefly explain the 
study being carried out. If the patient expressed an interest in taking part in the 
study, he/she was put in touch with the principal investigator (the author). If the 
patient wished to take part in the study after the first contact with the principal 
investigator, full consent was obtained.
4.3.4.2 Problems with the venous cannulation
One of the main issues encountered in the pilot study was cannula failure. 
Therefore, a large proportion of the recruited participants failed to provide a 
complete set of blood samples for this reason. It was decided that improvement 
of cannulation skills should be attempted by the author attending a course 
organised by the ‘in-house’ phlebotomy service and planned to use the biggest 
possible cannula that the patient’s vein will allow and where possible get 
experts (e.g. anaesthetists in the operating theatre for TURP patients) to insert 
the cannula.
4.3.4.3 Keeping cannula patent with IV fluid
A slow intravenous infusion of normal saline was used in the pilot study to keep 
the cannula patent. This extra step did not improve the patency of the cannulae. 
In fact, this extra step made the whole process cumbersome, with the additional 
need for a drip stand. Therefore, it was decided to drop this step and not utilise 
IV fluid for the prospective study.
4.3.4.4 Timing of blood samples
It was decided to obtain only one rather than three post-procedure samples. It 
made the prospect of entering the study easier for patients, especially those 
scheduled for catheter manipulation. They did not have to wait long after their 
procedure before they could go back home. Furthermore, to cut costs, it was felt 
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that having three post-procedure samples would not provide any additional 
information, as only one post-procedure sample in the pilot study was positive 
for bacteraemia. The shorter in situ time for the cannula improved its patency 
for the duration of the recruitment period.
4.3.4.5 Urine samples
Obtaining a pre-procedure urine sample was felt to be important to be able to 
interpret the bacteraemia result. Therefore, it was decided to acquire a urine 
sample to check for bacteriuria for the prospective study.
4.3.4.6 Procedure
Running three prospective studies for three different procedures was too 
time-consuming, both in terms of recruiting patients and processing the 
samples. It proved to be too costly as well. A decision was made only to recruit 
patients having TURP and catheter manipulation. In the pilot study, only 
patients having catheter change were recruited. This group was broadened to 
patients having catheter manipulation (catheter change and removal) to 
improve the recruitment rate.
4.4 Prospective studies looking at bacteraemia during TURP 
and catheter manipulation
4.4.1 Introduction
A study protocol was designed to answer the questions:
x ‘Does bacteraemia occur during urological procedures? If so, when does 
it occur, how many bacteria are involved, for how long does it last and 
which bacteria are implicated?’ 
As discussed previously, the two categories of patients studied were patients 
having TURP and catheter manipulation. Two prospective cohort studies were 
designed to evaluate bacteraemia in patients undergoing TURP and catheter 
manipulation.
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4.4.2 Methods
4.4.2.1 The recruitment of patients
Patients recruited in the study were counselled about the study prior to their 
contact with the research team. Potential TURP recruits were approached in the 
outpatient department by the clinician listing the patient for the procedure. The 
urology nurse specialist approached potential recruits undergoing catheter 
manipulation before they had any contact with the research team. If the 
potential recruits expressed an interest in taking part in the study, they were put 
in touch with the principal investigator.
4.4.2.1.1 Recruitment for the TURP group
Patients having TURP were identified via number of different sources:
x the admissions list circulated weekly by the urology admissions office. 
This document was used to identify patients having a scheduled TURP 
on an elective urology list. The date of the procedure, the operating 
theatre and the admitting ward were identified;
x patients having TURP after an acute admission for urinary retention were 
identified via word-of-mouth from the ward staff;
x patients having a day-case TURP were identified through the secretaries 
of the urological surgeon choosing to list the patient to have the 
operation.
4.4.2.1.2 Recruitment for the catheter manipulation group
Patients having catheter manipulation were identified through the urology nurse 
specialist who performed all the scheduled catheter manipulations (for patients 
in the community, who require their catheter to be manipulated by the urology 
department in Leeds) at the Leeds Teaching Hospitals NHS Trust.
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4.4.2.1.3 Inclusion/Exclusion Criteria
The inclusion criteria for the patients recruited into the study were:
x adults (> 18 years old);
x both male and female1;
x patients undergoing the following procedures (transurethral resection of 
the prostate and urinary catheter change or removal) at the Leeds 
Teaching Hospital NHS Trust.
The absolute exclusion criteria for the study were:
x patient aged less than 18 years;
x patients who were not competent to consent for enrolment in the study;
x signs and symptoms of an ongoing infection (of any source) at the 
admission to the hospital.
There were some relative exclusion criteria and each patient was assessed 
individually. The relative exclusion criteria were:
x the use of systemic antibiotics within the two weeks of presentation to the 
hospital;
x recent (within two weeks) instrumentation of the urinary tract (not 
including urethral or suprapubic catheterisation);
x patients with poor veins, leading to difficult venous cannulation.
Based on these inclusion and exclusion criteria, there was an expectation to 
recruit fifty participants in each of the two groups of patients.
                                           
1 Only male patients have a TURP
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4.4.2.2 Consent
Once the patient expressed a wish to take part in the study, their full consented 
to participate in the study was obtained using the consent form included in 
Appendix 6. At the same sitting as consent was obtained, patients were given a 
patient information sheet, describing the study and their involvement in the 
study (Appendix 5). Both the consent form and the patient information sheet 
were vetted and approved by the ethics committee and the R&D department at 
the Leeds Teaching Hospitals NHS Trust. Once consented, the patient was 
assigned a research identification number. The TURP patients were assigned 
T-identification numbers (e.g. T001) and the catheter manipulation patients 
were assigned C-identification numbers (e.g. C001).
4.4.2.3 Medical History to collect data on potential risk factors for 
developing bacteraemia
On the day of their procedure, a detailed medical history was obtained using the 
specially designed data collection form (Appendix 7). The form was divided into 
three main sections (exclusion criteria, general risk factors for bacteraemia, 
specific risk factors for infective endocarditis).
4.4.2.4 Processing of urine samples
4.4.2.4.1 Obtaining the urine sample
Once the medical history form was completed, a urine sample was collected 
from the patient in a standard, sterile urine pot. The pot was labelled using the 
patient identification number. The date of the collection of the sample was also 
recorded on the pot. The pot was stored in a bio-sample transportation bag (as 
per the Trust policy). If the patient was not catheterised, the patient was asked 
to void spontaneously and a mid-stream urine sample (MSU) collected. The 
patient was given clear verbal instructions of how to collect the urine sample. If 
the patient was catheterised, a urine sample was obtained from the catheter 
bag. The urine sample obtained was processed in the laboratory within 
24 hours of collection.
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4.4.2.4.2 Handling of the urine sample in the laboratory
The urine sample was processed as follows. The urine pot was shaken and a 
10 ȝ/ inoculating loop was dipped in the urine. The loop was spread on a CLED 
agar plate (Thermo Scientific, Basingstoke, UK). The CLED agar plate as 
incubated in air at 37° C for 24 hours and then read. If growth was noted, the 
following identification protocol was performed:
x the colony morphology on the CLED agar plate was noted;
x the isolate was Gram stained and microscopy was performed (as per the 
protocol in Chapter 4);
x simple preliminary identification tests (oxidase, catalase) were performed 
depending on the results obtained in the previous steps;
x the number of colony forming units (cfu) was counted to provide a 
quantitative value to the bacteriuria. Since the number of cfu per 10 ȝ/
was known, the concentration of bacteria in the original urine was 
calculated. For practical purposes, a cut-off value of 104 cfu/mL was 
used to define bacteriuria.
x the organism(s) grown was stored in glycerol broth at -70° C for further 
processing.
Once a reasonable number (thirty) of stored bacterial samples were obtained, 
all the stored organisms were inoculated on CBA plates (Thermo Scientific, 
Basingstoke, UK) and incubated at 37° C in air for 24 hours. The fresh cultures 
were processed for bacterial DNA amplification as follows:
x a 10 ȝ/ inoculating loop was used to touch a single colony on the CBA 
plate and then transferred into a tube containing sterile water. The 
mixture was homogenised by stirring the loop in the tube. This mixture 
was used for bacterial DNA amplification as per the standard protocol. 
Once the bacterial DNA was amplified and Ct values obtained, the 
bacterial DNA present in the sample was identified by the sequence 
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determination method using the BLAST website 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).
4.4.2.5 Processing of the blood samples
The next step was to obtain blood samples. This procedure was done using 
standard aseptic technique in compliance with local guidelines.
4.4.2.5.1 Cannulation of the patient
The method used in the pilot study was modified to insert a cannula, which was 
left in situ for the duration of the study, rather than using a syringe and a 
needle. This was done using a 16G, 18G or 20G cannula, inserted in the 
antecubital fossa of the patient. The size of the cannula depended on the size 
of the veins available. This step was done by the principal investigator or an 
experienced anaesthetist, if available. Once the cannula was in place and fixed, 
a three-way tap was connected. Patients having TURP under general or spinal 
anaesthesia had their arms out on an arm board during the procedure, to 
provide easy access to of the cannula in the antecubital fossa. Patients in the 
catheter manipulation group did not require their arms out on an arm board as 
the patients were not anaesthetised and were compliant to instructions.
4.4.2.5.2 Obtaining the blood samples
Firstly, the nozzle of the three-way tap was cleaned with an ‘alco-wipe’ 
(alcoholic 2% chlorhexidine skin wipes by Clinell®). Then, 2 mL of blood was 
aspirated using a 5 mL syringe after opening the three-way tap. This blood 
sample was discarded and 20 mL of blood was aspirated using a 20 mL 
syringe. The cannula was flushed with 2 mL of normal saline and the three-way 
tap closed.
4.4.2.5.3 Timing of the blood samples
This above process was repeated at each time point that a blood sample was
required, shown in Table 66. For the TURP group, patients who had a urethral 
catheter in situ prior to the procedure had an extra time point at which an extra 
blood sample was obtained. This was done in order to assess whether the 
catheter removal just pr
in this group of patients. For the catheter manipulation group, patients having 
catheter removal only missed time point C as shown in 
Procedure
A
(pre-procedure)
TURP
(no catheter)
 
TURP
(urethral 
catheter)
 
Catheter 
Manipulation
 
Table 66. Time points for blood sample collection in the two 
studies
The 20 mL of blood obtained at each time point were transferred in three 
separate tubes as per the algorithm shown in Figure 3
Figure 33. Distribution of the 20
Once all the blood samples were acquired, the cannula was removed from the 
antecubital fossa of the patient and haemostasis was achieved with pressure. 
The blood samples obtained were processed in the laboratory within 24
of collection.
20 ml of blood
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ior to TURP influenced the development of bacteraemia 
Table 66.
B
(C
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C
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in into 
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D
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E
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       
       
     
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mL of blood obtained at each time point
8 ml in a Biomerieux BacT/ALERT® aerobic b
7 ml in a Biomerieux BacT/ALERT® anaerobic bottle
5 ml in a EDTA tube
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 
 
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4.4.2.5.4 Processing the blood samples by the culture method
The two inoculated blood culture bottles obtained at each time point were 
placed in the BACTEC™ 9050 Blood Culture instrument. The BACTEC™ 9050 
Blood Culture System is an automated system for incubation and agitation of 
culture bottles. However, the automation setting was disabled and only the 
incubation and agitation properties of the instrument were used. After ten days, 
all samples were plated as described in the Table 67. Ten days (as opposed 
the standard four to five days) was chosen to improve sensitivity. Samples were 
obtained from the blood culture bottles using the venting unit provided by the 
manufacturer of the blood culture bottles. The blood culture bottles were then 
discarded.
Standard Medium Incubation Plates Read
Temperature Atmosphere Time
48-72 hours
Blood (CBA)
35-37° C
5-10% CO2
48 hoursFAA Anaerobic
CLED Air
Table 67. Media for subculture (adapted from ‘Investigation of Blood 
Cultures by The Health Protection Agency – now Public Health 
England)
At 48-72 hours, all the plates were read. Any bacterial growth was noted and 
characterised as follows:
x the colony morphology on the plate was noted
x the organism was Gram stained and microscopy was performed (as per 
the protocol in Chapter 4);
x simple tests (oxidase, catalase) were performed depending on the 
results obtained in the previous steps.
Thereafter, a loop was used to sample any bacterial growth obtained and this 
was stored at -70° C in tubes containing glycerol broth. Once a reasonable 
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number (ten to twelve samples) of stored bacterial samples were obtained, they 
were processed as for the bacterial samples obtained from urine (described in 
Section 4.4.7.1). This process allowed the identification of all bacteria grown 
from blood samples that were incubated and cultured. 
4.4.2.5.5 Extracting bacterial DNA from blood
Bacterial DNA was extracted from the 5 mL of blood the EDTA tube. This 
process was carried out within 24 hours of the collection of the sample, using 
the standard protocol for MolYsis5 Complete by Molzym GmbH & Co, Bremen, 
Germany. Each 5 mL blood sample yielded 100 ȝ/RIHOXDWH7KHHOXDWHZDV
stored at -70° C and bacterial DNA was amplified and the sources identified in 
batches of twenty-four. For further processing, the eluate was thawed and 
diluted with molecular grade water to a volume of 220 ȝ/
4.4.2.5.6 Processing the extracted bacterial DNA
4.4.2.5.6.1 Processing the extracted bacterial DNA by the Plex-ID System
The diluted eluate was plated according to the Plex-ID automated protocol (see 
Appendix 5). Samples were processed in batches of twenty-four, as this was 
the maximum number of samples that could be plated by the automated Plex-ID 
fluid handler system. A 220 ȝ/ YROXPH RI WKH HOXDWH ZDV SODFHG LQ WKH
designated well on the 24-well plate. The fluid handler was loaded with four 
BAC-SF plates, which had previously been thawed according to the protocol.
Each sample was plated into the sixteen corresponding wells on BAC-SF plates 
in 10 ȝ/YROXPHVXVLQJDWRWDORI ȝ/$OORZLQJIRUSLSHWWLQJHUURU ȝ/RI
the eluate was left, which was used for the further processing (Section 
4.4.7.2.2.2). A positive control (a sample with confirmed bacterial DNA) and 
negative control (molecular grade water) was used for each plating run. The 
loaded BAC-SF plates were processed according to the standard protocol, 
going through the following steps:
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x sealing of BAC-SF plates;
x PCR amplification in the thermocycler;
x detection, identification and quantification of the products in the Plex-ID 
analyzer.
The results obtained from this method are shown in section 4.4.3.3.2. The Plex 
software allocated any organism that was detected two parameters. For 
example, 0.90 and 14; the first parameter (0.90) refers to the probability of the 
organism detected by the Plex-ID system being a correct identification. A 
probability of > 0.85 is considered a positive result. The second parameter (14) 
is a semi-quantitative measure of the amount of bacterial DNA present in the 
sample. For the purposes of this study, it was decided that a level of < 10 
should be considered a negative result to avoid false positives, especially 
relating to skin contaminants.
4.4.2.5.6.2 Processing the extracted bacterial DNA by the 16S PCR method
The 40 ȝ/RI WKHHOXDWHOHIWIURPWKH3OH[-ID processing was used for the 16S 
broad-range PCR process. PCR was performed using the in-house 16S primer 
and the eluate. The protocol and primers used for the PCR is described in 
Appendix 4. The Ct values and fluorescence level for each sample were 
ascertained.
The set of rules below was used to process the results from the 16S PCR 
(Figure 34). This algorithm was devised with the help from Dr Deborah 
Gascoyne-Binzi, a senior clinical scientist in the molecular laboratory. By 
following these criteria, the aim was to:
x maximise true positive results from the samples processed;
x minimise the number of samples processed in an attempt to avoid 
unnecessary costs.
Figure 34. Criteria for defi
These rules yielded a large number of false positive results after the initial batch 
of sequencing. Therefore, all the definite and possible results (C
melting curves and fluorescence level) were 
Gascoyne-Binzi, an experienced clinical scientist, to determine which samples 
were likely to produce a positive result on sequence analysis. This step was 
done in an attempt to keep the costs down and to avoid the unnecessary, 
labour-intensive processing of the samples. Once the samples were 
sequenced, identification was done using Basic Local Alignment Search Tool 
(BLAST). BLAST is an online website (
that provides an algorithm for the identification of biological sequences, 
including bacterial nucleotide sequences [223].
4.4.2.6 Follow-up of patients after their procedure
Three months after their procedure, participants were contacted by tel
and a semi-structured telephone interview was carried out, using a 
questionnaire (Appendix 8). The data collected from the telephone interview 
included whether, within the preceding three months, the patient:
Rule 1
• The no
Ct value =30
Rule 2
• Definite positive samples
•Ct value < 27.5
•Characteristics of dissociation curve
•Peak temperature: 88
•Fluorescense level> 500
Rule 3
• Possible positive samples
•Ct value <30
•Characteristics if dissociation curve
•Peak temperature: 88
•Fluoresecence level>500
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http://blast.ncbi.nlm.nih.gov/
-template control (NTC) was calibrated
-92o C
-920 C
t values, 
Deborah 
Blast.cgi) 
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x felt unwell;
x had lower urinary tract symptoms;
x developed a post-procedure UTI;
x had antibiotic therapy for an infective cause;
x was re-admitted to hospital.
The patient management server and the results server at the hospital were also 
accessed to obtain further information regarding:
x the timing of discharge from hospital;
x urine culture post-procedure sent by either the general practitioner or 
hospital staff;
x blood culture sent by either the general practitioner or hospital staff.
4.4.2.6.1 Histological analysis of prostatic tissue from the TURP group
After presenting the above data at learned conferences, one issue that was 
raised was the presence of inflammation and calcification in the prostate tissue 
and the association with the development of bacteraemia. Inflammation and 
calcification can be surrogate markers for infections [224]. Therefore, the 
prostatic tissues collected at the TURP operation were re-examined by Dr 
Selina Bhattarai, an experienced consultant uro-histopathologist, for signs of 
malignancy, inflammation and calcification.
4.4.2.7 Statistical comparison of the three different methods used to 
detect bacteraemia
To compare how the three tests to detect bacteraemia performed, McNemar’s 
test was used. It was used to compare the frequencies in dichotomous data 
sets. SPSS Version 20.0.0, IBM Corporation was used to perform the tests. The 
culture method was considered the gold standard against which the other tests 
were compared.
4.4.2.8 Multi-level modelling to evaluate the association between the 
development of bacteraemia and the tim
statistically
The model was designed to determine whether there was an association 
between the development of bacteraemia and the time point at which the blood 
samples were collected. It was hypothesised that both the procedure (T
catheter manipulation) and the timing of collection of the blood sample had a 
bearing on the development of bacteraemia. To test this hypothesis, a 
multi-level model was designed, with the help of Professor Robert West, 
professor in biostatistics, u
Version 2.15 (http://www.r
diagrammatically below.
Figure 35. Multi-level model design to show evaluate the association 
between the development of bacteraemia and
collection of the blood samples
The model assumes that the presence or absence of bacteraemia is influenced 
by the nature of the procedure and the timings of when the blood samples were 
taken. The model developed by the software was a gene
model fit by the Laplace approximation (a 
differences in by normalising the data).
The formula of the modelled could be summarised as:
Bacteraemia 
Multi
TURP (n=278)
Time Points
A B C
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ings of the blood samples 
sing the open source statistical programme R, 
-project.org). The model was designed as shown 
the timings of 
ralised linear mixed 
statistical method to smooth out large 
§3URFHGXUH + Time + (1/sample)
-level modelling (n=441)
D E F
Catheter Manipulation (n=163)
Time Points
A B G
URP or 
F
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4.4.2.9 Statistical analysis to evaluate the association between bacteriuria 
and bacteraemia
To assess the association between the presence of bacteriuria and 
bacteraemia, Pearson F2 test was performed using SPSS, Version 20.0.0, IBM 
Company.
4.4.2.10 Data collection and analysis following the procedure
During the recruitment process, data were collected regarding possible 
‘patient-related’ risk factors, using the history form (Appendix 7). The variables 
are shown in Table 68 below.
Risk factors
Mean age (years) Diabetes Recurrent UTIs Infective endocarditis
Mean weight (kg) Smoking Urinary calculus Prosthetic device
Recent antibiotics Co-existing infection Urinary catheter Organ transplant
Immunosuppression Long hospital stay Cardiac history
Table 68. Patient-related risk factors to developing bacteraemia
The following data regarding the journey of the patient following the procedure 
was also collected (Table 69, over the page), via the telephone interview and 
the hospital results and patient management server.
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Parameters from hospital server
Patients discharged within two days
Patients with positive MSU within three months of procedure
Patients with a positive blood culture within three months of the procedure
Malignant prostate histology
Parameters from telephone interview
Felt unwell
Lower urinary tract symptoms
Urine sample to GP
Antibiotics from GP
Readmission For Infection
For other causes
Table 69. Data regarding the post-procedure journey of the patient
A multivariate logistic regression model (SPSS Version 20.0.0, IBM Company) 
was used to assess the association between ‘patient-related’ risk factors and 
the development of intra-procedure bacteraemia. To improve the accuracy of 
the logistic regression model, not all of the collected parameters were included 
in the analysis. The variables deemed to be significant on univariate analysis 
were included.
4.4.3 Results
4.4.3.1 Demographics of patients recruited in the studies
The demographics obtained from the medical history form are described in this 
section. The two algorithms below summarise the number of participants at the 
various stages of the two prospective studies.
Figure 36. Algorithm showing the patients recruited in the two studies
Figure 36 shows that fifty patients in the TURP group had all the required blood 
samples to assess for bacteraemia. In the catheter manipulation group, 
forty-nine patients provided all the required blood samples. The post
telephone interview had a low ‘pi
contactable by telephone included the wrong telephone number being held in 
records, no answer despite multiple attempts (at least three separate 
occasions), change of address and death.
TURP patients 
recruited
N=77
Medical History Form
N=74
Urine sample
N=74
All required blood 
samples
N=50
Post-procedure results 
from server
N=73
Telephone interview
N=43
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Medical History Form
N=58
Urine sample
N=58
All required blood 
samples
N=49
Post-proecedure 
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Telephone interview
N=32
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4.4.3.1.1 Demographics of the TURP Group
Parameter N=73
Mean age (years) 72.7
Mean weight (kg) 86.6
Within two weeks, the number of patients who 
had:
Antibiotics 18
Urological instrumentation 3
a UTI 10
Immunosuppression 2
Diabetes 6
Smoking 8
Co-existing infection 3
Long hospital stay 20
Recurrent UTIs 9
Urinary calculus 4
Urinary catheter 38
Cardiac history 29
Infective endocarditis 0
Prosthetic device 21
Organ transplant 0
Table 70. Basic demographics of patients recruited into a study of 
bacteraemia caused by TURP
A minority of patients had a UTI, urological instrumentation and antibiotic 
therapy within two weeks of the TURP. Twenty patients (27.3%) had a long 
(greater than three days) inpatient hospital stay within three months of the 
procedure, for various medical conditions including urological pathologies. Only 
nine patients (12.3%) had a history of documented recurrent UTIs. The majority 
of patients (52.0%) had a urinary catheter in situ at the time of their surgery. 
The range of duration of catheterisation varied from a few days to many 
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months. In this cohort of patients, it should be noted that almost 40% (29) of the 
patients who went on to have a TURP operation had an underlying cardiac 
pathology. This figure is in line with the big epidemiological studies investigating 
the prevalence of cardiac disease as reported by the National Academy of an 
Aging Society (http://www.agingsociety.org/agingsociety). It must also be noted 
that 28.8% of the cohort of patients had a prosthetic device in situ.
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4.4.3.1.2 Demographics of the Catheter manipulation Group
Parameter N=57
Male Sex 52
Mean age (years) 72.3
Mean weight (kg) 84.4
Type of catheter manipulation
Urethral
Removal 39
Change 10
Suprapubic
Removal 1
Change 7
Within 2 weeks, the number of patients 
who had
Antibiotics 18
Urological instrumentation 3
a UTI 5
Immunosuppression 2
Diabetes 10
Smoking 8
Co-existing infection 3
Long hospital stay 5
Recurrent UTIs 8
Urinary calculus 5
Cardiac history 19
Infective endocarditis 0
Prosthetic device 14
Organ transplant 0
Table 71. Basic demographics of patients recruited in the catheter 
manipulation group
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In the catheter manipulation group, most patients had a urethral catheter 
removal. All the catheters had been in situ for at least three weeks. In some 
cases, the patient has had catheters for many years. Most patients had their 
current catheters in situ for a period of three months. Ten out of the fifty-seven 
patients (17.5%) had diabetes in this group. A third of the patients had an 
underlying cardiac pathology and a quarter had prosthetic devices in situ.
None of the patients recruited in the two groups have had previous episodes of 
infective endocarditis or organ transplant. Most of the patients recruited were 
aged above 60 years and were male.
4.4.3.1.3 The number of recruited participants
Table 72 shows the patients recruited in the study. Only ninety-nine out of the 
one hundred and thirty eight patients recruited had a full data set (a completed 
medical history form, a urine sample, and all the required blood samples). The 
main reason for the inability to obtain a complete data set was the failure of the 
cannula, which resulted in the failure to obtain blood samples.
Procedure Patients 
recruited
Full data set Incomplete set of 
blood samples
No blood 
samples
TURP Group 77 50 3 24
Catheter manipulation Group 61 49 4 8
Total 138 99 7 32
Table 72. The number of patients recruited for the two prospective studies
4.4.3.2 Bacteriuria from urine samples
4.4.3.2.1 Bacteriuria in the TURP Group
All the isolates from the positive urine samples from the TURP patients were 
identified and are shown in Table 73. Most of the urine samples demonstrated 
mixed growth of bacteria. The predominant organism cultured was identified. In 
two samples, it was not possible to differentiate between the different organisms 
present.
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Identification of urine culture samples from TURP patients
Sample Origin Predominant organism (s)
T005 MSU Escherichia coli + Shigella sp.
T013 Urethral catheter Failed well
T015 Urethral catheter Staphylococcus epidermidis
T017 Urethral catheter Enterococcus faecalis
T018 Urethral catheter Enterococcus faecalis
T020 MSU Escherichia coli
T021 Urethral catheter Corynebacterium amycolatum
T023 Urethral catheter Staphylococcus hominis
T024 Urethral catheter Enterococcus faecalis + Pseudomonas aeruginosa
T027 Urethral catheter Enterococcus faecalis
T028 MSU Streptococcus agalactiae
T030 Urethral catheter Escherichia coli
T031 MSU Enterococcus faecalis
T033 MSU Klebsiella oxytoca
T034 Urethral catheter Enterococcus faecalis
T043 Urethral catheter Corynebacterium amycolatum
T044 MSU Morganella morganii
T045 Urethral catheter Pseudomonas aeruginosa
T046 Urethral catheter Proteus mirabilis
T049 Urethral catheter Enterococcus faecalis
T052 MSU Staphylococcus aureus
T053 Urethral catheter Pseudomonas aeruginosa
T054 MSU Escherichia coli
T055 Urethral catheter Pseudomonas aeruginosa
T059 Urethral catheter Mixed
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Sample Origin Predominant organism (s)
T061 Urethral catheter Enterococcus faecalis
T065 Urethral catheter Pseudomonas aeruginosa
T067 Urethral catheter Klebsiella penumoniae
T069 MSU Klebsiella oxytoca
T071 Urethral catheter Failed well
T072 MSU Enterococcus faecalis
T075 MSU Enterococcus faecalis
T076 Urethral catheter Klebsiella penumoniae
T077 Suprapubic catheter Mixed
Table 73. The identity of bacteriuria in TURP patients (Mixed: more than one 
sequence that could not be separated)
Thirty-four (45.9%) patients undergoing TURP had preoperative bacteriuria, 
with Enterococcus faecalis being the most common organism encountered in 
this group accounting for 29.4% of patients with bacteriuria. Eleven of the 
thirty-four patients (32.3%) with bacteriuria did not have a urinary catheter in 
situ, though four out of those eleven patients (36.4%) performed clean 
intermittent self-catheterisation on a regular basis. Two samples yielded mixed 
sequences that could not be separated without the use of commercially 
available tools. However, this study did not have the funding to use these tools.
Figure 37. Histogram showing distribution of organisms causing bacteriuria in 
patients undergoing TURP
4.4.3.2.2 Bacteriuria in the Catheter Manipulation Group
Bacteriuria of > 104 cfu
identity of the bacteriuria was determined only in patients who were noted to 
have bacteraemia during the procedure. Table 77 (over the page) shows the 
results of the bacteriuria in bacteraemic patients.
0
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/mL were detected in all the patients. Therefore, the 
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Identification of urine culture samples in catheter manipulation patients
Sample Origin Predominant organism (s)
C004 Suprapubic catheter Staphylococcus epidermidis + Pseudomonas putida
C019 Urethral catheter Proteus mirabilis
C020 Urethral catheter Mixed
C022 Urethral catheter Enterococcus faecalis
C024 Urethral catheter Klebsiella oxytoca
C025 Urethral catheter Propionibacterium acnes
C034 Urethral catheter Escherichia coli
C036 Urethral catheter Klebsiella oxytoca
Table 74. Identity of bacteriuria in the catheter manipulation group
Seven out of the eight patients with both bacteriuria and bacteraemia had a 
urethral catheter in situ. The other patient had a suprapubic catheter. The 
organisms found in the urine were quite diverse as shown in the table. One 
sample yielded mixed sequences that could not be separated without the use of 
commercially available tools. However, this study did not have the funding to 
use these tools.
4.4.3.3 The detection of bacteraemia in the two prospective studies
Bacteraemia was detected by three different methods: the culture method, the 
broad-range 16S method and the Plex ID methods as described in Section 
4.4.2.5. The results of the different methods are described in Section 4.4.3.1-3.
4.4.3.3.1 The detection of bacteraemia by the culture method
4.4.3.3.1.1 The detection of bacteraemia by the culture method in the 
TURP group
Table 75 shows the results of bacteraemia in patients undergoing TURP, 
detected from blood samples processed by incubation and culture. The bacteria 
grown in the culture broth was identified using molecular methods (described in 
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Section 4.4.7.1). To validate the identity of the bacteria further, simple 
biochemical tests were also performed. The results are shown in Table 75.
TURP Group (Recruited 77, Full data set 50)
Samples
Presence of 
catheter
Identity of Bacteraemia
Basic Identification 16S PCR on culture
T012A No GP cocci, catalase positive, coagulase negative Staphylococcus caprae
T021D
Yes
GP rods, catalase negative Actinomyces turicensis
T021E GP rods, catalase negative Actinomyces turicensis
T021F GP rods, catalase negative Actinomyces turicensis
T024D Yes GN rods, oxidase positive Pseudomonas aeruginosa
T024E Yes GN rods, oxidase positive Pseudomonas aeruginosa
T027C Yes GP cocci, catalase positive, coagulase negative Staphylococcus epidermidis
T028D
No
(CISC)
GP cocci, beta haemolytic Staphylococcus epidermidis
T028E GP cocci, beta haemolytic Staphylococcus epidermidis
T028F GP cocci, beta haemolytic Staphylococcus epidermidis
T033A
No
(CISC)
GP rods, catalase negative Actinomyces neuii
T033C GP rods, catalase negative Actinomyces neuii
T033D GP rods, catalase negative Actinomyces neuii
T033E GP rods, catalase negative Actinomyces neuii
T033F GP rods, catalase negative Actinomyces neuii
T039C No
GP coccobacilli, catalase negative, oxidase 
negative
Actinobaculum massiliense
T039D
GP coccobacilli, catalase negative, oxidase 
negative
Actinobaculum massiliense
T040F No
GP coccobacilli, catalase positive, oxidase 
negative
Corynebacterium 
glucuronolyticum
T045C Yes GN cocci, anaerobic growth Veillonella dispar
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Samples
Presence of 
catheter
Identity of Bacteraemia
Basic Identification 16S PCR on culture
T046B
Yes
GN rods, oxidase negative Proteus vulgaris
T046C GN rods, oxidase negative Proteus vulgaris
T046D GN rods, oxidase negative Proteus vulgaris
T046E GN rods, oxidase negative Proteus vulgaris
T046F GN rods, oxidase negative Proteus vulgaris
T049A
Yes
GP cocci, catalase negative Enterococcus faecalis
T049B GP cocci, catalase negative Enterococcus faecalis
T049C GP cocci, catalase negative Enterococcus faecalis
T049F GP cocci, catalase negative Enterococcus faecalis
T050E Yes GP cocci, catalase negative Streptococcus anginosus
T053D
Yes
GN rods, oxidase positive Pseudomonas aeruginosa
T053E GN rods, oxidase positive Pseudomonas aeruginosa
T053F GN rods, oxidase positive Pseudomonas aeruginosa
T055C
Yes
GN rods, oxidase positive Pseudomonas aeruginosa
T055D GN rods, oxidase positive Pseudomonas aeruginosa
T055E GN rods, oxidase positive Pseudomonas aeruginosa
T055F GN rods, oxidase positive Pseudomonas aeruginosa
T061 Yes GP cocci, catalase negative Enterococcus faecalis
T064 Yes GP cocci, catalase positive, coagulase negative Staphylococcus epidermidis
T065D
Yes
GP cocci, beta haemolytic Streptococcus agalactiae
T065E GP cocci, beta haemolytic Streptococcus agalactiae
Table 75. Identity of positive blood cultures from TURP patients
Fifty participants provided a total of two hundred and seventy six (276) blood 
samples. Fourteen out of the seventeen (82.4%) patients who developed 
bacteraemia during their procedure had a urinary catheter in situ prior to the 
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procedure or were performing CISC prior to the procedure. Of the forty-one 
positive blood cultures, two were regarded as contaminants (T012A and T040F) 
as the organisms detected (Staphylococcus caprae and Corynebacterium 
glucuronolyticum respectively) are known skin contaminants and were
recovered only from single samples [225]. Of the thirty-nine true bacteraemia 
cases (those that did not include skin contaminants), the most common 
organisms detected in the TURP group were Enterococcus faecalis and 
Pseudomonas aeruginosa. Fourteen out of the fifty patients (28.0%) undergoing 
TURP had bacteraemia peri-operatively, detected using the culture method.
4.4.3.3.1.2 The detection of bacteraemia by the culture method in the 
catheter manipulation group
Catheter Group (Recruited 61, Full data set 49)
Sample
Type of 
catheter
Identity of Bacteraemia
Basic Identification 16S PCR on culture
C002A Urethral GP cocci, catalase positive, coagulase negative Staphylococcus epidermidis
C004A
Suprapubic
GP cocci, catalase positive, coagulase negative Staphylococcus epidermidis
C004B GP cocci, catalase positive, coagulase negative Staphylococcus epidermidis
C004C GP cocci, catalase positive, coagulase negative Staphylococcus epidermidis
C004D GP cocci, catalase positive, coagulase negative Staphylococcus epidermidis
C005D Urethral
GP coccobacilli, catalase positive, oxidase 
negative
Corynebacterium amycolatum
C007D Suprapubic GP rods, anaerobic growth Propionibacterium acnes
C019A
Urethral
GP cocci, not bile soluble
Streptococcus 
pseudopneumoniae
C019B GP cocci, not bile soluble
Streptococcus 
pseudopneumoniae
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Sample
Type of 
catheter
Identity of Bacteraemia
Basic Identification 16S PCR on culture
C020B
Urethral
GP coccus, catalase negative Streptococcus mitis
C020B GP coccus, catalase negative Streptococcus mitis
C022A
Urethral
GP coccus, coagulase negative Staphylococcus warneri/pasteuri
C022D GP coccus, coagulase negative Staphylococcus warneri/pasteuri
C024B
Urethral
GN rods Klebsiella oxytoca
C024D GN rods Klebsiella oxytoca
C025B Urethral GP cocci, catalase positive, coagulase negative Staphylococcus epidermidis
C034A Urethral GN cocci, aerobic Neisseria flavescens
C036D Urethral GN cocci, aerobic Neisseria flavescens
C047A Suprapubic GP cocci, oxidase positive Micrococcus species
C050D Urethral GP cocci, catalase positive, coagulase negative Staphylococcus epidermidis
Table 76. Identity of bacteraemia in patients in the catheter manipulation 
group
Forty-nine participants in the catheter manipulation group provided a total of 
one hundred and sixty-three (163) blood samples. Of the forty-nine participants 
recruited, thirty-four patients had urethral catheter removal, seven had urethral 
catheter change, seven had suprapubic catheter change and one had 
suprapubic catheter removal. Seven out of thirty-four patients (20.6%) in the 
urethral catheter removal group and one out of the seven patients (14.3%) in 
the suprapubic catheter change group had bacteraemia. No bacteraemia was 
noted in the urethral catheter change and the suprapubic catheter removal 
groups. The main organisms causing bacteraemia were Staphylococcus 
epidermidis and Klebsiella oxytoca.
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4.4.3.3.2 The detection of bacteraemia by the Plex-ID System
4.4.3.3.2.1 The detection of bacteraemia by the Plex-ID System in the 
TURP group
The Plex-ID detected thirty-four positive samples in the TURP group. However, 
based on the quantification cut-off of < 10 and the knowledge of skin 
contaminants, only four samples were considered true positives (T028D, 
T028E, T028F and T049B). The organisms detected were Streptococcus 
agalactiae and Streptococcus penumoniae. The thirty other positive samples 
were considered to be false positives as they were either skin contaminants 
and/or were detected at levels < 10. Table 77 shows all the results not reported 
as ‘negative’ by the Plex-ID.
Blood Sample Identification of bacteraemia using the Plex-ID
T005A Staphylococcus hominis (0.99; 24)
T015D Bacillus subtilis (0.97; 45)
T015F Bacillus subtilis (0.93; 46)
T017C Well failure
T020A Staphylococcus aureus (0.90; 5)
T021E Well failure
T022C Well failure
T022D Well failure
T023A Staphylococcus aureus (0.99; 4)
T023C Staphylococcus aureus (0.99; 3)
T023E Plate failure
T023F Plate failure
T024A Plate failure
T024B Plate failure
T024C Plate failure
T024D Plate failure
T024E Plate failure
T024F Plate failure
T026A Plate failure
T026B Plate failure
T026C Plate failure
T026D Plate failure
T026E Plate failure
T026F Plate failure
T027A Plate failure
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Blood Sample Identification of bacteraemia using the Plex-ID
T027B Plate failure
T028D Streptococcus agalactiae (1.00; 69)
T028E Streptococcus agalactiae (0.99; 43)
T028F Streptococcus agalactiae (1.00; 22)
T043F Pseudomonas putida/stutzeri (0.93; 27)
T044D Pseudomonas putida/stutzeri/entomophilia (0.94; 22)
T045A Pseudomonas putida/entomophilia/stutzeri (0.94; 38)
T045C Pseudomonas putida/entomophilia/stutzeri (0.93; 29)
T046A Pseudomonas putida/entomophilia/stutzeri (0.94; 32)
T046E Streptococcus oralis/sanguinis (0.93; 5)
T049A Pseudomonas putida/stutzeri (0.93; 37)
T049B Streptococcus penumoniae (0.93; 11)
T049D Staphylococcus saprophyticus (0.99; 11)
T050B Pseudomonas putida/entomophilia/stutzeri (0.94; 24)
T053C Pseudomonas putida/stutzeri (0.94; 53)
T055A Propionibacterium acnes (0.98; 22)
T055B Corynebacterium xerosis (0.93; 10)
T055D Micrococcus luteus (0.96; 25)
T059A Propionibacterium acnes (0.98; 30)
T059E Acinetobacter baumannii (0.94; 3)
T062B Staphylococcus hominis (0.99; 12)
T062C Bacillus cereus group (0.96; 7)
T062F Pseudomonas stutzeri (0.98; 56)
T064C Staphylococcus hominis (1.00; 40)
T067B Staphylococcus aureus (0.92; 3)
T067E Cellulomonas humilata (0.94; 44)
T071C Staphylococcus aureus (0.90; 3)
T076E Propionibacterium acnes (0.93; 21)
T076F Propionibacterium acnes (0.97; 21)
Table 77. Identities of bacteria from blood samples taken from patients 
undergoing TURP as detected by the Plex-ID
4.4.3.3.2.2 The detection of bacteraemia by the Plex-ID System in the 
catheter manipulation group
In the catheter manipulation group, twenty-four samples were positive. 
However, all the samples were considered false positives as the organisms 
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detected were skin contaminants and/or were too few. Therefore, the Plex- ID 
did not pick up any bacteraemia in the catheter manipulation group. Table 78 
shows all the results not reported as ‘negative’ by the Plex-ID.
Blood Sample Identification of bacteraemia using the Plex-ID
C002A Lactobacillus acidophilus (0.94; 17) + Enterococcus durans/haire(0.97; 17)
C002C Weissella confusa (0.97; 13)
C005B Staphylococcus aureus (0.93; 7)
C006B Macrococcus caseolyticus (0.92; 8)
C009D Pseudomonas putida/stutzeri (0.96; 69)
C013A Staphylococcus aureus (0.95; 7)
C015B Staphylococcus aureus (0.91; 4)
C016B Staphylococcus haemolyticus (1.00; 11)
C019A Staphylococcus hominis (0.98; 15)
C026A Methylobacterium mesophilicum (0.93; 8)
C026D Staphylococcus aureus (0.91; 4)
C029B Staphylococcus hominis (0.99; 16)
C032B Staphylococcus epidermidis (0.92; 12)
C035B Staphylococcus aureus/haemolyticus (0.95; 10)
C037D Staphylococcus aureus (0.95; 16)
C038A Staphylococcus aureus (0.95; 6)
C041A Streptococcus vestibularis (0.91; 6)
C041D Propionibacterium acnes (0.95; 21)
C047C Streptococcus penumoniae (0.92; 4)
C053A Propionibacterium acnes (0.97; 24)
C055A Staphylococcus aureus (0.94;8)
C057A Staphylococcus aureus (0.99; 13)
C057D Acidovorax temperans (0.91; 7)
C058B Staphylococcus aureus (0.92; 7)
Table 78. Identities of bacteria from blood samples taken from patients 
undergoing catheter manipulation as detected by the Plex-ID
4.4.3.3.3 The detection of bacteraemia by the 16S PCR method
By following the criteria described in Section 4.4.2.5.6.2, forty-five samples in 
the TURP group were ‘possible’ positive samples and fifty-three samples were 
‘definite’ positive samples. In the catheter manipulation group, forty-one 
samples were ‘possible’ positive samples and thirteen were ‘definite’ positive 
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samples. The detailed results are shown in Appendix 9. The following samples 
were identified for sequence determination and analysis (as described in 
Section 4.4.2.5.6.2) after review by the experienced molecular microbiology 
scientist, Dr Deborah Gascoyne-Binzi.
Positive samples (Expert review) Ct Value
T017E 26.74
T017F 26.90
T018E 23.28
T020A 26.88
T020C 24.33
T020F 24.24
T021A 24.18
T021D 24.50
T021E 24.13
T021F 24.22
T022C 24.19
T022D 26.68
T027F 25.63
T031F 25.75
T036D 25.37
T038E 27.49
T043A 24.02
T044A 23.87
Table 79. Samples determined that eventually had their sequences 
determined
Out of the eighteen samples examined, three of the samples yielded sequences 
that could be read and compared with sequences from BLAST 
(http://blast.ncbi.nlm.nih.gov).
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Sample Ct Value Identity from BLAST
T027F 25.63 Streptococcus agalactiae
T031F 25.75 Enterobacteriacae
T036D 25.37 Acinetobacter spp.
Table 80. Identification of the positive sample using BLAST
The three samples identified were not positive when using the two other 
methods (culture and Plex-ID). The broad-range 16S PCR method 
demonstrated that three samples had evidence of bacteraemia.
4.4.3.4 Results from the follow-up of patients following the procedure
A summary of the results from the post-procedure telephone interview, the 
results server and the review of the prostate histology are shown below.
4.4.3.4.1 Follow-up data from the TURP group
Parameters from hospital server n=73
Patients discharged within two days 52
Patients with positive MSU within three months of procedure 41
Patients with a positive blood culture within 3 month of the procedure 7
Malignant prostate histology 20
Parameters from telephone interview n=43
Felt unwell 15
Lower urinary tract symptoms 16
Urine sample to GP 15
Antibiotics from GP 15
Readmission For Infection 7
For other causes 6
Table 81. Data from the telephone interview from patients in the TURP 
group
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Fifty-two patients (71.2%) having a TURP operation were discharged within two 
days of the procedure, with haematuria being the main reason for delays in 
discharge from the hospital. Forty-one patients (56.1%) had a documented 
bacteriuria within three months of the procedure. Twenty out of the 
seventy-three patients (27.4%) recruited had prostate cancer, based on 
histopathological results of the prostate chips obtained from the TURP 
operation. Forty-three of the recruited patients (58.9%) were contactable by 
telephone for an interview. Sixteen of the patients contacted (37.2%) said they 
felt unwell following the procedure, mainly from lower urinary tract symptoms. 
Their general practitioner reviewed them, and a urine sample was sent for 
culture. Fifteen patients (34.9%) were prescribed antibiotics for their symptoms. 
Thirteen of the patients contacted (27.1%) were readmitted to the hospital. 
Seven of the patients who were readmitted to hospital, presented with infective 
symptoms. Data from four patients were missing and, therefore, it was possible 
to obtain post-operative parameters for seventy-three of the seventy-seven 
patients recruited
4.4.3.4.1.1 Prostate histology from the TURP group
Variables N=73 (%)
Malignant histology 21 (28.8)
Presence of acute inflammation 3 (4.1)
Presence of chronic inflammation 23 (35.6)
Presence of calcification 3 (4.1)
Number of patients with bacteraemia 15 (20.5)
Table 82. The presence of inflammation and calcification in TURP patients 
based on histopathological analysis following the procedure
Twenty-six patients had evidence of prostatic inflammation, twenty-three 
patients had chronic inflammation, one had acute inflammation and two patients 
had both acute and chronic. Only three patients had evidence of prostatic 
calcification.
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Univariate analysis (Pearson F2 test) showed that there was an association 
between the development of intraoperative bacteraemia and prostatic 
inflammation (F2 (1) = 4.97, p = 0.026). The frequency of calcification was too 
low to detect any statistical association with intraoperative bacteraemia.
4.4.3.4.2 Follow-up data from the catheter manipulation group
Parameter from hospital server n=57
Patients with positive MSU within three months of procedure 10
Patients with a positive blood culture within three months of the procedure 1
Parameters from telephone interview n=32
Felt unwell 5
Lower urinary tract symptoms 6
Urine sample to GP 8
Parameters from telephone interview n=32
Antibiotics from GP 6
Readmission For Infection 0
For other causes (e.g. pain) 3
Table 83. Follow-up data from the catheter manipulation group
Examination of the results server revealed that only a minority of patients who 
had catheter manipulation had urine and blood samples sent within three 
months of their procedure. Thirty-two participants (56.1%) responded to the 
telephone interview with less than 20% of the respondents reporting any 
urological complaint. Three of the respondents were readmitted within three 
months of their procedure but none of these admissions were owing to infective 
complications.
4.4.3.5 Methods for the detection of bacteraemia detection: how do they 
compare?
The bacteraemia results obtained using the three different methods (culture, 
broad-range 16S PCR and Plex-ID) are compared in Table 84 below. Four 
hundred and forty-one blood samples were obtained in all. All the results were 
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available for the culture and 16S PCR methods. Twenty results were missing 
from the Plex-ID methodology owing to plate failure during the amplification 
process. The results of the three different methods are shown in Table 84.
Blood 
Sample
Culture+ DNA Extraction + 16S 
PCR DNA Extraction + Plex-ID16S PCR
T005A Negative Negative Staphylococcus hominis (0.99; 24)
T012A Staphylococcus caprae Negative Negative
T015D N/A Negative Bacillus subtilis (0.97; 45)
T015F N/A Negative Bacillus subtilis (0.93; 46)
T020A Negative Negative Staphylococcus aureus (0.90; 5)
T021D Actinomyces turicensis Negative Negative
T021E Actinomyces turicensis Negative Well failure
T021F Actinomyces turicensis Negative Negative
T023A Negative Negative Staphylococcus aureus (0.99; 4)
T023C Negative Negative Staphylococcus aureus (0.99; 3)
T024D Pseudomonas aeruginosa Negative Plate failure
T024E Pseudomonas aeruginosa Negative Plate failure
T027C Staphylococcus epidermidis Negative Negative
T027F Negative Streptococcus agalactiae(Ct: 25.63)
Negative
T028D Staphylococcus epidermidis Negative Streptococcus agalactiae (1.00; 69)
T028E Staphylococcus epidermidis Negative Streptococcus agalactiae (0.99; 43)
T028F Staphylococcus epidermidis Negative Streptococcus agalactiae (1.00; 22)
T031F Negative Enterobacteriacae(Ct:25.75)
Negative
T033A Actinomyces neuii Negative Negative
T033C Actinomyces neuii Negative Negative
T033D Actinomyces neuii Negative Negative
T033E Actinomyces neuii Negative Negative
T033F Actinomyces neuii Negative Negative
T036D Negative Actinobacter(Ct: 25.37)
Negative
T039C Actinobaculum massiliense Negative Negative
T039D Actinobaculum massiliense Negative Negative
T040F Corynebacterium glucuronolyticum Negative Negative
T043F Negative Negative Pseudomonas putida/stutzeri /entomophilia (0.93; 27)
T044D Negative Negative Pseudomonas putida/stutzeri/entemophilia(0.94; 22)
T045A Negative Negative Pseudomonas putida/sturtzeri/entomophilia(0.94; 38)
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Blood 
Sample
Culture+
16S PCR
DNA Extraction + 16S 
PCR DNA Extraction + Plex-ID
T045C Veillonella dispar Negative ASA (0.93; 29)
T046A Negative Negative Pseudomonas putida/stutzeri/entomophilia(0.94; 32)
T046B Proteus vulgaris Negative Negative
T046C Proteus vulgaris Negative Negative
T046D Proteus vulgaris Negative Negative
T046E Proteus vulgaris Negative Streptococcus oralis/sanguinis (0.93; 5)
T046F Proteus vulgaris Negative Negative
T049A Enterococcus faecalis Negative Pseudomonas putida/stutzeri/entemophilia (0.93; 37)
T049B Enterococcus faecalis Negative Streptococcus penumoniae (0.93; 11)
T049C Enterococcus faecalis Negative Negative
T049D Negative Negative Staphylococcus saprophyticus (0.99; 11)
T049F Enterococcus faecalis Negative Negative
T050B Negative Negative Pseudomonas putida/stutzeri/entemophilia (0.94; 24)
T050D Negative Negative Propionibacterium acnes (0.97; 9)
T050E Streptococcus anginosus Negative Negative
T053C Negative Negative Pseudomonas putida/stutzeri/entemophilia(0.94; 53)
T053D Pseudomonas aeruginosa Negative Negative
T053E Pseudomonas aeruginosa Negative Negative
T053F Pseudomonas aeruginosa Negative Negative
T055A Negative Negative Propionibacterium acnes (0.98; 22)
T055B Negative Negative Corynebacterium xerosis (0.93; 10)
T055C Pseudomonas aeruginosa Negative Negative
T055D Pseudomonas aeruginosa Negative Micrococcus luteus (0.96; 25)
T055E Pseudomonas aeruginosa Negative Negative
T055F Pseudomonas aeruginosa Negative Negative
T059A Negative Negative Propionibacterium acnes (0.98; 30)
T059E Negative Negative Acinetobacter baumannii (0.94; 3)
T061C Enterococcus faecalis Negative Negative
T062B Negative Negative Staphylococcus hominis (0.99; 12)
T062C Negative Negative Bacillus cereus group (0.96; 7)
T062F Negative Negative Pseudomonas stutzeri (0.98; 56)
T064A Staphylococcus epidermidis Negative Negative
T064C Negative Negative Staphylococcus hominis (1.00; 40)
T065D Streptococcus agalactiae Negative Negative
T065E Streptococcus agalactiae Negative Negative
T067B Negative Negative Staphylococcus aureus (0.92; 3)
T067E Negative Negative Cellulomonas humilata (0.94; 44)
T071C Negative Negative Staphylococcus aureus (0.90; 3)
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Blood 
Sample
Culture+
16S PCR
DNA Extraction + 16S 
PCR DNA Extraction + Plex-ID
T076E Negative Negative Propionibacterium acnes (0.93; 21)
T076F Negative Negative Propionibacterium acnes (0.97; 21)
C002A Staphylococcus epidermidis Negative
Lactobacillus acidophilus (0.94; 17)
Enterococcus durans/haire (0.97; 17)
C002C Negative Negative Weissella confusa (0.97; 13)
C004A Staphylococcus epidermidis Negative Negative
C004B Staphylococcus epidermidis Negative Negative
C004C Staphylococcus epidermidis Negative Negative
C004D Staphylococcus epidermidis Negative Negative
C005B Negative Negative Staphylococcus aureus (0.93; 7)
C005D Corynebacterium amycolatum Negative Negative
C006B Negative Negative Macrococcus caseolyticus (0.92; 8)
C007D Propionibacterium acnes Negative Negative
C009D Negative Negative Pseudomonas putida/stutzeri/entemophilia(0.96; 69)
C013A Negative Negative Staphylococcus aureus (0.95; 7)
C015B Negative Negative Staphylococcus aureus (0.91; 4)
C016B Negative Negative Staphylococcus haemolyticus (1.00; 11)
C019A Streptococcus pseudopneumoniae Negative Staphylococcus hominis (0.98; 15)
C019B Streptococcus pseudopneumoniae Negative Negative
C020B Streptococcus mitis Negative Negative
C020D Streptococcus mitis Negative Negative
C022A Staphylococcus warneri/pasteuri Negative Negative
C022D Staphylococcus warneri/pasteuri Negative Negative
C024B Klebsiella oxytoca Negative Negative
C024D Klebsiella oxytoca Negative Negative
C025B Staphylococcus epidermidis Negative Negative
C026A Negative Negative Methylobacterium mesophilicum (0.93; 8)
C026D Negative Negative Staphylococcus aureus (0.91; 4)
C029B Negative Negative Staphylococcus hominis (0.99; 16)
C032B Negative Negative Staphylococcus epidermidis (0.92; 12)
C034A Neisseria flavescens Negative Negative
C035B Negative Negative Staphylococcus aureus/haemolyticus(0.95; 10)
C036D Neisseria flavescens Negative Negative
C037D Negative Negative Staphylococcus aureus (0.95; 16)
C038A Negative Negative Staphylococcus aureus (0.95; 6)
C041A Negative Negative Streptococcus vestibularis (0.91; 6)
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Blood 
Sample
Culture+
16S PCR
DNA Extraction + 16S 
PCR DNA Extraction + Plex-ID
C041D Negative Negative Propionibacterium acnes (0.95; 21)
C047A Micrococcus species Negative Negative
C047C Negative Negative Streptococcus penumoniae (0.92; 4)
C050D Staphylococcus epidermidis Negative Negative
C053A Negative Negative Propionibacterium acnes (0.97; 24)
C055A Negative Negative Staphylococcus aureus (0.94;8)
C057A Negative Negative Staphylococcus aureus (0.99; 13)
C057D Negative Negative Acidovorax temperans (0.91; 7)
C058B Negative Negative Staphylococcus aureus (0.92; 7)
Table 84. Bacteraemia in all the blood samples obtained using the three 
different methods to detect bacteraemia (culture, 16S PCR and Plex- ID)
The three methods performed very differently. The ‘gold standard’ culture 
method produced the most positive results. This may be owing to the fact that 
the incubation period was extended to achieve maximal sensitivity. However, 
sensitivity tests were not done during the in-vitro studies to establish how 
sensitive the ‘culture method’ was. The Plex-ID method detected a significant 
number of false positives, likely to be contaminants [226]. These bacterial 
contaminants were largely skin commensals, which may have been introduced 
during the large number of steps needed to extract bacterial DNA from blood 
and the subsequent identification of the nucleotides present. This processing 
problem was not picked up by the other molecular method (16S PCR) as only a 
small, selected number of the samples had their sequences determined. None 
of the 16S PCR tests produced positive results from the catheter manipulation 
samples. The Plex-ID method also detected a number of skin contaminants. 
The culture method also picked up a number of contaminants.
4.4.3.5.1 Statistical comparison of the different methods used to detect 
bacteraemia
McNemar’s Test to compare the different methods (Culture vs 16S PCR, 
Culture vs Pled-ID and 16S PCR vs Plex-ID) showed no concordance between 
the three methods of detecting bacteraemia. The gold standard method in this 
study was the culture method. Therefore, bacteraemia results from this method 
were used for further analysis.
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4.4.3.6 Statistical evaluation of the association between the development 
of bacteraemia and the timings of the blood samples
Four hundred and thirty-three observations from one hundred and five patients 
were included in the model. Eight samples were not included for the analysis as 
the bacteraemia results were not available from the culture method. The results 
are shown in Table 85 below. All the variables were compared with Time point 
A. Time point A is the pre-procedure time point and was used as the negative 
control as it is assumed that no bacteraemia was present at that point. This is 
based on the premise that under normal conditions, blood is a sterile 
environment [227]. For the purposes of this statistical analysis, the time point 
when the catheter was re-inserted was renamed Time Point G (instead of C), as 
shown in Table 85.
Time Points Time when the blood sample was taken
A Before the procedure
B When catheter comes out
C 5 minutes into procedure
D 10 minutes into procedure
E 20 minutes into procedure
F End of procedure
G When catheter is re-inserted
Table 85. Definitions of the time points at which blood samples were taken
From Table 85 above, it can be shown that time point G occurred only in 
patients having catheter change. Time points C, D and E only occurred in 
patients having a TURP.
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Variable Estimate Standard Error z-value p-value
Procedure (TURP) -0.56 1.08 -0.52 0.61
Time points B -0.27 0.70 -0.40 0.69
Time points C 1.20 0.77 1.56 0.12
Time point D 1.48 0.76 1.94 0.05
Time point E 1.67 0.79 2.12 0.03
Time Point F 1.01 0.61 1.65 0.09
Time Point G -1.48 1.86 -0.79 0.43
Table 86. Results from multi-level model evaluating the association between 
the development of bacteraemia and the timings of the blood 
samples.  Results in bold are statistically significant.
Table 86 shows the results from the linear model. The model shows that time 
points D and E are important in determining the presence of bacteraemia 
compared with time point A. The procedure (TURP or catheter manipulation) 
and the other time points (B, C, F and G) were not statistically significant in 
determining the presence of bacteraemia. These results are interpreted as 
follows:
x blood samples taken 10 minutes (Time point C) and 20 minutes (Time 
point D) into a TURP operation are more likely to have bacteraemia 
compared to a blood sample taken before the procedure;
x the removal of a catheter (Time point B) did not increase the likelihood of 
developing bacteraemia in either a patient having catheter manipulation 
or a patient having a TURP;
x catheter manipulation did not have any statistical association with the 
development of bacteraemia.
The odds of developing bacteraemia during TURP are shown in Figure 38. At 
time point D, it was 4.39 times more likely to detect bacteraemia compared to 
time point A. At time point E, it was 5.31 times more likely to detect bacteraemia 
compared with time point A.
Figure 38. Odds ratio of 
during a TURP compared with time point A
Figure 38 above demonstrates that the likelihood of developing bacteraemia 
increases as the TURP operation proceeds, with bacteraemia most likely to be 
detected twenty minutes into the procedure. This study has demonstrated that 
having a TURP leads to a transient bacteraemia, as the likelihood of detecting 
bacteraemia at the end of the procedure (Time point F) is the same as the 
likelihood of detecting bacteraemia befo
4.4.3.7 Relationship between bacteriuria and bacteraemia in the TURP 
group
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developing bacteraemia at different time points 
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test performed to evaluate the association between 
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Bacteraemia
TotalNo Yes
Bacteriuria
No 35 6 41
Yes 22 11 33
Total 57 17 74
Value df
Asymp. Sig 
(2-sided)
Pearson F2 3.74 2 0.15
Likelihood ratio 3.94 2 0.14
Table 87. F2 tests to compare bacteriuria and bacteraemia in patients with 
TURP
No association was found between the presence of bacteriuria and the 
subsequent development of bacteraemia during a TURP. This goes against 
traditional teaching as described in Chapter 1. In the catheter group, statistical 
analysis was not carried out to evaluate the association between bacteriuria 
and the subsequent development of bacteraemia as every patient in this group 
had bacteriuria.
4.4.3.8 Risk factors, bacteraemia and post-procedure infections
This work established that asymptomatic bacteraemia happens both during 
TURP and catheter manipulation. The rate of asymptomatic bacteraemia was 
higher than the previously reported rate of symptomatic bacteraemia. TURP 
was a cause of asymptomatic bacteraemia confirmed by the timing of 
bacteraemia during the procedure. The next step was to establish whether 
there was any relationship between ‘patient-related’ risk factors and the 
development of intra-procedure bacteraemia, using the logistic regression 
model described in Section 4.4.2.10.
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4.4.3.8.1 The risk factors in the TURP group and the association with 
bacteraemia and post-procedure infection
Three risk factors were chosen out of the all the risk factors collected, based on 
the estimated likelihood of impact on bacteraemia, in an attempt to make the 
logistic regression model as accurate as possible. Antibiotic use within two 
weeks of the procedure can affect the development of bacteraemia [230]. 
Histological changes in the prostate gland (benign or malignant) can be a 
surrogate marker of initial bacterial colonisation of the prostate [229]. The 
presence of a urinary catheter is known to predispose patients to bacteriuria 
[112], and the prolonged presence of the catheter place patients at risk of 
developing bacteraemia [115].
Risk factors Frequency
Antibiotics use within two weeks of the procedure
No 55
Yes 18
Prostatic histology
No 51
Yes 22
Presence of a catheter
No 35
Yes 38
Table 88. Frequency table of the risk factors used in the logistic regression 
model.
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Coefficient Standard 
Error
p-value OR 95% C.I. for OR
Lower Upper
Antibiotics 
Use
-1.47 0.69 0.032 4.34 1.14 16.62
Catheter 1.59 0.75 0.034 4.92 1.13 21.51
Histology 1.59 0.68 0.019 4.90 1.30 18.46
Table 89. Multivariate analysis using the logistic regression model to 
evaluate the association between the development of bacteraemia 
and the associated risk factors
A patient with histological evidence of malignancy was five times more likely to 
develop bacteraemia than a patient with no evidence of malignancy in the 
prostatic tissue (OR: 4.90, CI: 1.30-18.46, p = 0.019). This result suggests that 
the presence of a prostate adenocarcinoma increases the likelihood of 
developing bacteraemia during a TURP procedure. A patient who had 
antibiotics within two weeks of a TURP was four times less likely to develop 
bacteraemia than a patient who did not receive antibiotics (OR: 4.34, CI 
1.14-16.62 p = 0.032). This may be explained by the fact that patients who were 
administered antibiotics were more likely to have any bacteria present in the 
system eradicated during the use of the antibiotics. Therefore, there is less 
chance of detecting bacteria in the blood. Having a urinary catheter in situ was 
associated with the development of intra-TURP bacteraemia (OR: 4.92, CI 
1.13-21.51, p = 0.034). This association has been described in the literature 
previously [112,115].
It was not possible to fit prostatic inflammation in the model owing to the 
multi-level association between antibiotic use, prostatic malignancy, age and 
bacteraemia. On univariate analysis, an association between prostatic 
inflammation and intraoperative bacteraemia was found (F2 (1) = 4.97, 
p = 0.026). Further interpretation of this result is difficult in the sample 
population as univariate analysis showed that a malignant prostatic histology 
was associated with prostatic inflammation (F2 (1) = 7.46, p = 0.006).
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4.4.3.8.2 The risk factors in the catheter manipulation group and the 
association with bacteraemia and post-procedure infection
For the catheter manipulation group, the following risk factors were selected to 
evaluate an association with bacteraemia, as shown in Table 90.
Frequency
Suprapubic catheter
No 37
Yes 20
Antibiotics use
No 39
Yes 18
Long hospital stay
No 52
Yes 5
Duration of catheterisation
(> 3 months)
No 48
Yes 9
Table 90. Frequency table of the risk factors in the logistic regression model
Coefficient Standard 
error
p-
value
Exp(B) 95% C.I. for 
EXP(B)
Lower Upper
Suprapubic catheter -0.63 0.88 0.47 0.53 0.10 2.97
Antibiotics use 0.96 0.86 0.26 2.60 0.49 13.97
Age 0.02 0.03 0.51 1.02 0.96 1.09
Recent Hospital Stay 0.52 1.28 0.68 1.69 0.14 20.65
Duration of catheter 
(>3 month)
0.02 0.73 0.98 1.02 0.25 4.27
Constant -3.54 3.02 0.24 0.03
Table 91. Results from the logistic regression model
The logistic regression model did not show any association between the 
development of bacteraemia and the risks factors. It could be that there was no 
association or the numbers were not sufficient to show any association.
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4.4.4 Discussion
The studies reported above have demonstrated that bacteraemia is prevalent 
during both TURP and catheter manipulation, when the results from the culture 
method are analysed. All the episodes of bacteraemia detected in this study 
were asymptomatic. In the TURP group, two patients had symptomatic 
bacteraemia following the procedure and were treated by the clinical team. The 
issues related to bacteraemia, risk factors and symptoms are discussed further 
in Chapter 5.
4.4.4.1 Issues with the interpretation of the prostate histology
It is possible that during the fixing process of the prostatic tissue, tissue that 
was hard and appeared calcified was not embedded. This was a protective 
measure utilised by the histopathologist to avoid damaging the microtome knife. 
Therefore, the incidence of calcification of the prostate may be higher than 
reported in this study, though it is not possible to have an exact figure.
4.4.4.2 Relationship between bacteriuria and bacteraemia
Many patients had bacteriuria and bacteraemia in this study. Were patients with 
bacteriuria more likely to develop bacteraemia? The literature suggests that the 
presence of pre-operative bacteriuria in patients having transurethral
procedures makes them more likely to develop a symptomatic inflammatory 
response (pyrexia with or without a positive blood culture) following the 
procedure [2, 70, 228-9]. According to traditional teaching, patients with 
preoperative bacteriuria require antibiotic treatment or prophylaxis to eradicate 
their bacteriuria before proceeding to transurethral surgery. However, this study 
failed to demonstrate an association between pre-procedure bacteriuria and 
intra-procedure bacteraemia. This lack of association is discussed further in 
Chapter 5.
4.5 Conclusions
The prospective studies evaluating the incidence of bacteraemia in patients 
who had TURP and catheter manipulation showed some surprising results. The 
traditional ‘culture’ method to detect bacteraemia outperformed the 
contemporary ‘molecular’ methods. Many patients having urological procedures 
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had bacteriuria. Bacteraemia was more prevalent during the two urological 
procedures than previously thought. The bacteraemia present was largely 
asymptomatic. Contrary to perception, the presence of bacteriuria did not 
influence the development of bacteraemia in this study. In the TURP group of 
patients, the timing of the blood samples was related to the development of 
bacteraemia. The presence of prostate adenocarcinoma was associated with 
the development of bacteraemia during a TURP. The salient point of the two 
clinical studies was the presence of asymptomatic bacteraemia in urological 
patients having procedures. The relevance of this bacteraemia is discussed 
further in the Chapter 5.
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Chapter 5: Discussion
5.1 Introduction
This thesis addresses a number of important issues related to infections in 
urological practice. The largest case-control study in the published literature 
investigating urological procedures and infective endocarditis has been carried 
out. The study found a statistically significant association between urological 
procedures and the development of infective endocarditis. Infective endocarditis 
normally requires the presence of bacteraemia, though the latter is not essential 
in the diagnosis of IE when using the modified Duke’s criteria [231]. To evaluate 
the association between infection and urological procedures further, two studies 
were designed to determine the incidence of bacteraemia during TURP and 
catheter manipulation. The reported incidence of sepsis following urological 
procedures is less than 1% [71, 104]. However, the studies in this thesis have 
shown that bacteraemia is more common than previously thought, but with the 
bacteraemia being largely asymptomatic and detectable during the procedure.
5.2 Urological procedures and infective endocarditis
A review of the literature demonstrated a number of case reports and case 
series linking urological instrumentation to the development of infective 
endocarditis. At the time of writing, the author was made aware of a case of IE 
developing in the immediate post-operative period for a patient undergoing a 
TURP. The published literature shows that the incidence of sepsis, pyrexia, 
UTIs and even bacteriuria can be reduced with antibiotic prophylaxis, but there 
is no evidence to suggest that antibiotic prophylaxis prevents or decreases the 
rate of infective endocarditis in patients having urological procedures, largely 
because this has not been studied. Traditionally, urological surgeons have been 
very wary of performing procedures on patients at high risk of developing 
infective endocarditis without the use of antibiotic prophylaxis [232]. However, 
this cautious approach has not been supported by a high level of evidence. For 
this reason, the advice published in the guidelines pertaining to urological 
practice (EAU, AUA and NICE guidelines) and infective endocarditis (AHA, 
BSAC guidelines) has recently changed [191, 200, 233-5]. None of the major 
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guidelines at the time of writing advocated the use of antibiotic prophylaxis for 
the prevention of IE post urological procedures.
It has been demonstrated that there is a statistically significant association 
between the development of IE and prior urological procedures in patients who 
developed IE subsequent to prior urological procedures. The study 
demonstrated that a patient who had developed enterococcal IE was eight 
times more likely to have had one or more urological procedures within the year 
preceding the diagnosis of the disease, than a patient who had developed IE 
caused by CoNS, Streptococcal bovis group or oral streptococci. Enterococci 
are commonly found in the human gastrointestinal tract and associated with 
urinary tract infections [182]. In fact, enterococci are among the top three most 
common organisms causing urinary tract infections, together with Escherichia 
coli and Staphylococcus epidermidis [182]. Because of the association between 
enterococci and both urinary tract infection and endocarditis and because of 
anecdotal experience of cases of enterococcal IE developing after urological 
procedures (Sandoe, pers comm), it was decided to study the link between 
urological instrumentation and enterococcal IE. It was hypothesised that a 
urological procedure might cause an enterococcal bacteraemia and that this 
may lead to the subsequent development of IE.
In the case-control study, an odds ratio of 8.21 (CI: 3.54–19.05, p < 0.05) for 
patients with preceding urological procedures to develop enterococcal IE was 
suggested. It is possible that the design of the study may have also contributed 
to the results, with an odds ratio of 8.21 when no previous study has 
demonstrated any statistical association. It is important to point out that the 
control group consisted of patients who had all developed IE caused by 
organisms other than enterococci rather than patients who had not developed 
IE. Therefore, it must be stressed that the odds ratio of 8.21 does not mean that 
a patient is eight times more likely to develop enterococcal IE if he or she 
underwent a urological procedure within one year. This would have been true 
for a conventional case-control study. It has been demonstrated that if a patient 
developed IE caused by an enterococcus, they were more likely to have had a 
urological procedure than were patients with IE caused by one of the 
comparator groups of organisms.
It is not known how long the incubation period is prior to the development of 
symptoms in IE, but it is known that patients with enterococcal IE may have 
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symptoms for many months before the diagnosis is made [236]. There is 
therefore a potentially long period prior to presentation. In order to encompass 
this uncertainty and maximise the chances of identifying the initial event in the 
development of IE, It was assumed that any bacteraemia that may have 
occurred within the year preceding the development of IE might be that initial 
event. This is the reason data were collected about urological procedures that 
had occurred within one year of the diagnosis of the IE episode, rather than 
over a shorter period. During that one year, the patient may have had one or 
more procedures affecting the urinary tract and it is impossible to determine 
which one of the instrumentation episodes, if any, caused the bacteraemia that 
eventually led to the development of the IE episode. This argument can be 
extended further by inferring that the reason the patient was having the 
instrumentation of his urinary tract in the first place was because of urological 
symptoms. One can speculate that a patient having urological procedures may 
have an underlying urological pathology, which would be the reason why the 
patient is having a urological procedure. This underlying urological pathology 
may be the cause of the bacteraemia, rather than the procedure per se. One 
may even contemplate that repeated episodes of bacteraemia from urological 
pathogens occur in a patient with a urological pathology, similar to a patient with 
gingival pathology developing repeated episodes of bacteraemia from oral 
organisms [237-8].
It is not known whether repeated bacteraemia episodes occur in patients with 
urological pathology of non-infective origin. There is evidence that bacteraemia 
does occur during urological procedures (see Chapter 1). Is it possible that an 
episode of bacteraemia during urological instrumentation is sufficient to lead to 
the development of IE in a patient who is not immunocompromised? One could
argue that the host defences would be capable of dealing with such an insult 
and would not be overwhelmed, especially if the bacteraemia is temporary and 
of a small magnitude. It is also possible that repeated episodes of bacteraemia, 
before the host defences had a chance to overcome the episode of 
asymptomatic bacteraemia, cause repeated insults to the endocardium 
eventually to lead to the bacterial seeding of the heart valves and the 
development of IE. Elucidating these issues has proved difficult for researchers 
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and clinicians to date as such studies would have to be longitudinal and require 
massive resources. A related issue that is discussed in the next section is the 
potential association between prostatic adenocarcinoma and the development 
of bacteraemia. This reinforces the hypothesis that urological pathology, 
possibly prostatic adenocarcinoma, makes patients more prone to bacteraemia 
and the subsequent bacterial seeding of the endocardium.
Epidemiological studies have shown that the incidence of IE is increasing [239]. 
One of the possible reasons is that the population is growing older and hence 
frailer. Older patients tend to have a larger number of medical problems, 
including urological and cardiac pathologies [240]. Therefore, it is not 
unreasonable to speculate that the aging population is undergoing more and 
more procedures to investigate and treat their pathologies. At the same time, 
this ageing population would have a greater number of underlying risks factors 
for the development of IE. In the face of this ‘at-risk’ population undergoing a 
larger number of procedures, it is possible that this is contributing to the 
increasing incidence of IE. There may be alternative explanations: It is known 
that the ageing population have a larger number of pathologies and these 
pathologies may predispose them to repeated episodes of bacteraemia. For 
example, with respect to urological pathologies, the incidence of bladder outflow 
obstruction secondary to benign prostatic hyperplasia is known to increase with 
age [53]. Therefore, more patients are requiring procedures to treat this 
pathology as the population ages. It is also possible that this obstructive picture 
may cause repeated bacteraemia episodes in these patients, leading to 
bacterial seeding of the endocardium.
The studies that are reported in this thesis have also shown that enterococcal 
bacteriuria was present in a proportion of patients who developed enterococcal 
IE. In the TURP group of patient, ten patients (13.0 %) patients had enterococci 
in urine at presentation and just two patients (2.6%) had documented evidence 
of an enterococcal UTI in the twelve months prior to presentation. It is not 
known which condition might have occurred first: the development of bacteriuria 
that subsequently led to the bacteraemia and thereafter the development of IE 
or the development of IE, which then led to the development of bacteriuria 
owing to the bacterial load in blood. The studies presented herein were not 
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designed to determine whether asymptomatic enterococcal bacteriuria was 
more prevalent prior to their diagnosis, in patients who developed enterococcal 
IE. It was possible to study patients from whom cultures had been sent but, 
owing to the small number of patients with documented enterococcal 
bacteriuria, this seemed unlikely to be a key event in the pathogenesis. By 
definition, symptomatic bacteriuria, if it occurred in these patients, would not 
have been noticed and would therefore not be detected clinically. There is 
evidence that patients with a urological pathology suffer from a higher incidence 
of UTIs [241]. It is possible, therefore, that there is a higher incidence of 
bacteriuria in patients with urological pathology, thereby subjecting the patient 
to repeated subclinical episodes of bacteraemia. These episodes of 
asymptomatic bacteraemia may eventually lead to the development of IE in the 
group of patients with urological pathology that go on to be investigated by 
urological procedures.
In conclusion, this work has led to two main theories to explain the initial events 
which may lead to the development of IE in patients having urological 
procedures: 1) bacterial seeding of the endocardium occurs secondary to 
bacteraemia caused by urological procedures and 2) bacterial seeding of the 
endocardium occurs secondary to repeated episodes of (a) symptomatic 
bacteraemia in patients with underlying urological pathology. The next section 
addressed the first of these theories (urological procedures cause bacteraemia) 
suggested to explain the statistical association found between urological 
procedure and the development of enterococcal IE.
5.3 Methods to detect bacteraemia in urological practice
The traditional method to detect bacteraemia (the culture method) in patients 
undergoing urological procedures has been described in the literature. Newer, 
more contemporary technologies to detect bacteraemia have mushroomed over 
the last ten to fifteen years [130, 134, 242], which have shown promise. To 
date, these new technologies have not gained widespread adoption in 
diagnostic bacteriology owing to on-going technical difficulties. To date, there 
are no reports of the use of the new molecular technologies, such as 
broad-range 16S PCR examination, to detect bacteraemia in urological practice. 
187
The study presented in this thesis is the first of its kind to use the newer 
molecular technologies to detect bacteraemia in the urological setting, although 
further work is required to optimise these techniques before they will be 
available for routine use.
A decision was made to evaluate the use of DNA detection methods to detect 
bacteraemia in urological practice, primarily to determine if it had greater 
sensitivity for detection of bacteraemia, particularly as many of the study 
patients would have received antimicrobials. Firstly, the molecular technology 
chosen is a relatively novel technology, which has never been used in 
urological practice before. Secondly, this molecular technology had the potential 
to detect and quantify bacteraemia, even when the bacterial load in the blood 
sample was low, as well as the detection of non-cultivable bacteria (such as 
those affected by antimicrobials). Thirdly, molecular methods offer the promise 
of relatively quicker result reporting than the traditional culture method. In the 
context of this study, the rapidity of the process was not crucial. However, in 
clinical practice, the sooner bacteraemia can be detected, the quicker the 
patient can be started on the optimal treatment.  This will, however, involve 
further challenges since there is currently no easy way of predicting 
antimicrobial susceptibilities of pathogens identified using DNA detection 
technology. A decision was made to explore the merits of the molecular 
technologies in providing a quick answer to patients having low-level 
bacteraemia. Fourthly, the molecular methods employed to detect bacteraemia 
utilised a smaller volume of blood than the traditional culture method and 
therefore, allowed both the traditional culture method and a molecular method 
to be performed in parallel. And finally, the molecular methods offered the 
possibility of detecting bacterial DNA irrespective of whether the bacteria were 
alive or dead. Therefore, it detected the presence of bacteria by using bacterial 
DNA as a surrogate marker for the presence of bacteria, in spite of the use of 
antimicrobial prophylaxis, which may have killed the bacteria. This was 
particularly relevant in the TURP group of patients, where all patients at the 
Leeds Teaching Hospitals NHS Trust received gentamicin as antibiotic 
prophylaxis. Developmental work in the laboratory confirmed that the molecular 
technology was able to detect low-level bacteraemia (the Plex-ID was able to 
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detect and identify bacterial suspensions with concentration of 10 cfu/ml), albeit 
with an uncertain reliability, and provided results quicker than the culture 
method. Experiments using different volumes of blood using the molecular 
technology were undertaken to see if use of larger volumes of blood would 
improve the sensitivity. The blood culture method used 10 mL blood, whereas 
methods of detection of microbial DNA usually use much smaller volumes 
(1-5 mL); a fairer comparison of the molecular and culture methods was 
considered desirable. However, the molecular method did not perform as well 
as the simpler culture methodology during the in vivo trial samples. The reasons 
for this are discussed below.
5.3.1 Bacterial DNA extraction
In routine clinical practice in the UK, it is uncommon to use diagnostic tests that 
rely on the extraction of bacterial DNA from blood. The molecular technology 
has, to date, been largely devoted to the extraction of bacterial DNA from 
‘cultured’ samples, with the diagnostic pathway of meningitis and mycobacterial 
infections being exceptions [242]. For example, bacterial DNA has been 
extracted from blood or human samples that had been incubated (in order to 
increase the bacterial yield) [214]. The work in this part of the thesis focussed 
on the extraction of bacterial DNA from blood that had not been previously 
cultured. Therefore, the expectation was that the amount of bacterial DNA 
would be significantly less than in previously incubated blood. Developmental 
work began using 1 mL of ‘spiked’ blood. Although it was easier to handle this 
small volume of blood in the molecular laboratory, to make a fair comparison 
with the blood culture method and maximise sensitivity by using larger volumes 
of blood was considered desirable. Utilising a larger volume of blood for 
bacterial DNA extraction allowed the molecular method to become more 
comparable to the gold standard culture method, which utilised larger volumes 
of blood. The DNA extraction process starts with a relatively large sample 
volume and it ends with a relatively small sample. This concentration process 
consisted of multiple steps and each of the steps has the potential for loss of 
bacterial DNA. Therefore, it was possible for no bacterial DNA to be left in the 
extract after the extraction process because the entire sampled DNA had been 
lost during the process. By using a larger volume of blood, it was hypothesised 
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that we would be working with a larger amount of target bacterial DNA. 
Although some bacterial DNA was presumably lost during the extraction 
process, the extract (which was of exactly the same volume as previously 
obtained when using the smaller starting volume of blood for processing) 
contained enough bacterial DNA for further processing (amplification and 
detection). In the final protocol, 5 mL of blood for the molecular processing was 
examined compared with 7-8 mL used for the culture bottles.
One of the major issues when extracting bacterial DNA from a larger volume of 
blood is the increasing presence of “background” DNA, especially the human 
DNA present in blood cells. During the extraction process, the main aim was to 
get rid of the maximum amount of background (human) DNA whilst preserving 
the maximum amount of bacterial DNA. Studies have shown that Molzym’s 
MolYsis offered a consistent technology to this effect [141, 243]. However, 
because larger volumes of blood (5 mL) were being used, the amount of human 
DNA was significantly larger than reported in the previous studies (which had 
used small volume samples from the oral cavity). At the time of the study, using 
large volumes of blood (> 1 mL) for bacterial DNA extraction was uncommon, 
even in the research setting. The in vitro studies (described in Chapter 3), 
showed that it was possible to extract and detect tiny amounts of bacterial DNA 
reliably (as little as < 100 copies/mL) from large volumes (5 mL) of blood, 
without significant noise to signal issues. This means that the process was able 
to detect bacterial DNA without much interference from the background DNA. 
Therefore, a standard operating procedure (SOP) was developed to extract 
bacterial DNA reliably from 5 mL of blood, which was later used during the 
clinical trial on patients undergoing TURP operations and catheter manipulation, 
although it still does not currently out-perform standard culture and more work is 
required before it can be used routinely.
5.3.2 Bacterial DNA amplification and identification
During the developmental work, it was found that the process of broad range 
amplification of sequences encoding bacterial 16S rRNA from blood was 
complicated by the cross-reactivity of the primer with background human DNA. 
This led to ambiguous chromatograms on sequence analysis. This made 
190
sequence interpretation hard and unreliable. Furthermore, in SYBR green 
real-time PCR assays, human DNA can also affect crossing threshold (Ct) 
values and consequently affect the sensitivity of the assay [244]. In order to 
avoid the issues relating to cross-reactivity, a number of primers that bind to 
and amplify sequences encoding bacterial rRNA were considered, including 
long and short 16S primers. Bacteria-specific, genus specific, 
Gram-positive/negative primers were also evaluated as described in Chapter 3. 
It was concluded that the in-house 16S primer would provide optimal results. 
Firstly, restricting the target to one bacterium or one genus of bacteria was not 
considered desirable, as it was not possible to predict the identity of the 
pathogen causing bacteraemia that would be encountered during urological 
procedures. In fact, this standpoint was validated as bacteraemia caused by 
Actinobaculum massiliense, a bacterium not routinely detected from clinical 
urological samples was identified using a 16S primer pair (forward primer: 
AGAGTTTGATCCTGGCTCAG, reverse primer 
CTACGCATTTCACCGCTACAC). UTIs caused by Actinobaculum massiliense 
have been reported but this study is the first to identify bacteraemia caused by 
this organism in the urological setting [245]. The bacterial species was detected 
in the culture arm of the study in a patient undergoing TURP. Secondly, by 
using the in-house 16S primer pair (forward primer 
AACTGGAGGAAGGTGGGGAT reverse primer AGGAGGTGATCCAACCGCA) 
[246], which is a short primer pair (producing an amplimer of less than 300 base 
pairs), it was hoped to detect as many bacteria as possible, while minimising 
cross-reactivity and the pick-up of “background” human DNA.
Primer length and the target region were important considerations when 
deciding which primer would be the most suitable for this study. The in-house 
16S primer pair provided the most consistent results during the in vitro
experiments for the amplification of sequences encoding bacterial 16S rRNA, 
without sacrificing the sensitivity of the assay (Chapter 3). Optimising the PCR 
conditions allowed the assay to perform to maximum sensitivity without the 
problem of background human DNA. All assays were amplified over forty 
cycles, and the negative blood control was assigned a fixed Ct value of 30. 
These strict criteria to assess all the samples ensured that only a minimum 
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number of samples had to be cleaned up for sequence determination reactions, 
therefore increasing the specificity of the test. This strict regimen was followed 
in an attempt to minimise the cost of processing a large number of samples, 
with only a few positive results. In fact, during the developmental process, the 
molecular methods detected bacterial level as low as 10 cfu/mL. However, this 
was not replicated in the blood samples from the clinical trial. It was speculated 
that the reason for this disparity is that the level of bacteraemia in the blood 
samples from the two studies was very low in both groups of patients. The 5 mL 
of blood used for the molecular methodology was insufficient to account for the 
bacterial DNA loss that invariably occurred during the extraction process. The 
in vitro experiments were carried within 1-2 hours after the seeding of blood. 
The samples from the studies were processed within 24 hours of collection, with 
most samples processed within six hours. This delay in processing between the 
in vitro and in vivo samples may explain the inability of the same methodology 
to detect low levels of bacteraemia owing to the phenomenon bacterial DNA 
degradation and background DNA increase, which have been described 
previously [247]. Furthermore, it is likely that the bacteraemia in the clinical 
samples was not constant but intermittent and at very low-levels. It was likely 
the blood sampling managed to capture only one or two of the organisms, if 
any. However, it is possible that the patient still had bacteraemia, which was not 
captured during the sampling process owing to the small number of bacteria 
involved.
Whilst the culture method, which was optimised for maximum sensitivity (an 
extended incubation period), was able to amplify this small number of bacteria 
during the incubation process, the molecular method instead failed to do so as it 
progressively lost the low number of bacterial DNA during the extraction 
process. This may explain the discrepancy between the two methods. The 
culture method was not designed to quantify the bacteria present during 
episodes of bacteraemia; it was designed with sensitivity as the primary 
concern. As the bacteraemia was not detected by the molecular methods, it was 
impossible to quantify the bacteraemia encountered during the study for TURP 
and catheter manipulation patients. This is a failure of the molecular 
methodology as it is not entirely efficient in the detection of bacteria. The results 
192
from the in vitro experiments were not reproduced in vivo during the trial. It is 
also possible that background DNA, mainly human DNA masked the presence 
of bacterial DNA. When the results from the 16S PCR amplifications were 
processed, eighteen samples were believed to be positive based on Ct values 
and the shape and temperature of the melting curve. However, bacterial 
sequences were identified in only three of these eighteen samples. The fifteen 
other samples were considered negative as no bacterial DNA could be 
identified. The reason for this could be two-fold: either no bacterial DNA was 
present at all, or the bacterial DNA present was masked by the presence of 
human DNA and could not be detected.
5.3.3 Bacteraemia and urology
Multiple methods were used to evaluate the presence of bacteraemia in 
patients having urological procedures. The two studies conducted revealed 
surprising results. The most important result was the fact that bacteraemia 
occurred in 30% of patient having a TURP, in spite of antimicrobial prophylaxis. 
This level of asymptomatic bacteraemia has never been reported before. The 
significance of this bacteraemia can only be speculated upon at this stage.
5.3.3.1 TURP: Risk factors, bacteraemia and symptoms
There are a number of studies that have investigated the incidence of infection 
during TURP. There is evidence that bacteriuria, UTIs, sepsis and symptomatic 
bacteraemia can occur during the procedures, with varying incidence and 
significance, which is discussed at length in Chapter 1. Guidelines therefore 
recommend the use of antimicrobial prophylaxis to prevent these infective 
episodes [233, 235]. However, the evidence to support this practice is poor; 
there are some randomised studies to show that antimicrobial prophylaxis 
prevents the development of infective episodes, pyrexia and bacteriuria 
(Chapter 1). However, there is no evidence that antibiotics prophylaxis can 
prevent the development of infective endocarditis following urological 
procedures. In fact, there is no conclusive published evidence to link the 
development of infective endocarditis to previous urological procedures. 
Therefore, all the major guidelines are in agreement in not recommending 
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antimicrobial prophylaxis in patients having urological procedures for the 
prevention of infective endocarditis.
Procedure
Anecdotally
associated
with
endocarditis
% 
Bacteraemia
Requires IE 
prophylaxis Comment
Cystoscopy NK 0-26 Yes Standard perioperative 
prophylaxis may need 
modification
Risk of bacteraemia 
increases with presence 
of bacteriuria.   If 
possible, treat bacteriuria 
before the procedure
Urethral 
catheterization
Yes 0-17 No a
Urethral dilation Yes 18-33 Yes Standard perioperative 
prophylaxis may need 
modification
Transurethral 
prostatic 
resection
Yes 70-76 Yes Standard perioperative 
prophylaxis may need 
modification
Transurethral 
prostatic biopsy
Yes 12-46 Yes Standard perioperative 
prophylaxis may need 
modification
Vasectomy Yes NK No Cases developing after 
vasectomy have been 
reported without known 
cardiac defects
Lithotripsy of renal 
stones
Yes 8 No a
Circumcision Yes NK No
Cosmetic piercing 
involving 
urethral mucosa
No NK No
a Risk of bacteraemia increases with presence of bacteriuria.  Treatment is recommended pre-procedure
NK, Not Known
Table 92. Bacteraemia and infective endocarditis in urology (adapted from 
Gould et al. [194])
Table 92 shows the recommendations for antibiotic prophylaxis based on the 
anecdotally reported risks of infective endocarditis from various urology 
procedures. The incidence of bacteraemia in TURP patients from this table is 
70-76%, even higher than transrectal biopsy of the prostate. This high figure
might seem counter-intuitive as the urinary tract is perceived to be a sterile 
while transrectal biopsy of the prostate is a ‘dirty’ procedure. It may be a 
reflection of the pathogenesis of the urological pathology that leads to the 
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TURP, whereby patients have underlying bacteriuria, causing bacteraemia. In 
fact, the available evidence shows that pre-procedure bacteriuria is an 
independent factor for the development of post-procedure infective episodes. 
However, the study presented in this thesis did not show an association 
between bacteriuria and bacteraemia. It is possible that asymptomatic 
bacteraemia occurs irrespective of the presence or absence of bacteriuria. It is 
speculated that the source of the bacteria leading to the bacteraemia is not the 
urine but the prostate gland instead. This concept is discussed further in the 
next section.
In this study, a third of patients developed bacteraemia during the procedure. 
Only two patients showed symptoms of sepsis in the immediate post-operative 
period, but no intra-operative bacteraemia was detected in either patient. These 
two patients required an extended course of antimicrobial therapy following 
TURP. However, the thirteen patients with intraoperative bacteraemia were 
asymptomatic perioperatively. It was not possible to determine the amplitude of 
bacteraemia (see next paragraph), but it was possible to determine the duration 
of the bacteraemia. Bacteraemia occurred after the insertion of the instrument 
used for the procedure. The bacteraemia did not last for the duration of the 
procedure. Patients were more likely to develop bacteraemia between ten to 
twenty minutes after the start of the procedure. Thereafter, the risk of 
bacteraemia fell to pre-procedure levels. Presumably, the bacteraemia was 
‘mopped up’ by the host defences once the presence of bacteria in the 
bloodstream has been detected; this would explain why most of the patients did 
not have symptoms of sepsis perioperatively. It has been demonstrated that it is 
possible to have asymptomatic episodes of bacteraemia during urological 
procedures. It is possible that spontaneous bacteraemia may occur in patients 
in the community, who have an underlying urological pathology and develop 
intermittent, transient and asymptomatic bacteraemia, but confirming this would 
require a separate study. Interestingly, the removal of a ‘colonised’ urethral 
catheter and the potential trauma it may have caused to the urothelium was not 
associated with the development of bacteraemia. This reinforces the hypothesis 
that the source of the bacteria was other than bacteriuria and colonised foreign 
material.
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The methodology that was used for this study did not, in the end, allow an 
accurate quantification of the bacteraemia. The ‘culture’ methodology was a 
qualitative method but it was hoped that the molecular methodology would give 
an idea of the amplitude of the bacteraemia by using surrogate parameters like 
Ct values from the 16S PCR and ‘quantity’ value from the Plex-ID. 
Unfortunately, the molecular methods failed to detect the bacteraemias that 
were identified by the culture method and quantification was therefore not 
possible. The reasons for this are discussed in Section 5.2
5.3.3.1.1 Prostate adenocarcinoma and bacteraemia
A noteworthy finding from the studies we carried out was a statistically 
significant association between the presence of prostate adenocarcinoma and 
the development of bacteraemia. Why do patients who have carcinoma in the 
prostate at the time of TURP more likely to develop bacteraemia during the 
procedure? It was felt that bacteria may be present in the prostate gland of 
these patients and these bacteria were introduced into the bloodstream during 
the procedure. If this was the case, bacteria may have caused colonisation in 
the abnormal gland (intermittently or constantly for an undetermined period). If 
longstanding infection had been present in the prostate gland of these patients, 
there is a possibility that this might contribute to prostatic tumourgenesis, 
leading to prostatic adenocarcinoma. As mentioned in Chapter 1, previous 
literature has shown that almost half of the prostate tissue obtained at TURP 
and cultured demonstrated evidence of bacteria [58, 62]. The study in this 
thesis has suggested a link between prostatic adenocarcinoma and 
intra-operative bacteraemia that warrants further investigation. There is a study 
that alludes to a bacterial aetiology of prostatic adenocarcinoma [248]. 
However, an association between prostatic inflammation and the presence of 
prostatic adenocarcinoma was demonstrated on univariate analysis. 
Inflammation, prostatic adenocarcinoma and bacteraemia could not be 
incorporated in a multivariate analysis owing to the possible bi-directional 
relationships between the variables. It may be that the inflammation plays a role 
in the development of the adenocarcinoma. It is also possible that the 
inflammation is the result of adenocarcinoma in the prostate. However, without 
microbiological samples of the prostate only speculation about the association 
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between prostatic adenocarcinoma, inflammation and bacteraemia is possible. 
These issues should be explored in further studies to shed more light on the 
relationship between bacteraemia, prostatic inflammation and prostate 
adenocarcinoma, because an infective aetiology would potentially enable earlier 
diagnosis and preventative strategies.
5.3.3.2 Catheter manipulation: risk factors, bacteraemia and symptoms
The catheter manipulation group involved patients, both male and female, 
having a urinary catheter changed or removed. This group of patients was 
heterogeneous. A urinary catheter (urethral or suprapubic) offers easy access 
for bacteria into the bladder. A urethral catheter is a recognised risk factor for 
UTIs. It is thought that a urethral catheter carries a greater risk of infection than 
a suprapubic catheter as it lies in the perineal area, which has a larger 
concentration of bacterial commensals compared with the anterior abdominal 
wall skin [249]. However, a recent review of the literature showed that the 
incidence of urinary tract infections was similar in both urethrally and 
suprapubically catheterised patients [250]. Male and female patients have 
different lengths of urethra. The shorter urethra in females offers relatively little 
barrier to bacterial migration from the outside body (mainly from the vagina and 
rectum) to the bladder. Therefore, a urethral catheter in a woman is a ‘better’ 
portal of access for bacteria into the bladder than a urethral catheter in a man. 
There is also the argument that the prostate surrounds the male urethra at its 
junction with the bladder and may act as a defence mechanism against 
infection (physically acting as a barrier to the bladder but also via its 
zinc-enriched secretions). However, it is hypothesised that the prostate is not a 
sterile organ. Bacteria may be present on or in the prostate gland commensally, 
either as colonies or as biofilms, without acute injury to the human host. This 
notion has been reinforced by studies that have shown that a significant 
proportion of TURP chips grew bacteria when cultured [58, 67]. Therefore, male 
catheterisation may carry a higher infective burden that previously suspected. 
However, the microbiological methods used in this study did not allow this issue 
to be addressed sufficiently. Further studies looking specifically at the 
microbiology of the prostate are required.
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Bacteraemia can happen during catheter manipulation, however minor the 
procedure is as demonstrated in this study. No statistical association between 
catheter manipulation and the development of bacteraemia was identified. In 
fact, it is possible to speculate that the mere presence of a urethral catheter 
may predispose a patient to bacteraemia, as demonstrated in Patient C002, 
who had a bacteraemia from Staphylococcus epidermidis prior to any catheter 
manipulation and this bacteraemia persisted after the catheter change. Though 
this bacteraemia may have been a contaminant, it is unlikely that the same 
bacteria would grow from four separate blood samples if it were the case. 
However, this finding needs to be demonstrated in further studies to validate 
and strengthen this argument. It may not be unrealistic to envisage that many 
patients with indwelling urinary catheters have intermittent, asymptomatic 
bacteraemia. This thesis may have captured a small snapshot in time of the real 
picture with respect to bacteraemia and the presence of a urinary catheter. 
There is good evidence that the presence of a urinary catheter predisposes a 
patient to bacteriuria [112, 251-2] and it may be that this constant bacteriuria 
leads to repeated, transient episodes of bacteraemia. This postulated 
mechanism is akin to a patient with a urological pathology. The underlying 
urological pathology may predispose the patient to unrecorded episodes of 
bacteriuria, which in turn predisposes the patient to episodes of asymptomatic 
bacteraemia. The telephone interview following the procedure did not reveal 
any significant septic episodes, confirming that patients tend to be 
asymptomatic, even if they have episodes of bacteraemia.
5.4 Asymptomatic bacteraemia: the unifying theory for IE and 
urology?
The bacteriuria associated with urinary catheterisation, particularly urethral 
catheterisation, is of unknown significance. It is commonly accepted that this 
asymptomatic bacteriuria does not have any detrimental effect on the patient 
and should not be treated. The study of catheter manipulation undertaken for 
this thesis found one patient with a Staphylococcus epidermidis bacteraemia, 
which was detected before any catheter manipulation and persisted following 
catheter change. The urine sample taken from this patient confirmed 
Staphylococcus epidermidis bacteriuria. This patient was completely 
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asymptomatic. Therefore, it is possible that this patient has been having 
multiple, repeated episodes of asymptomatic bacteraemia during the duration of 
urinary catheterisation. As this patient has had a catheter for over a year, it is 
possible that the occurrence of this bacteraemia has been repeatedly 
happening over a prolonged period. A similar phenomenon has been described 
in the dental literature, evaluating patients with periodontal disease and tooth 
brushing [237-8, 253]. A meta-analysis showed that the presence of 
bacteraemia was associated with tooth brushing in patients with plaque 
(OR: 2.6, CI: 1.4-4.7) [253]. The significance of such bacteraemias is not 
known.
A high incidence of bacteriuria post TURP is well documented and the duration 
of this bacteriuria can last for months (Section 1.2.3.3.1). Therefore, it is 
plausible that these patients may be having repeated episodes of asymptomatic 
bacteraemia. This bacteraemia may have long-term sequelae. For example, 
having repeated bacteraemias may eventually lead to cardiac valvular seeding 
and the onset of IE. It has also been shown that there is a statistical association 
between urological procedures and IE [254]. Patients with underlying urological 
pathology may also have recurrent asymptomatic bacteraemias in addition to 
those associated with urological procedures and devices. Therefore, it is 
possible that patients in the community, with underlying urological pathologies, 
are having repeated asymptomatic bacteraemias of unknown duration. 
Repeated episodes of bacteraemia may have far-reaching consequences that 
can only be speculated on. This may explain the association between urological 
instrumentation and the development of enterococcal IE. It is also possible that 
other infective episodes that stem from repeated bacteraemias may develop in 
this group of patients. For example, patients with prostheses (metal joint 
replacements, vascular grafts, etc.) may have delayed seeding of these 
prostheses from the repeated asymptomatic bacteraemias.
This argument goes against the popular view that the vascular system is a 
sterile environment and the presence of bacteria is, by definition, pathological. 
Any bacteria gaining access to the vascular system is dealt with by the immune 
system and other host defences, rendering blood a sterile environment. It is not 
known how quickly bacteraemia is dealt with once bacteria gain access to the 
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vascular system. We assume that a host response is mounted for every 
bacterium that gains access to the vascular system, so that every foreign body 
is ‘mopped up’ to maintain the sterility of the vascular system. However, it may 
be possible that if an immune response is not raised, the patient does not show 
the stigmata of a bloodstream infection, for example, pyrexia. This may involve 
a scenario whereby asymptomatic bacteraemia prevail. This may be a ‘learned’ 
phenomenon whereby the immune system detects that this low-level 
bacteraemia does not respond as if this poses an imminent, major threat to the 
body and thus allows its presence without invoking all the energy-dependent 
processes to mount a full response. Although the body is safe from any 
immediate danger, this ‘under-the-radar’ bacteraemia may pose a threat in the 
long term. For example, the heart valves may be seeded, especially in ‘at risk’ 
patients, leading to the development of infective endocarditis.
There is a growing consensus that bacteraemia can result from mundane 
activities of daily living [194]. For example, tooth brushing and chewing can 
cause bacteraemias. There is a school of thought that believes that cumulative 
bacteraemias is more significant in the pathogenesis of infective endocarditis 
than one single episode of bacteraemia that occurs during a procedure. This 
reinforces the hypothesis that patients who are undergoing urological 
procedures may have underlying urological pathologies that may predispose 
them to repeated bacteraemias over time.
5.5 Conclusions
This present study confirms the presence of asymptomatic bacteraemia in 
patients having urological procedures, at a rate higher than previously thought. 
A link between urological procedures and IE has been identified. It has been 
postulated that the presence of asymptomatic bacteraemia in patients with 
urological pathologies offers a possible explanation for the link between IE and 
urological patients. This concept of asymptomatic bacteraemia, though 
referenced in the literature, has not been described outside the dental literature. 
It is thus postulated that asymptomatic bacteraemia exists in patients with 
urological pathologies.
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Chapter 6: Conclusion
6.1 Introduction
An aim of the work reported in this thesis was to evaluate whether there was an 
association between having a urological procedure and the subsequent 
development of infective endocarditis. A novel design for a case-control study 
was utilised to perform the study. The second part of the project focussed on 
bacteraemia during urological procedures. It is known that some urological 
procedures cause bacteraemia, which may, in turn, explain the connection 
between urological procedures and infective endocarditis. A second aim was to 
evaluate different methods to detect and possibly to quantify bacteraemia. 
Thereafter, the optimised methods used for the detection of bacteraemia were 
used to evaluate the presence of bacteraemia in patients undergoing TURP and 
catheter manipulation.
6.2 Main findings
The main findings of this thesis are briefly described below. The two main 
questions were:
x are urological procedures associated with the development of infective 
endocarditis?
x do urological procedures (TURP and catheter manipulation) lead to 
bacteraemia? If so, what is the cause, the amplitude and duration of the 
bacteraemia?
6.2.1 Hypothesis: there is no association between urological 
procedures and the subsequent development of infective 
endocarditis
The case-control study is the first study of its kind to show a statistical 
association between the development of enterococcal infective endocarditis and 
prior urological procedures. The fundamental assumption of the study is that 
members of the normal human microbiota occupy specific ecological niches in 
201
the human body. The literature supports the assumption that enterococci are 
the most likely organisms to be introduced into the urinary tract during urological 
procedures. The high odds ratio and low p value reinforced the strong 
association between the urological procedures and enterococcal IE. Therefore, 
the first hypothesis was not supported. The association between prior urological 
instrumentation and the development of enterococcal IE does not necessarily 
mean that there is a causal association between the two episodes. However, it 
is not unreasonable to assume that there might be a link between the two 
instances and we speculate about the possible reasons for this association in 
Chapter 2.
6.2.2 Hypothesis: molecular methods are better than the traditional 
culture method to detect and quantify bacteraemia in urological 
patients
The initial experiments carried out in the laboratory showed that the molecular 
methods were able to detect low levels of bacteraemia. The 16S PCR method 
reliably detected and quantified bacteraemia to a level of 103 cfu/mL. The 
Plex-ID performed even better detecting and giving a rough estimate of the 
amplitude of bacteraemia; bacteraemia of < 10 cfu/mL were detected. Based on 
these results, it was decided to use the molecular as well as the culture 
methods to identify bacteraemia during the clinical studies. However, the 
molecular methods performed poorly during the clinical studies. This may be 
because the levels of bacteraemia were so low that the methods were unable to 
detect it. The culture method was optimised for maximum sensitivity explaining 
the reason why it performed better than the molecular methods. Therefore, the 
hypothesis that molecular methods to detect bacteraemia outperform traditional 
culture methods was not supported.
6.2.3 Hypothesis: the incidence of bacteraemia is high during 
urological instrumentation and it lasts for the duration of the 
procedure
Two of the most common procedures performed in a urology department were 
investigated: transurethral resection of the prostate (TURP) and urological 
catheter manipulation. Fifty patients in the TURP group and forty-nine patients 
in the catheter manipulation group were recruited to the study.
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6.2.3.1 Transurethral resection of the Prostate (TURP)
Fifty patients were recruited in this group and an incidence of bacteraemia of 
28% was noted in spite of the use of standard antibiotic prophylaxis. This 
bacteraemia was largely asymptomatic. The bacteria detected were common 
urological pathogens. The bacteraemia started after the start of the procedure 
and was transient and cleared before the end of the procedure. The 
methodological methods we used did not allow determination of the scale of the 
bacteraemia. This was probably because the levels of bacteraemia were too 
low to allow the molecular methods to quantify the bacteria present during 
bacteraemia. A high incidence of transient, asymptomatic bacteraemia in 
patients undergoing TURP was demonstrated, in spite of the use of antibiotic 
prophylaxis; this has not been previously reported in the literature.
6.2.3.2 Catheter Manipulation
Forty-nine patients in this group were recruited and the incidence of 
bacteraemia was 16.3%. This shows that a simple procedure like catheter 
manipulation, which lasts less than a few minutes, can still be associated with a 
transient, asymptomatic bacteraemia. The organisms cultured (the molecular 
methods did not detect any bacteraemia) were bacteria likely to cause urinary 
infections. It is speculated that it is possible for patients to have long-term 
asymptomatic, bacteraemia irrespective of catheter manipulation. The mere 
presence of a urinary catheter may be the cause of the repeated, asymptomatic 
bacteraemia.
6.3 Contributions and novelty of the study
This study has highlighted the fact that bacteraemia may be more prevalent in 
patients undergoing urological procedures than previously thought. The most 
important finding is that almost a third of patients undergoing TURP develop 
bacteraemia in spite of the current recommendations of antibiotic prophylaxis. 
This study highlights the fact that current antibiotic prophylaxis is inadequate in 
preventing episodes of asymptomatic bacteraemias during TURP, though it did 
prevent symptomatic infective episodes. The possibility of recurrent, transient, 
asymptomatic bacteraemia as a concept in patients with urological pathology 
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has also been discussed. This may explain the second finding, which has never 
been reported previously, that there is a statistical association between 
urological procedures and the development of enterococcal infective 
endocarditis. Although the literature is interspersed with case reports and case 
series about the association of urological procedures with the development of 
infective endocarditis, a statistical association has never been shown to exist. 
This study, by virtue of its novel design as a case-control study, has finally 
provided some evidence of a possible link between urological instrumentation 
and infective endocarditis.
6.4 The future
There are still many unanswered questions regarding infection and urology. Is 
there really an association between urological procedures and the development 
of IE? Does one cause the other? Other researchers should investigate the 
association between infective endocarditis and urological procedures. The 
findings of our study should be confirmed or disproved by studying different 
patient populations, in different settings. A national database of patients with 
endocarditis has recently been setup with a number of centres in the United 
Kingdom collaborating and is currently being populated. This database will 
hopefully provide more evidence on the interaction between iatrogenic 
procedures and the subsequent development of infective endocarditis.
It is also important to investigate the incidence of bacteraemia in different 
urological procedures, including upper urinary tract instrumentation. It may be 
possible that previous series have underestimated the incidence of 
bacteraemia, particularly asymptomatic bacteraemia. It is also possible that 
current antibiotic prophylaxis regimes are not adequate to the prevention of 
symptomatic bacteraemia (though they prevent sepsis) and head-to-head trials 
between newer antibiotic regimes are required. Bigger series from different 
centres will shed more light on the incidence of asymptomatic bacteraemia 
during urological procedures. Furthermore, newer methodologies to detect 
bacteraemia should be used to provide contemporary figures about the 
incidence of bacteraemia. Most studies relating to urology and bacteraemia 
have been done decades ago, using technology available at the time.
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The other important issue that needs resolving is the presence of asymptomatic 
bacteraemia in patients with urological pathologies, irrespective of 
instrumentation. Does asymptomatic bacteraemia occur more regularly than 
traditional teaching has led us to believe? It may be possible that the prostate 
gland is not a bacteria-free organ. Although there are a few studies looking at 
culture of prostate chips and tissue from prostate biopsies, newer 
methodologies like PCR and electron microscopy may help shed light on 
whether bacteria reside in or on the prostate, and whether they reside as 
colonies or biofilms that are hard to culture. A non-urological question that 
needs to be answered is the relevance of asymptomatic bacteraemia. What are 
the implications of recurrent, asymptomatic bacteraemia?
At present, it is not possible to answer all these questions adequately and it is 
incumbent on future researchers to resolve these issues.
6.5 Conclusions
This study has shown that patients who undergo urological procedures are 
more likely to develop enterococcal infective endocarditis than any other kind of 
infective endocarditis. The reasons for this can only be speculated upon and 
revolve around the actual procedure causing the bacteraemia or the underlying 
urological disease process causing the bacteraemia. This study has also 
demonstrated that bacteraemia is more prevalent during TURP operations and 
urinary catheter manipulation than previously thought. The bacteraemia is 
largely asymptomatic but may have long-standing implications like the 
development of infective processes such as infective endocarditis.
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Appendix 1: Patient Information Sheet
REC Number 10/H137/5, R&D number UR09/9173, ISRCTN89902973
Infection after urological procedures: is there a risk to the heart?
PART 1
The information in Part 1 should allow you to decide whether the study is of 
interest to you. If you are interested, please read Part 2 and discuss with your 
study doctor.
Invitation to take part in this research study
You are being invited to take part in a research study. Before you decide, it is 
important for you to understand why the research is being done and what it 
will involve. Please take time to read the following information carefully.
x Part 1 tells you the purpose of this study and what will happen to you if 
you take part
x Part 2 gives you more detailed information about the conduct of the 
study.
If there is anything that is not clear to you or you would like more information, 
ask your study doctor and his team. Take time to decide whether or not you 
wish to take part.
1. What is the purpose of the study?
The purpose of the study is to determine whether having urological 
procedures -Transurethral Resection of the Prostate (TURP) and Urinary 
Catheter Change - allows bacteria to enter the blood stream. If so, to what 
extent, and whether this has any bearing on developing infective endocarditis 
(infection of the inner lining of the heart) later on in life.
Infection after surgery occurs in 1-3% of cases. Recognising this early and 
taking the necessary precautions minimise the infective risk caused by having 
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surgery. The information collected from this study will give us a clearer picture 
about bacteria in the blood stream during the three above urological 
procedures. It will allow us to formulate a more scientific approach to 
managing infection during the operative period and hence minimise further 
infective complications further down the line.
2. Why have I been invited to take part?
You are being asked to take part in this study as you are undergoing one of 
the following three procedures: Transurethral Resection of the Prostate 
(TURP) and Urinary Catheter Change at the Leeds Teaching Hospitals NHS 
Trust.
We aim to recruit between 50 patients for each of the above procedures.
3. Do I have to take part?
No. It is up to you to decide whether to take part or not. If you decide to take 
part, you will be given this information sheet to keep and asked to sign a 
consent form. You are still free to withdraw from the study at any time without 
giving any reason. If you decide not to take part in the study or withdraw at 
any time, this will not affect the standard of care you receive.
4. What will happen to me if I take part?
After you have signed the consent form, your study doctor will give you 
contact details of medical staff to contact if you have any questions about the 
study or any problems you want to ask them about.
If you agree to take part in the study, you will be involved in the study for a 
total of 1 year. You will be in contact with the Research Team on 2 separate 
occasions.
Occasion 1:
This is the day you come in the hospital for the procedure planned for you by 
your Urological Surgeon.
Before any study-related procedures are carried out, you will be asked to 
read and sign the consent form. If you wish to participate, you will be asked a 
set of questions to determine your suitability.
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If you are a suitable candidate, a urine sample will be collected from you 
before the start of your planned procedure. Then, a cannula will be inserted in 
your arm, which will be connected to a drip. At specific time points before, 
during and after your planned procedure, blood will be withdrawn from the 
cannula and transferred to blood bottles for the purposes of the study. The 
total volume of blood we will need for the study is 160 ml (6oz). This 
corresponds to around 30 ‘spoonful’ of blood. The cannula will be removed 
once we have gathered all the blood for the study.
Occasion 2:
Within one year after Occasion 1, a member of the Research Team will give 
you a telephone call and mail you (a self-addressed envelope) to ask you a 
few questions about any episodes of infection (especially of the heart) you 
suffered in the last year requiring hospital admission. The telephone call is 
expected to last 5 minutes.
5. Expenses and Payments
There will be no remuneration for participating in this study. Providing us with 
your blood and urine for Occasion 1 is on a completely voluntary basis for the 
purpose of the study. The follow-up telephone call is completely voluntary as 
well.
6. What do I have to do?
The study does not preclude you from doing your normal daily activities at 
any point in time.
7. What are the possible disadvantages and risks of taking part?
We do not anticipate any major disadvantage or risk of taking part in this 
study. For some patients, there may be slight bruising in the arm at the site 
where the cannula went in.
8. What are the possible benefits of taking part in this study?
There will be no benefits for the participants of the study. However, the 
information obtained from the study will help patients undergoing the following 
procedures (Transurethral Resection of the Prostate (TURP) and Urinary 
Catheter Change) in the future.
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9. What happens when the research study stops?
If you want to know the results of the study, you will be able to contact the 
Research Team to have a copy of any results published in the medical 
literature.
10. What if there is a problem?
Any complaint about the way you have been dealt with during the study or 
any possible harm you might suffer will be taken very seriously. The detailed 
information on this is given in Part 2.
11. Will my taking part in the study be kept confidential?
Yes. We will follow ethical and legal practice and all the information about you 
will be handled in confidence. The details are included in Part 2.
THIS COMPLETES PART 1
If the information in Part 1 has interested you and you are considering 
participation, please read the additional information in Part 2 before making 
any decision.
PART 2
The additional information in Part 2 should be read and understood before 
you decide whether to take part in the study and give informed consent.
12. What will happen if I don’t want to carry on with the study?
If you decide that you don’t want to carry on with the study, then you can 
withdraw at any time, without any prejudice to your treatment.
13. What if there is a problem?
If you are worried about your health during the study, please contact your 
study doctor. Should you need to consult another doctor during the study, 
please inform him/her that you are taking part in the research study. You may 
even show this information leaflet for more clarification. 
If you have a concern about any aspect of this study, you should speak to 
your Study Doctor who will do his best to answer your questions. If you 
remain unhappy and wish to complain formally, you can do this by following 
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the complaints procedure in place at the Leeds Teaching Hospitals NHS 
Trust.
The Leeds Teaching Hospitals NHS Trust provides compensation and 
indemnity for this study under the NHS Indemnity Arrangement for clinical 
negligence claims in the NHS, issued under cover of HSG96/48. Your right in 
law to claim compensation for injury where you can prove negligence is not 
affected. Copies of these guidelines are available on request from your Study 
Doctor.
14. Will my taking part in this study be kept confidential?
All information concerning your participation in this study will be kept 
confidential. If you consent to take part in the research, any of your medical 
records may be inspected by the Research Team for the purpose of 
analysing the results. They may also be looked at by the people from 
regulatory authorities to check that the study is being carried out correctly.
Your name, however, will not be disclosed. In the event that the results of this 
study are published, confidentiality will be maintained. During the study, your 
study number only will identify you. In signing the consent form, you are 
authorising your Study Doctor to disclose details of your relevant medical 
history in strict confidence. In signing this form, you are agreeing to co-
operate with your doctor and for your General Practitioner (GP) to be 
informed that you are taking part in this study.
15. What will happen to any samples I give?
The blood and urine samples you give will be identified by the study number 
only. Your name will not be given outside of the Leeds Teaching Hospitals 
NHS Trust. Once the analysis of the blood and urine samples is complete, 
they will be destroyed. No long-term storage of samples is planned for this 
study. No human genetic testing will be performed.
16. What will happen to the results of the research study?
Results of the study will be written up in a report and may be published in the 
medical literature and/or presented at medical conferences. You will not be 
identified by name in any study results. When available, a summary of the 
results of the study may be obtained from a member of the Research Team.
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17. Who is organising and funding the research?
This study has been conceived by Dr Amar Mohee, the Chief Investigator and 
his supervisors, Mr Ian Eardley, Consultant Urological Surgeon and Dr 
Jonathan Sandoe, Consultant Microbiologist. This study is being done in 
conjunction with the University of Leeds. The study is being funded by the 
Pyrah Department of Urology at the St James University Hospital NHS Trust 
in Leeds. The study is registered with the University of Leeds and the chief 
investigator will obtain a higher degree (MD) at the submission of all the data 
to the university.
You will not receive payment for taking part in this study.
18. Who has reviewed the study?
Before the study started, it was reviewed and approved by an independent 
Ethics Committee: the Leeds (West) Research Ethics Committee (REC). The 
study has also been reviewed by the Research and Development Department 
at the Leeds Teaching Hospitals NHS Trust.
19. Further information and contact details
If you have any questions about the study or your health at any time during
the study, please contact one of the named people below. You should also 
contact one of these people in an emergency. They will answer your 
questions or give you advice.
Doctor: Dr Amar Mohee Phone Number: 0113 206 6994
Nurse: Ms Lorraine Lamb Phone Number: 0113 206 4883
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Appendix 2: Consent Form
REC Number 10/H137/5, R&D number UR09/9173, ISRCTN89902973
Patient Identification Number: ...............................
CONSENT FORM
Full Title: A One-Year, Prospective, Observational, Cohort, Single-Centre
Study on the Incidence, Intensity, Duration and Identity of Bacteraemia in 
Patients undergoing Transurethral Resection of the Prostate (TURP) and 
Urinary Catheter Change.
Short Title: Bacteraemia post-urological instrumentation: endocarditis risk?
Name of Researcher: ................................................................................... 
Please Initial Boxes
1. I confirm that I have read and understand the information 
sheet for the above study and have had the opportunity to 
ask questions.
2. I understand that my participation is voluntary and that I am 
free to withdraw any time, without giving any reason, 
without medical care or legal right being affected.
3. I understand that relevant sections of any of my medical 
notes and data collected during the study may be looked at 
by responsible individuals from the Research team, from the 
regulatory authorities or from the NHS Trust, where it is 
relevant to my taking part in this research. I give permission 
for these individuals to have access to my records.
4. I have been given adequate time to consider my decision 
and have been given a copy of the participant information 
leaflet and a copy of this form.
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5. I agree to take part in the above study.
6. I give permission for my GP to be informed of my 
participation in this study.
7. I give permission for the collection and use of my samples. I 
understand that the Research Team will take all reasonable 
steps to protect my right to privacy.
------------------------------           ----------------------------         ------------------------
Name of Patient Date Signature
-------------------------------        ----------------------------         ------------------------
Name of Person 
taking consent Date Signature
---------------------------------         ----------------------------         ----------------------
Name of Researcher Date Signature
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Appendix 3: PCR for the identification of positive cultures
Specimens
Cultures for identification may be referred from blood cultures and routine
Only use pure cultures.  
Prepare culture for direct use as template immediately prior to use: make a 
slightly turbid suspension of the culture in PCR water. Use neat and 1/10 
dilutions directly in place of DNA extract. 
16S PCR analysis
The preparation of PCR reactions and use of the Stratagene MX3000P 
thermocycler are described in MBNTP64 Real-time PCR detection of bacteria 
using SYBR green and the Stratagene MX3000P.
Whilst preparing the reagents, turn on the MXP3000P thermocycler to warm 
up.
In the PCR clean room, prepare the reagents required for PCR amplification 
of a short segment of the 16S rRNA gene as described in MBNTP64 using 
primers and conditions described below:
Forward primer: (MycF) AGAGTTTGATCCTGGCTCAG
Reverse primer: (Uni690R) CTACGCATTTCACCGCTACAC
Primer mixes are prepared by mixing equal volumes of forward and reverse 
primers and diluting 1/10 (i.e. 10 µl of each primer and 180 µl PCR water). 
These are then stored at -20° C.
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Use the following table to calculate the volumes of reagents required:
Each sample is to be run using 3 µl of extracted template extractions and 
following dilution at 1/5 or culture at neat and 1/10. The final reaction volume 
is 30 µl.
(Number of reactions = 2 x number of samples (n) + Negative control + 
Positive controls + No template control (NTC) i.e. 2 x n + 3). 
Table of reagents required in reagent mix for 27 µl volumes (3 µl template)
Number of 
reactions 1 2 3 4 5 6 7 8 9 10 11 12
Mastermix 15 30 45 60 75 90 105 120 150 165 180 195
Primer mix 0.8 1.5 2.3 3.0 3.7 4.5 5.3 6.0 7.5 8.3 9 9.8
H2O 11 22 34 44 55 66 77 88 110 121 132 142
UNG 0.3 0.6 0.9 1.2 1.5 1.8 2.1 2.4 3 3.3 3.6 3.9
Allowance has been made for pipetting errors, etc.
In the designated setting up area within the extraction room, add the template 
to the prepared reagents, cap the tubes and briefly centrifuge so that the 
template and reagents are in the bottom of the tubes. Place the tubes into the 
wells in the Stratagene MX3000P and set up the machine using the thermal 
profile below, stored as “Tony/MR Final”:
37° C 10 min; 95° C 10 min; (95° C 30 sec, 62° C 1 min, 72° C 1.5 min) x 
40; 72° C 10 min (fluorescence collected at end of extension)
95° C 1 min, ramp down to 55° C then ramp up to 95° C (collecting 
readings at ALL points)
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Data analysis and interpretation
The PCR products should be analysed according to the protocol described in 
MBNTP64 Real-time PCR detection of bacteria using SYBR green 1 and the 
Stratagene MX3000P. 
Check that the positive amplification plots have a lower Ct than the negative 
and NTC controls. The Ct of the negative controls must be >30 cycles. Where 
there is not a clear distinction between the Ct and the negative controls 
(minimum 2 cycles), then the result should be interpreted as equivocal and 
the PCR repeated.
For cultures, the amplification curves should have a low Ct of < 27 cycles and 
the melting curve of the PCR products should have a sharp peak – with a 
high Tm (> 82° C). If there is no sharp peak visible, the preparative PCR 
should be repeated. 
For clinical specimens, the amplification curves must have a 
Ct of < 30 cycles. Where the Ct > 30 cycles, the amplification may be 
repeated once more. If Ct > 30 cycles then the results is NEGATIVE and a 
comment (code: 16S) added to the report:
To avoid the detection of contaminating bacteria, the sensitivity of 16S-PCR is 
lower than PCR for specific bacterial targets. A negative PCR result cannot 
entirely exclude bacterial infection.
All positive PCR products should be stored at -20° C until they are cleaned 
and sent for nucleotide sequence determination and analysis.
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Appendix 4: PCR Protocol for bacterial DNA extracted from 
blood
PCR for bacterial 16S rDNA
Primers:
“Short 16S” (Greisen et al. (1994): J Clin Microbiol 32: 335-351)
RW01 (F) AACTGGAGGAAGGTGGGGAT
DG74 ® AGGAGGTGATCCAACCGCA
Product length ~390
Kathryn Harris (Harris & Hartley (2003): J Med Microbiol 52: 685-691)
16S Fa (F) GCTCAGATTGAACGCTGG
16SFb (F) GCTCAGGAYGAACGCTGG
16SR TACTGCTGCCTCCCGTA
Product length ~320bp
“Enteric 16S” (Greisen et al. (1994): J Clin Microbiol 32: 335-351)
RW01
RDR140 (reversed) CATGAATCACAAAGTGGTAAGCGCC
Product length ~312bp
Ensure all tubes, pipettors and racks are clean before use (use DNAse Away 
and UV light).
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Per 25 ȝO5[
2.5 x Mastermix 10
50 SPROȝOFRPELQHGSULPHUV 0.65
Staining solution 2.5
Water 8.6
MolTaq 0.8
Template/DNA 2.5
For each reaction (25 ȝO
Primer mixes are prepared by mixing 10 µl of each primer, make up to 200 µl 
with PCR water. Store at -20° C.
Make up a pool of reagents ensuring included positive, negative and no 
template controls, and allow at least 1 reaction for pipetting errors.
N.B. water and template volumes can be varied according to the proportion of 
template that is required in the final reaction.
Tubes come in strips of eight - used pipette boxes can be used as a rack to 
transport them.
Prepare a plan for the positions of each tube in the PCR machine (A1-A12; 
G1-G12).
Dispense the reagent pool (e.g. 22.5 ȝODOORZVURRPIRU ȝO WHPSODWH LQWR
Stratagene tubes. Minimise labelling of the tubes if possible – the caps can 
be labelled at the ends.
Take tubes to the place where the DNA template can be added (extraction 
lab). 
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In the PCR machine room
1. Switch on the Stratagene MX3000P at the back (rocker switch, left hand 
side above power cable) and then the computer.
2. Double click MX3000P icon to open up software.
3. Select experiment type –SYBR green with dissociation curve.
4. If the top light bulb icon is red (and red LAMP OFF sign at bottom of 
screen is indicated), click the icon – it should turn yellow. The lamp takes 
about 20 min to warm up.
In the extraction room
1. Prepare a list of all templates before starting, to ensure that the correct 
sample is loaded into the correct tube.
2. Add appropriate volume of template to each tube.
3. Orientate the caps so that the “A” on the end of the strip lies with the first 
tube of the strip. Carefully cap each strip of tubes, ensuring that the caps 
lie flat. If more than one strip is used, alter the label of the tab of the 
subsequent strips to B, C….etc. Tube 1 will be the one nearest to the 
labelled tab.
4. Briefly spin tubes in the special centrifuge to ensure that all contents are 
at the bottom of the tubes.
In the PCR machine room
1. Place the tubes into the PCR machine – pull the black “handle” forward 
and lift up to reveal the locations. Arrange the strips from left to right with 
tube “A1” in the top left hand corner.
2. On the “Plate setup” screen, select the wells on the grid that correspond 
to the samples and positive controls and assign these as “unknown”; 
select dye as FAM. Assign the NTC wells as “NTC”; dye FAM.
3. (This can be completed once the programme is running)
To label the wells individually double click on the well and type into the 
dialogue box. Alternatively to label multiple wells, you need to click the 
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“Full screen Plate” box, select wells and click “name and comments” box 
to open the dialogue box.
4. Select the “Thermal profile” button. Import the required programme
using the import button and double clicking on the file. Alternatively, the 
machine can be programmed by editing the default programme.
Cycling conditions (Harris & Hartley):
3 min @ 94º C
40 cycles: 30 sec 94º C; 1 min 60º C; 1 min 72º C
x Stratagene melt curve.
5. Select “Start run” button bottom left hand side of screen to start the 
programme.  Tick the “Turn off lamp at end” box. If the lamp has not 
warmed up, you will get a dialogue box requesting information about 
when to start run. Cancel the run and then tick the “Turn off lamp…” box 
and then select the “Start run” button to start run. When the dialogue box 
reappears, select the option “start run when lamp has warmed up”.
6. If the run has begun the “raw data plots” will allow real time monitoring of 
the reactions.
Expected running time for 40 cycles with melting curve analysis 2 hr 30 min
Data analysis
1. Select plateau for amplification analysis by the clicking the “amplification” 
button. This will be found in segment 2. Click OK
2. Select ramp for dissociation analysis by the clicking the “dissociation” 
button. This will be found in segment 4. Click OK
3. Select wells for data analysis on the grid, click “data analysis” button. 
If there are several different assays, it is helpful to select and print off each 
group individually.
4. Working from the top of the list on the right hand side down, click on 
each of the options: 
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Amplification: Print off and label any positives (hover mouse over the curve). 
Check that the threshold line lies above the background readings, if not it can 
be moved by dragging. A summary of the Ct values are displayed in the box 
on the right hand side, if there are no Ct values where there are good curves, 
the threshold should be adjust. If the threshold is set too high, then late Ct 
values will be counted as negative.
Dissociation curve: The colours of the curves will correspond to those from 
the amplification plots. Print off and label any positives. Check whether the 
characteristic “double peak” is visible for any of the specimens (not just those 
with positive amplification).
Text report. Tick the box for Tm product 1 to be reported along with the 
defaults. Print out report. 
You can print off a composite report by ticking the information required on 
the final report, selecting the number of areas per page and printing off.
Data Interpretation
1. Check that the positive amplification plots have lower Ct than the 
negative and no template controls. Where there is not a clear distinction 
between the Ct and the negative control, then the result should not be 
interpreted as positive. It is good practice to ensure there are >3 Ct s 
between amplification plot and the NTC/neg control.
2. Check all positive samples have a sharp peak at the appropriate Tm for 
the melting curve. Primer dimer and non-specific DNA is usually present 
with a lower TM. Samples where there is a mixed PCR product are 
unlikely to have a sharp peak.
Both the dissociation curve and the Tm of the text report should be 
considered when interpreting the result.
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Appendix 5: Protocol for using PLEX System with BAC SF kit
PCR Setup Procedure (manual)
Remove SF plate from freezer and allow to thaw before use. Ensure that 
contents are in the bottom of the wells. Remove the protective foil. Turn on 
the plate sealer to warm up (see 1.1 below).
For each sample pipette 10 ȝO RI HOXDWH LQWR WKH ZHOOV RI WKH GHVLJQDWHG
column – note “column 1 and column 7” = sample 1; “column 2 and column 8” 
= sample 2; etc. (8 wells per column) piercing the foil cover.
If you are only using the first 6 columns, ensure that you use PLEX-ID 
reagent in the unused wells.
Resealing PCR plates
Seal the PLEX-ID Assay Plate(s) with Foil Seals after PCR setup is complete.
NOTE:  Gloves should be worn during the heat sealing process to avoid 
contaminating the seal.
x Depress the heat button on the Heat Sealer to initiate the warming cycle.  
While the Heat Sealer is warming, the light will blink on and off.  When 
the Heat Sealer has reached the set point of 180° C, the light will remain 
on. 
x Place the PLEX-ID Assay Plate on the Heat Sealer.
x Immediately prior to use, remove a foil seal from the bag, and apply to 
the plate, making sure the seal is centered for minimal overlap on either 
side and the proper side of the seal is Up as indicated on the seal bag.  
x Lower the handle to engage the heat block and hold until the timer has 
counted down to zero and three audible beeps have been heard.  
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x Raise the handle to disengage the heat block, and allow plate to cool 
slightly.  Carefully remove the plate from the Heat Sealer.  Check sealed 
properly or turn and return plate briefly to sealer.
x If more than one plate is to be sealed, allow Heat Sealer to warm back 
up to the set point before sealing subsequent plates.
Plates can be frozen if they are not to be used immediately.
PLEX-ID TC Operation
x Slide open PLEX-ID TC lid, if closed, and place PLEX-ID BAC Spectrum 
SF Assay Plate in the block. Slide lid completely closed. 
x Repeat for each Assay Plate to be loaded. 
x Using arrow buttons on control panel, select PLEX-ID directory, then 
“Diagnostic Programs” then “BAC_SF_TCv01” for each Thermal 
Cycler used.
x Press Start button.
x Select cycler that has been loaded with the PLEX-ID BAC Spectrum SF 
Assay Plate. (If only one thermocycler is on, this will be omitted)
x Press OK button. 
NOTE:  Thermal cycled plates can be stored up to 24 hours in the thermal 
cycler before being placed on the PLEX-ID Analyzer. If plates are not placed 
on the analyzer within 24 hours, they can be stored for up to 48 hours at 2-
8° C.  
Transport plates in designated PCR box
Spin plates for 1 min at 800 rpm in plate centrifuge in Sequencing Lab.
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Preparation of the PLEX-ID Analyzer
x Select completed plates from the corresponding Thermal Cycler and 
press Mark Completed.  
x Follow the procedure described in the Plex-ID operations manual for 
instructions on how to run the Plex-ID analyser.
x Provision the Plex-ID analyser with clean-up micro particles, cleanup 
1,2,3 and 4 if necessary.
NOTE:  A PLEX-ID Analyzer Check Kit plate should be run weekly or 
immediately following each Clean-up Reagent change on the PLEX-ID 
Analyzer.  While the PLEX-ID BAC Spectrum BC Assay Plates are being 
processed in the PLEX-ID TC, load and run a PLEX-ID Analyzer Check plate 
(if required). Results from the PLEX-ID Analyzer Check plate should be 
obtained before loading the PLEX-ID BAC Spectrum BC Assay Plates
Calibration plates (in clean room freezer or PCR machine room freezer) can 
be placed directly into the loading area of the Plex.
Barcode should be on the side with A1 and faces the back of the loader.
Sample Clean-up and Analysis on the PLEX-ID Analyzer
If the PLEX-ID Analyzer Check plate is run, the results should be obtained 
before proceeding to run the PLEX-ID BAC Spectrum BC Assay Plates.  If the 
PLEX-ID Analyzer Check plate report indicates that the results are not 
satisfactory, do NOT proceed to run PLEX-ID BAC Spectrum BC Assay 
Plates. Contact your Abbott Representative for troubleshooting.
x Load the amplified PLEX-ID BAC Spectrum BC Assay Plates in the input 
stacker of the PLEX-ID Analyzer for sample clean-up and analysis.
x Select plate order from the available plates in the menu – note you need 
to have told the equipment that the PCR has been completed.
x Select “Run” on the user console.
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Logging process
Computer: logon using username: Plex-ID
                                          p/w: Plex-ID
Log in to the PLEX-ID Front-End Software on the PLEX-ID computer 
workstation and select the “Pre-Extraction” step on the menu.
NOTE: For step-by step instructions on the PLEX-ID Front-End Software, see 
the PLEX-ID Front-End Processing Guide.
x Select PLEX-ID BAC Spectrum (no EC) protocol and create a batch. 
x Put in sample ID then press “+”, then number for the specimen tube (this 
should be noted by the computer) and press “+” 
Press Done when batch completed.
x Return to the workstation and select the “Extraction" step from the 
software menu. 
x Select the created batch and “auto-assign” the process tubes to the 
process tube block for the PLEX-ID FH.  Press Next.
x Elution Plate number (see note by computer) and scan the PLEX-ID BAC 
Spectrum SF Assay Amplification Reagent Kit Lot Number when 
prompted. Press “Next”. Follow instruction on the screen for the 
extraction procedure.
1. Return to the workstation and select PCR Setup.
2. Identify batch and add in the Scan Elution plate number (above).
3. Scan Barcode on the PLEX-ID BAC Spectrum SF Assay Plate(s). 
4. Number BAC Spectrum BC Assay Plate(s) as indicated on the screen. 
Press Done.
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1. Return to the workstation and select Amplification.  Select the Thermal 
Cycler to be used.
2. Select the PLEX-ID BAC Spectrum BC Assay Plate(s).  Press Done.
3. Also Select Complete Amplification at this point!
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Appendix 6: Protocol for collecting blood from patients (Local 
Guidelines)
Using a needle and syringe. N.B. Using vacuum-assisted blood collection 
system is the preferred technique and the needle and syringe method should 
only be used as a last resort.
1. Prepare all the equipment you will require. 
2. Remove the caps from the blood culture bottles and wipe the bottle tops 
with a sterile wipe containing 2% chlorhexidine in 70% isopropyl alcohol. 
Allow to air dry. 
3. Identify the correct patient e.g. name band and verbally where possible 
and explain the procedure and obtain verbal consent where appropriate. 
4. Wash hands with soap and water, then dry hands and put on disposable 
apron. 
5. Selecting a venepuncture site. N.B. Use the femoral vein only if 
venepuncture is not possible at other sites. In this case, clean the skin as 
below (7) and repeat. 
6. Apply a tourniquet if required. 
7. Clean the venepuncture site using a 2% chlorhexidine in 70% isopropyl 
alcohol wipe. 1,2 Apply the disinfectant by pressing the swab in the centre 
of chosen venepuncture site. Then apply the disinfectant with a spiral 
outward motion from the centre of the venepuncture covering 1-2 finger 
breadth to each side. Allow to air dry (the drying process kills the 
bacteria). 
8. Put on sterile examination gloves while skin disinfectants dry. 
9. Attach a butterfly needle or straight needle to a Mel (or larger) syringe. 
10.Perform venepuncture and withdraw 16-Mel of blood for blood culture 
sampling and more if other tests are required. 
11.Remove tourniquet 
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12.Place a swab or cotton wool over the venepuncture site and apply gentle 
pressure while withdrawing the needle. Press firmly over the 
venepuncture site until bleeding has stopped (the patient can be asked 
to do this if appropriate). 
13.Transfer 8-10 ml of blood into each bottle. NB. If the peripheral blood 
cultures are being taken as part of a set to identify intravascular catheter 
colonisation, the volume of blood needs to be the same as that collected 
from the central venous catheter (CVC). Fill anaerobic bottle first then 
aerobic. DO NOT change needle between sample collection and 
inoculation. 
14.Discard needle and syringe into a sharps bin. 
15.Write patient details and clinical information on blood culture bottles 
according to Trust policy. 
16.Wash hands with soap and water, then dry hands. 
17.Arrange transport of the sample to the laboratory. 
18.Ensure that sampling details and any subsequent positive results 
communicated by the microbiology department are accurately 
documented in the patients’ notes and advice is acted on. 
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Appendix 7: Medical history form
Patient Identification Number: .......................................................
Name: Age: 
Sex: Weight:
Telephone:
Planned procedure:
Date of planned procedure:
Within 2 weeks of the above date:
1. Have you had any antibiotics therapy? : Yes or No
Is Yes, what was the indication? ___________________________
2. Any instrumentation of the urological tract? : Yes or No
3. Any symptomatic UTIs? Yes or No
x
General questions
1. Any immunosuppressants? Yes or No 
________________________________
2. Diabetes Mellitus? Yes or No
________________________________
3. Smoking? Yes or No
________________________________
4. Co-existing infection? Yes or No
________________________________
5. Recent long hospital stay? Yes or No
________________________________
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6. Recurrent UTIs? Yes or No
________________________________
7. Urinary Stones? Yes or No
________________________________
8. Catheter in situ? Yes or No
If catheter present, for how long?  ____________________________
Specific Questions
1. Cardiac History? Yes or No
_______________________________________
2. Previous Endocarditis? Yes or No
_______________________________________
3. Prosthesis (e.g. joint, pacemaker, penile)? Yes or No
_______________________________________
4. Organ Transplant? Yes or No
_____________________________________
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Appendix 8: Interview Questionnaire
Good morning Mr/Mrs
I am Dr Amar Mohee from the urology research team at St James Hospital.
You took part in a study when you came for your catheter 
change/removal/prostate operation. We took some blood and a urine sample 
from you. Do you remember?
We are just calling to see how you are doing and we want to ask you a few 
questions. Is it ok?
1. Firstly, have you felt unwell or flu-ey after your procedure? 
(if yes, elaborate)
2. Have you had any water infection after your procedure?
(if yes, elaborate)
3. Did you have to go to your GP
a. For antibiotics? (yes/no)
b. To provide a urine sample (yes/no)
4. Did you have to be re-admitted after your procedure?
(if yes, when and why?)
5. Did you come into hospital for treatment of any infection?
x (if yes, when and what type of infection?)
That is all.
Thank you once again for taking part in our study.
I wish you a good day.
  Good Bye
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Appendix 9: 16S PCR results
Catheter Manipulation Samples
Possible positive 
samples
Ct Value
Definite positive 
samples
Ct Value
C003A 28.81 C002C 27.28
C004C 27.64 C005A 20.62
C006C 28.50 C005B 22.45
C007B 28.73 C005C 22.60
C009A 29.76 C005D 21.13
C023A 29.53 C006A 26.07
C023B 29.32 C009D 26.69
C024D 29.58 C025D 25.46
C026D 28.46 C032D 27.36
C030B 28.92 C037D 26.10
C030D 29.43 C042D 22.41
C033D 29.43 C048B 27.30
C034B 29.45 C055A 24.99
C035B 29.95
C035D 28.28
C038A 28.70
C038B 29.38
C038D 28.11
C039A 28.69
C039B 29.98
C039D 28.41
C041A 28.74
C042A 29.19
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Possible positive 
samples
Ct Value
Definite positive 
samples
Ct Value
C042B 27.67
C045A 28.07
C045D 29.28
C046A 29.35
C047A 29.34
C047D 28.73
C048A 28.11
C048C 27.60
C050A 28.26
C050D 29.15
C052B 28.68
C054D 27.52
C056B 29.59
C057B 29.58
C057C 29.53
C060A 29.61
C060B 29.59
C060D 29.16
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TURP samples
Possible positive 
samples
Ct Value
Definite positive 
samples
Ct Value
T005A 28.99 T005D 27.22
T005E 27.62 T017C 25.10
T009E 29.74 T017E 26.74
T012E 29.79 T017F 26.90
T018F 27.94 T018E 23.28
T021C 27.59 T020A 26.88
T024C 29.32 T020C 24.33
T027C 28.85 T020F 24.24
T028E 29.44 T021A 24.18
T028F 29.96 T021D 24.50
T030A 28.88 T021E 24.13
T031C 29.17 T021F 24.22
T033D 28.98 T022C 24.19
T033E 29.65 T022D 26.68
T034F 28.65 T026F 25.37
T039C 28.18 T027D 26.40
T039D 27.96 T027F 25.63
T039E 29.04 T031F 25.75
T039F 29.63 T035C 26.37
T042F 28.22 T036D 25.37
T044D 28.59 T038E 27.49
T044E 27.88 T040A 24.11
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Possible positive 
samples
Ct Value
Definite positive 
samples
Ct Value
T045A 27.87 T040C 26.57
T045C 29.11 T040D 25.41
T045F 28.37 T040E 25.28
T046A 28.09 T041D 25.81
T046B 28.28 T041F 25.91
T046C 28.01 T042C 25.60
T046F 28.62 T043A 24.02
T049B 29.27 T043C 26.68
T049C 29.25 T043D 26.70
T052D 27.57 T043E 25.44
T053C 27.82 T044A 23.87
T053D 29.38 T049D 26.32
T054A 29.48 T049E 27.49
T054D 29.78 T050C 24.33
T059E 28.79 T050D 25.12
T060C 29.77 T050F 25.41
T060D 29.75 T052F 27.49
T063D 29.28 T054C 26.82
T064A 29.21 T055B 26.97
T064B 28.50 T055C 23.87
T064E 28.67 T055D 26.98
T064F 29.84 T062B 24.94
TO62F 27.17
T063A 26.24
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Possible positive 
samples
Ct Value
Definite positive 
samples
Ct Value
T064C 26.99
T065B 26.44
T065F 24.69
T071C 20.01
T075A 19.57
T077F 27.41
